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Abstract 
In addition to their bactericidal effects, antibiotics are potent signal mediators at sub-
inhibitory levels in the environment. The ability to modulate community structure in this 
niche raises concerns over their capacity to influence pathogenesis in patients during 
antibiotic therapy. This concept forms the basis of this thesis, and is explored using 
models of prophylactic therapy for recurrent urinary tract infection (UTI) management. 
Sub-inhibitory ciprofloxacin, ampicillin, and gentamicin were found to augment 
virulence in vitro, increasing adherence and urothelial cell invasion in uropathogenic 
Escherichia coli (UPEC) and Staphylococcus saprophyticus. In addition, biofilm 
formation was increased, and swarming motility decreased. In UPEC, the effect of 
antibiotics on these processes was abolished in SOS-deficient strains. 
Trans-urethral inoculation of mice with ciprofloxacin-primed S. saprophyticus or UPEC 
significantly increased bacterial burden in both bladders and kidneys at one and 14 days 
post-inoculation (dpi). Sub-therapeutic ciprofloxacin supplemented in the drinking water 
of chronically infected mice significantly increased bacterial urine load. In addition, mice 
previously infected but clinically resolved suffered recurrences. These mice had impaired 
urinary polymorphonuclear leukocyte infiltrates, in part due to antibiotic-dependent 
cytokine suppression during initial infection. Prophylactic intervention had no significant 
effect on UPEC clearance, but did significantly increase bacterial intracellular bladder 
reservoirs, raising concerns over the clinical efficacy of this management strategy and 
risks of promoting persistent infection. 
 iii 
 
The inability of antibiotics to clear infection in prophylaxis models was attributed to the 
presence of MDT persister cells. Sub-inhibitory antibiotic pre-treatments were found to 
increase persister fractions, but this effect was abolished in SOS-deficient strains. 
Conducting these assays with UPEC isolated from recurrent UTI patients revealed an 
enriched persister fraction compared to organisms cleared with standard antibiotic 
therapy, suggesting persister traits are either selected for during prolonged antibiotic 
treatment or initially contribute to therapy failure. 
This work represents the first attempt to illustrate that observed sub-inhibitory, pathogen 
associated antibiotic-dependent changes in vitro have significant in vivo consequences. It 
is hoped that this research will lead to a re-examination of how antibiotics are 
administered for management of patients suffering from recurrent UTI and other chronic 
diseases. 
 
Keywords 
Staphylococcus saprophyticus, Escherichia coli, UPEC, MDT, recurrent UTI, antibiotic, 
urothelium, murine model, uropathogenesis, hormesis, urothelial immunity. 
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1 INTRODUCTION 
 
1.1 THE INFLUENCE OF ANTIBIOTICS ON HOST AND 
PATHOGENS 
Since their discovery, antibiotics have been used with overwhelming success in treating 
and preventing infections, saving countless lives along the way. However, in recent 
times, questions have been raised about not only adverse effects and multi-drug 
resistance, but also the natural role of antibiotics in the environment and the potential role 
in complicating disease (Yim et al., 2007; Romero et al., 2011) and affecting long term 
health (Blaser, 2011). Thus, a potential paradigm shift is emerging on how we view 
antibiotics. A number of case reports and clinical trials corroborate this shift, with a 
growing regimen of antimicrobials associated with increased morbidity and mortality 
when used for purposes outside their recommended guidelines (Harbarth et al., 2003). It 
is critical that inappropriate prescription practices cease and that the current issues 
associated with antibiotic misuse be brought to light. 
 
1.1.1 A wider perspective of how antibiotics affect 
microorganisms 
Following Alexander Fleming's discovery that microorganisms secrete antimicrobial 
agents (Fleming, 1929), there has been an explosion in the number of compounds and 
synthetic derivatives that have become available for therapeutic use. Unsurprisingly, soil 
organisms such as Streptomyces spp. and the penicillin-producing Penicillium notatum, 
first observed by Fleming have been the indispensible work-horses of the 
chemotherapeutic field, supplying the vast majority of antimicrobial compounds used 
clinically today. However, it is surprising, perhaps even unnerving, that the natural roles 
of these small molecules in the environment from which they are derived are still largely 
unknown, with only a fraction of natural therapeutic products having been extensively 
studied (Romero et al., 2011). It had long been thought that antibiotics functioned simply 
as molecular weapons, whose inhibitory properties we readily take advantage of 
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clinically. We now know that they have diverse effects on microorganisms, depending on 
the dose administered (Davies et al., 2006). Many of these compounds are stimulatory at 
doses of less than the minimal inhibitory concentration (MIC) and are capable of 
modulating the expression of upwards of 5-10% of the entire bacterial genome (Goh et 
al., 2002) in a bimodal dose-response relationship referred to as hormesis (Southam and 
Erlich, 1943). A growing body of literature now supports their role as interspecies 
signalling molecules involved in optimizing multi-organism community structure and 
function (Bernier et al., 2013).  
Antibiotics can meet many of the criteria for functioning as signalling agents, whose 
production occurs during tightly regulated stages of growth, under certain physiological 
conditions, with accumulation generating a concerted response once a certain population 
threshold is achieved (Keller and Surette, 2006; Winzer et al., 2002; Hibbing et al., 
2010). The utility of this tight regulation is that antibiotics are delivered by an entire 
population at a very specific concentration, often which is many fold-lower than what is 
prescribed therapeutically and insufficient for antibiosis (Yim et al., 2007). Recent 
investigation of natural populations of Streptomyces spp. demonstrated that sub-
inhibitory antibiotics are important regulators of interspecies nutrient utilization 
strategies, and are effective in reducing niche overlap in mixed populations (Jauri et al., 
2013). In a seminal paper, Hoffman et al. (2005) demonstrated that sub-inhibitory 
aminoglycosides were capable of inducing bacterial biofilm formation in Pseudomonas 
aeruginosa. This response was mediated by the aminoglycoside response regulator (arr) 
gene, whose activity modulated levels of the major regulator c-di-GMP, influencing 
several genes important to motility and pili production amongst others. This interaction 
with a specific regulator supports the claim that antibiotics can have precise signalling 
targets. 
Other agents have similar effects but also up-regulate expression of secretion system 
genes. This increases cytotoxicity when challenged against a macrophage cell line and 
increases competition against other organisms in the environment (Linares et al., 2006; 
Jones et al., 2013). Antibiotics can influence the larger microbial community structure by 
hijacking inter-species regulatory systems of niche inhabitants. In Streptococcus 
pneumoniae, sub-inhibitory penicillin stimulates the production of the inter-bacterial 
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signalling agent autoinducer-2 (AI-2), a factor important in biofilm formation in many 
species (Rogers et al., 2007). The culmination of these responses in the environment may 
be to repel or defend against predatory eukaryote attack, which may be stimulated by 
'sensing' streptomyces, providing an obvious benefit to multispecies community 
lifestyles. Clearly, such antibiotic-induced changes may also have significant 
ramifications for patients receiving antibiotic therapy. This new understanding of 
antibiotic functions in natural environments necessitates a re-evaluation of their use in the 
clinical setting. 
 
1.1.2 Sub-inhibitory antibiotics are capable of modulating 
bacterial virulence and pathogenesis 
Clinicians are well aware of the common side-effects of antibiotic therapy which may 
include microbiota dysbiosis (gastro-intestinal distress, oral and vaginal candidiasis, 
bacterial vaginosis, skin rashes), the establishment of resistant variants and host toxicity 
(Dancer et al., 2004). Worsening patient prognosis is often attributed to confounding 
factors such as patient immune status, while the actual cause may be the prescribed agent 
itself. Here, the effects that antibiotics have on bacterial virulence will be explored, citing 
patient trials when possible, but relying mostly on the growing body of in vitro data. 
Effects on modulation of toxin production 
Since Julian Davies' group began the first serious investigations of sub-inhibitory 
antibiotic hormetic effects using promoter-luciferase expression libraries over a decade 
ago (Goh et al., 2002), there has been an increasing focus on characterizing phenotypes 
relevant to pathogenesis. The changes that sub-inhibitory antibiotics invoke can be 
dramatic and highly variable depending on the class and the organism challenged. Even 
slight modifications of chemical groups within the same antibiotic can affect its ability to 
augment pathogenesis (Nielsen et al., 2012). However, some antibiotic classes are 
associated with specific responses. For example, protein synthesis inhibitors generally 
suppress toxin expression while DNA and cell wall acting agents enhance it. These 
differences are likely attributed to their mechanism of action, with protein synthesis 
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inhibitors preventing toxin mRNA translation and subsequent release when supplied at 
appropriate levels. There may be several routes by which antibiotics modulate gene 
expression, involving specific signalling and general stress response systems (Hoffman et 
al., 2005; Kelley, 2006). Knowledge of how these responses augment pathogenesis will 
aid physicians in disease management for various infection milieu. 
The most characterized case of antibiotics directly influencing bacterial virulence is 
through the upregulation of shiga-toxin (Stx) production in enterohemorrhagic 
Escherichia coli (EHEC) and induced onset of hemolytic-uremic syndrome (HUS). This 
medical emergency carries a 5-10% mortality rate, and inappropriate antibiotic 
application is significantly associated with increased HUS risk from ~15 to ~50% (Wong 
et al., 2000; Serna IV and Boedeker, 2008). Antibiotic stress can drive bacteriophages 
from lysogeny, resulting in phage replication during the lytic cycle and concurrent 
production of phage related genes such as Stx. In the EHEC epidemic strain O157:H7, 
sub-inhibitory fluoroquinolone and co-trimoxazole drive Stx production, while antibiotics 
that target cell-wall, transcription and translation do not (McGannon et al., 2010). 
Conversely, other agents are capable of inhibiting Stx production even at low levels 
(McGannon et al., 2010). The reaction of organisms to antibiotics is highly variable, and 
is determined by the agent provided and targeted strain. Importantly, phage activation is 
not a requirement of antibiotic-induced virulence. Other mechanisms appear to exist 
which are much less well characterized but believed to be driven by changes in stress 
response-related systems. 
Non-phage associated virulence traits can also be induced with antibiotics. In group A 
streptococci (GAS), clindamycin and benzylpenicillin are commonly used therapeutics 
for ameliorating toxic shock-like syndromes by suppressing exotoxin SpeA/B production 
(Mascini et al., 2001). However, these and protein synthesis-inhibitors also increase 
levels of other potent toxins including streptolysin and streptococcal inhibitor of 
complement at sub-inhibitory levels (Tanaka et al., 2005). The effect of these agents is 
abrogated when supplied at levels higher than the MIC, highlighting the importance of 
maintaining therapeutic levels during treatment. This may be difficult when organisms 
are either highly tolerant or resistant, such as in methicillin resistant Staphylococcus 
aureus (MRSA). In these scenarios a combination of antibiotic ineffectiveness and 
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induced virulence expression could easily exacerbate an already complicated infection. 
The observation that resistant organisms are also in many cases hypervirulent may be a 
direct, yet unexplored consequence of inappropriate antibiotic therapy (Fluit, 2005). 
Indeed, there is a trend linking inappropriate therapy of resistant infections with negative 
outcomes in patients, and not just because of antibiotic failure (Dancer et al., 2004). 
Dumitrescu et al. (2011) demonstrated the induction of Panton-Valentine leukocidin 
(PVL) toxin in MRSA when various antibiotics interfered with penicillin binding 
proteins. Conversely, clindamycin and linezolid inhibit the release of PVL and other 
toxins (Dumitrescu et al., 2007; Otto et al., 2013). Some protein synthesis inhibitors 
increase expression of the agr virulence gene regulator in MRSA (Joo et al., 2010), 
resulting in the production of phenol-soluble modulins (PSM) responsible for neutrophil 
lysis and pro-inflammatory responses. Toxin production is likely attributable to sub-
inhibitory dosing which induces gene expression but is inadequate to prevent ribosomal 
translation (Joo et al., 2010). This could be clinically relevant during infections caused by 
resistant organisms which have a greater threshold for tolerating therapeutic dosing. 
Because there is a strong epidemiological link between PVL/PSM and severe infections 
such as necrotizing pneumonia, recurrent complicated osteomyelitis and sepsis (Mitchell 
et al., 2007), empirical use of certain antibiotics in locations with high MRSA incidence 
should be avoided. 
 
Effects on bacterial adherence, invasion and biofilm formation 
In resistant and non-resistant organisms, many antibiotics induce a hyper-adhesive 
phenotype that is characterized by an increase in surface adhesin production (Rasigade et 
al., 2011; Bisogano et al., 2000; Denève et al., 2009; Erdeljan et al., 2012). The increased 
capacity to adhere to tissues and medical device surfaces are of particular concern as it 
potentiates the formation of antibiotic tolerant biofilms (Hoffman et al., 2005). Once a 
biofilm is established, MIC shifting occurs, which may permit increased toxin production 
in the now tolerant organisms. In addition, sub-inhibitory antibiotics can promote the 
rapid formation of planktonic S. aureus aggregates with lowered susceptibility to 
antibiotic killing (10-100x less susceptible) (Haaber et al., 2012; McNabe et al., 2011). 
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These biofilm-like communities may be less susceptible to phagocytic immune predation 
(Foster, 2005), providing multivariate benefits to survival and persistence within the host. 
Kaplan et al., (2012) demonstrated that resistant isolates had higher fold-change in 
biofilm formation compared to sensitive strains following antibiotic exposure. In biofilm-
associated pathogens, such as Staphylococcus spp., antibiotic-induced biofilm formation 
likely occurs in both icaADBC-dependent (polysaccharide intercellular adhesin - PIA) 
and independent (proteinaceous and eDNA) manners (Wang et al. 2010; Rachid et al., 
2000), involving activation of both specific sensors (Hoffman et al., 2005) and general 
stress responses (Li et al., 2005
a
). Additionally, increased adherence also potentiates 
hyperinvasive phenotypes in some organisms including multidrug resistant (MDR) 
Salmonella enterica serovar Typhimurium (Brunelle et al., 2013). In this case, antibiotics 
cause the circumvention of temporally-regulated gene expression, inducing early and 
fully invasive phenotypes by upregulating hilA, prgH and invF. Similar to several other 
cases, this phenotype was found not to be ubiquitous, and did not occur in all S. enterica 
strains. Increasing the ability of organisms to adhere, internalize, and form antibiotic 
tolerant biofilms subverts early immune responses and increases infection severity. Of 
note, the vast majority of studies conducted thus far have relied on in vitro models, with 
in vivo characterization not considered. Clearly, the latter types of investigation are 
required to ensure the clinical relevancy of these observations, and to raise concern over 
the legitimacy of these claims. This formed a component of the current thesis. 
 
1.1.3 Immunomodulatory effects of antibiotics 
In addition to their potent bactericidal properties, some antibiotics have been 
demonstrated to have immunomodulatory functions which can affect the host. The 
majority of these responses seem to limit immune activation, and have been demonstrated 
primarily in macrolide and quinolone agents (Kanoh and Rubin, 2010; Dalhoff and 
Shalit, 2003). Most antibiotics which demonstrate immunomodulatory properties appear 
to function by augmenting the release of pro-inflammatory cytokines. Specifically, 
macrolides are well documented in dampen the release of interleukin (IL)-8 and tumor 
necrosis factor alpha (TNFα) (Čulić et al., 2001), while fluoroquinolones are capable of 
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suppressing IL-1α and TNFα, and superinducing IL-2 (Araujo et al., 2002; Riesbeck et 
al., 1998; Anderson et al., 2010). Although it is largely unknown how antibiotics 
modulate these processes, interruption of normal protein kinase A (PKA) activity is 
believed to play a role (Song et al., 2007). Antibiotics exhibiting immunomodulation 
often demonstrate phosphodiesterase inhibition which results in cellular cAMP 
accumulation, superoxide anion generation and subsequent inhibition of cytokine 
production (Blaine et al., 1997; Ono et al., 2000). Macrolides have been shown to reduce 
the stability and translation of cytokine transcripts resulting in decreased production 
(Wax et al., 2003). This in turn results in decreased immune cell infiltrate to the sites of 
infection or damage. It appears as though antibiotics do not suppress the immune 
response per se, but rather normalize it to basal activation levels, effectively dampening 
otherwise normal responses following stimulation (Shinkai et al., 2008). 
The modulatory properties of several antibiotics have already been taken advantage of 
clinically. For example, macrolide application has demonstrated improved outcome in 
patients suffering with chronic inflammatory pulmonary diseases (Cameron et al., 2012). 
These agents were also associated with decreased in-hospital mortality during treatment 
of community-acquired pneumonia compared to other antibiotics (Martinez, 2004). 
Direct effects on autoimmune diseases such as rheumatoid arthritis have been 
demonstrated, with minocycline decreasing disease activity and tender joint count (Stone 
et al., 2003). Together, these studies suggest that immune-related influences can be 
capitalized upon to yield positive outcomes for many diseases. However, 
immunosuppression also comes at a price, introducing a greater risk of patients going on 
to develop more severe infections including chronic disease, bacteremia, and potentially 
fatal sepsis (Gea-Banacloche et al., 2004). Therefore, characterization of these agents in 
different disease milieu is certainly warranted. 
 
1.1.4 Clinical implications of inadequate antibiotic therapy 
When antibiotics are prescribed, there are many pharmacokinetic, pharmacodynamic, 
host, and bacterial properties which can keep them from either reaching their full 
therapeutic potential, or decrease the period that they remain at levels greater than the 
9 
 
 
MIC (Ambrose et al., 2007). These transient non-suppressive periods provide pathogens 
with a window to replicate, evolve resistance and potentially express toxins. Therefore, 
outlining and understanding factors which limit these periods are critical for improving 
efficacy. A major problem with antibiotic administration today is that many management 
strategies are based on expert opinions and not empirical evidence indicating positive 
outcomes. For example, long-term, prophylactic approaches have not been altered in 
decades despite questionable efficacy and long-term effectiveness (Mattoo et al., 2009), 
and most of the ‘recommended’ drugs have not been formally approved by the US FDA 
for prophylaxis (Enzler et al., 2011). This could lead to inappropriate or unnecessary 
administration of antibiotics for problems that could have been resolved by different 
approaches. Therefore, it is critical for clinicians to understand how the antibiotics that 
they prescribe concentrate in the body and identify and address factors which might 
influence this process.  
The concentration of antibiotics at therapeutic sites is not always determined during drug 
development, with plasma concentration regarded as an appropriate marker for the 
provision of efficacious dose, despite reportedly high interpersonal variation (Drusano, 
2004). Recent studies have revealed poor correlation between vascular concentrations 
and those within the soft-tissue of patients for some antibiotics, with levels often never 
reaching therapeutic potential in certain sites (Matzneller et al., 2013). The situation is 
worse in patients undergoing prophylactic therapy, where antibiotics are present at low 
levels for extended periods (Pomeranz et al., 2000). Single dose therapies are at particular 
risk of falling below the organism's MIC threshold (Dvorchik et al., 2003). It is surprising 
that many prophylactic therapies are still used in practice despite their questionable 
effectiveness and demonstrated potential to increase the risk of developing resistant 
infections (Conway et al., 2007; Mattoo et al., 2009). Counter-intuitively, some 
preventative prophylactic strategies aimed at reducing hospital-acquired infections have 
resulted in more severe and numerous complications (Madden et al., 2010). Similarly, 
perioperative systemic prophylaxis does not necessarily reach uniformly therapeutic 
levels at all anatomical districts and may introduce the potential for off-target effects 
(Campoccia et al., 2010). Physician compliance in following dosing guidelines is 
reportedly poor, with many failing to cease therapy after surgery (Namias et al., 1999), or 
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disregarding intraoperative re-dosing when recommended (Miliani et al., 2009). 
Inadequate intraoperative or excessive post-surgery dosing is associated with increased 
patient risk of bacteremia, and line and surgical site infections (Namias et al., 1999; 
Miliani et al. 2009). Although these authors conclude no causative relationship for 
increased infection risk following inadequate or inappropriate therapy, it is possible that 
the sub-inhibitory levels achieved in situ are modulating the virulence potential of would-
be pathogens. This may explain why short courses of antibiotic therapy can increase the 
risk of developing secondary infections, for example sepsis following transrectal 
ultrasonography-guided biopsy (Patel et al. 2011). In addition, patients having received 
antibiotics within a month prior to sepsis onset are less responsive to therapy and 
associated with worse prognosis (Garnacho-Montero et al., 2003). It is perhaps not 
surprising that the increasing incidence of sepsis over the last 40-50 years may be a result 
of increasing antibiotic use (Martin et al., 2003; Roumie et al., 2005; McCaig and 
Hughes, 1995). 
Other overlooked factors which can influence the levels of antibiotics in the body include 
patient health (diabetes, ischemia, hepatic/renal dysfunction, sepsis), compliance and size 
(Patel et al., 2010; Ambrose et al., 2007). Diseases such as obesity which are becoming 
epidemic worldwide merit special consideration as physiological alterations can occur 
which affect distribution and clearance of antibiotics (Janson and Thursky, 2012). This 
suggests that the 'one-size-fits-all' dosing strategies are outdated, but can be improved 
upon by considering individual patient parameters to arrive at appropriate dosing 
regimens (Falagas and Karageorgopolos, 2010). Studies of the antibiotic-pathogen 
microenvironment indicate factors affecting bodily distribution need to be addressed, as 
the niche occupied by an organism influences its specific response to antibiotics (Zhang 
et al., 2011; Frisch et al., 2011). Recently, the development of antibiotic-leaching 
medical devices has been proposed to deliver agents at local wound sites while avoiding 
the unfavourable side-effects of systemic therapy. However, as is the case with many 
prophylactic therapies, there is an absence of strict harmonized guidelines for the use of 
these coated biomaterials (Campoccia et al., 2010). Specifically, there is no guarantee 
that the desired delivery curve is achieved and that adequate antibiotics diffuse into the 
surgical site in the appropriate period of time. It is possible that organisms could tolerate 
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therapy in what has been referred to as persister states until the device elutes sub-
inhibitory antibiotics and trigger a new infection. This seems to be the case for one 
patient, who was left with gentamicin eluting beads in situ for several years and went on 
to develop resistant infection at the implant site (Neut et al., 2003). For these reasons, it 
has been suggested that the personal and financial ramifications of using antibiotic-
impregnated devices may outweigh any associated benefits (Cummins et al., 2010).  
Together, these studies present overwhelming evidence that the types of antibiotics and 
dosages prescribed by primary caregivers can have broad ranging adverse side effects on 
patients. Inappropriate antibiotic prescriptions have resulted in the loss of life and 
prolonged hospitalization in the past and are unfortunate but avoidable consequences of 
non-specific guidelines and outdated policies (Dancer et al., 2004; Spoorenberg et al., 
2014). Of particular concern is the proposed capacity of antibiotic to propagate chronic 
disease such as recurrent urinary tract infection (UTI) through prophylactic application, a 
practice which is still widely adopted today despite questionable efficacy. Indeed, 
anecdotal evidence has suggested that increased frequency of recurrent UTI correlates 
with widespread antibiotic use (Nickel, 2005). Therefore, the capacity of antibiotics to 
affect disease severity during recurrent UTI is considered in this work. 
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1.2 URINARY TRACT INFECTIONS 
UTIs represent one of the most common diseases caused by bacteria. In 2006 alone, UTIs 
were the cause of 11 million physician visits, 1.7 million emergency room visits and cost 
the US health care system 3.5 billion dollars (Nielubowicz and Mobley, 2010). In 
addition to their high community incidence rate, at 40%, UTIs are also the most common 
cause of hospital acquired infection (Klevens et al., 2002). The female lifetime incidence 
is roughly 50%, with 44% of those infected going on to suffer recurrences within one 
year of initial infection (Raz et al., 2000). Infections in the elderly and prepubescent are 
also common, with subsequent potential for renal scarring in infants carrying severe 
consequences later in life. Comparatively, men suffer from UTI much less often, with 
most infection episodes related to anatomical abnormalities.  
Risk factors for uncomplicated UTI in otherwise healthy individuals include intercourse 
frequency, spermicide use, and familial or personal history of UTI (Foxman, 2010). 
Lower tract involvement includes bladder (cystitis) and urethral infection, while upper 
tract infections involve the kidneys (pyelonephritis) and ureters. Sub-populations of 
individuals with underlying urological abnormalities, spinal cord injury, medical device 
implantation, and diabetes are further susceptible to UTI and classified as complicated 
cases (Foxman, 2010). Cystitis symptoms, which in part are due to mucosal immune 
responses, often include burning and painful micturition, cloudy and odorous urine, 
frequent voiding, urgency and abdominal discomfort, while pyelonephritis is also 
characterized by fever, nausea, vomiting, and flank pain. These symptoms are often 
accompanied by additional signs including gross hematuria (bloody urine) and pyuria 
(the presence of 6-10 polymorphonuclear leukocytes per high powered field of unspun, 
voided midstream urine). 
Although UTI’s can develop into potentially life threatening conditions (eg. 
pyelonephritis, sepsis, kidney failure), most are relatively benign and often self-resolve 
without the need for clinical intervention (Christiaens et al., 2002; Reid et al., 2010). 
Despite this, the sheer number of people affected [150 million UTIs per annum 
worldwide (Stamm and Norrby, 2001)], the economic burden from antibiotic 
prescriptions [one fifth of all oral antibiotics prescribed in Ontario are for treatment of 
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UTI (Daneman et al., 2011)], and capacity to cause serious deterioration in the quality of 
life supports the need for continued research in this field.  
 
1.2.1 Contribution of host immune function to infection risk 
Host genetics strongly influence an individual's susceptibility of developing recurrent, 
chronic and severe UTI. For example, one study found that 42% of family members of 
patients with a history of UTI were UTI-prone compared to only 11% for controls who 
did not have a history of UTI (Stauffer et al., 2004). These hereditary links are believed 
to manifest in part due to the immune functionality of the host. Therefore, significant 
research focus is dedicated to flushing out genetic links which dictate UTI susceptibility, 
with recent studies yielding perplexing findings. Primary resistance to UTI is determined 
by the innate immune system, especially during acute phases of infection. Alterations in 
innate immune functionality can either exacerbate infection or impart protective benefits. 
For example, polymorphisms in genes which affect Toll-like receptor (TLR)-4 signalling 
are associated with decreased immune infiltration and resulting tissue damage. Despite 
their immunodeficiencies, rather than developing more severe infection these individuals 
are often associated with asymptomatic carrier states devoid of typical UTI pathology 
(Fischer et al., 2006). In addition, a polymorphism which decreased TLR4 signalling in 
vitro reduced the risk of recurrent UTI in premenopausal women (Hawn et al., 2009). 
Conversely, children prone to pyelonephritis typically demonstrate a reduced neutrophil 
infiltrate following E. coli infection, often due to deficiencies in the CXCR1 receptor 
(Svensson et al., 2011). These patients are at high risk of going on to suffer from severe 
complications of infection including the development of urosepsis. This dichotomy 
reveals the sensitivity of disease outcome to initial stages of infection, and are likely 
dependent on the cytokine profiles which are generated in response to UTI. This has been 
confirmed in mouse studies which reveal early severe inflammatory responses to 
infection predispose to chronic and recurrent disease. In these mice, elevated IL-6, G-
CSF, and IL-8 analog KC biomarkers were strong predictors of chronic cystitis 
development (Hannan et al., 2010). Conversely, treatment with immunosuppressive 
compounds prior to infection is sufficient to curtail this response and is protective against 
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UTI in this model. It is postulated that the severe collateral damage caused to mucosal 
surfaces by the immune cell infiltrate are responsible for disease sensitization (Hannan et 
al., 2010). 
 
1.2.2 Management strategies for recurrent and chronic UTI 
In general, UTI can be treated readily with short course antibiotic therapy (~3-7 days). 
This is primarily due to their very high urinary concentrations and the widely accepted 
superficial nature of bladder infections (Nickel, 2007). The effectiveness of single-dose 
therapies attest to this, with most antibiotics capable of clearing 90% of episodes (Nickel, 
2007). However, available data support three day, short course therapy for best outcome 
of acute, uncomplicated UTI management. In some cases recalcitrance occurs following 
therapy cessation, resulting in recurrent or persistent infections and warranting the 
application of additional agents. There are various strategies available to manage patients 
with recurrent UTI, including culture directed therapy, long-term, low-dose antimicrobial 
prophylaxis, and post-coital antimicrobial prophylaxis (Nickel, 2005; Barber et al., 
2013). During therapy, symptoms abate and bacterial loads in voided urine decrease. 
However, it has been shown that prophylactic strategies do not alter the long-term risk of 
recurrence, as infection rates return to pre-treatment levels following therapy (Nickel, 
2005) and device associated organisms are rarely cleared (Warren, 2001). In 2007 
Conway et al. showed in a retrospective study that antimicrobial prophylaxis did not 
reduce risk of recurrence after initial infection, and actually increased the risk of 
producing resistant organisms. Problems such as these question the effectiveness of 
antimicrobial prophylaxis in managing device-related and recurrent infections, and 
whether the benefits of such treatments outweigh the risk of promoting resistance. 
 
1.2.3 Issues with antibiotic therapy strategies and resistance 
In general, UTIs receive little recognition in the infectious disease research community. 
This is likely due to the perception that although common, UTI pose little individual risk 
of complication. However, issues with UTI extend far beyond individual morbidity. As 
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they are one of the largest contributors of antibiotic prescription (Daneman et al., 2011), 
it is not unreasonable to recognize UTI as one of the greatest driving forces behind 
antibiotic resistance (Johansen et al., 2006). Unsurprisingly, countries with a higher 
consumption of antimicrobials have a higher incidence of resistance (Mackenzie et al., 
2007).  This is reflected clinically, and despite their historic success in ameliorating acute 
cases, antibiotic therapy failure for UTI is on the rise (Pallett et al., 2010; Gupta et al., 
2001). For example, current first-line empiric therapy has largely included the use of 
trimethoprim-sulfamathoxazole (co-trimoxazole). However, this agent is associated with 
a high resistance potential, and communities are experiencing unparalleled rates of highly 
resistant and untreatable strains (Manges et al., 2001). Physicians have responded to this 
all-too-common problem by turning to fluoroquinolones for relief (Hooton, 2003). This 
practice has in turn resulted in increasing resistance rates against this important drug class 
(Johnson et al., 2008).  
Bacteria are able to take advantage of antibiotics to increase de novo mutation frequency 
and resistance, but are also able to enhance the acquisition of foreign resistance and 
virulence elements (Blazquez et al., 2012). The impressive plasticity and adaptability of 
these organisms is realised when considering the multiple approaches used to increase 
their chance of surviving lethal antibiotic dosing. For example, antibiotic stress often 
results in the egress of mobile genetic elements such as IS-, phage-encoded virulence 
genes, integrating conjugative elements and phage-related pathogenicity islands, 
permitting their transfer to new organisms via horizontal gene transfer (HGT) (Schreiber 
et al., 2013; Beaber et al., 2004). Generally, mobilization is accomplished through the 
activation of the ubiquitous, general stress response system SOS, which is involved in 
double-strand DNA break repair. This results in the transcription of integrase, and 
cleavage of phage repressors via activated RecA and subsequent egress of mobile 
elements (Cambray et al., 2011). However, antibiotic stress in organisms lacking SOS 
response systems can also potentiate transformation through the establishment of 
complement-type states and release of DNA via in trans allolysis (Prudhomme et al., 
2006). These processes could hypothetically contribute to the increasing frequency of 
recurrent UTI that has been observed since the widespread use of antibiotics. 
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Activation of SOS, and other general stress response systems such as RpoS results in 
low-fidelity PolIV expression, depletion of MutS and a reduction in mismatch-repair 
activity which induces hypermutator phenotypes (Gutierrez et al., 2013; Kahrstrom, 
2013). Beta-lactam, fluoroquinolones, aminoglycosides, tetracyclines and 
chloramphenicol all activate these systems to some degree in most organisms (Gutierrez 
et al., 2013; Kahrstrom, 2013; Foster, 2007; Baharoglu and Mazel, 2011). Pathogens 
appear to have adapted to antibiotic stress by increasing their genetic flexibility, which 
results in acquisition of resistance through a number of mechanisms. Concentrations of 
antibiotics several hundred times lower than the MIC can enrich resistant mutants and 
result in development of de novo resistant strains (Gullberg et al., 2011). Additionally, 
the acquisition of multiple copies of resistance elements can be accomplished through 
fluoroquinolone-dependent homologous recombination and homologous, redundant 
expansion of resistance determinants (López et al., 2009). The importance of such 
genetic changes extends beyond the test tube, and has been shown to promote resistance 
and epidemic hospital infections (Hocquet et al., 2012). Perhaps most worrisome is that 
these changes are cross-adaptive; that is, one antibiotic is capable of improving resistance 
against the same and multiple agents. In many cases, this occurs through the antibiotic-
dependent expression of endogenous efflux pumps which indiscriminately clear noxious 
agents from the intracellular environment (Mc Cay et al., 2010). Sub-inhibitory antibiotic 
treatments also have the capacity to increase tolerance through slight, stepwise changes to 
MICs often resulting in cross-resistance (Kohanski et al., 2010). This is in contrast to 
highly-resistant mutants that appear spontaneously through selection and demonstrate 
little-to-no cross-resistance (Kaufmann and Hung, 2010). These problems are often 
recurring themes in the prophylactic management of recurrent UTI, as antibiotics are 
present throughout the course of dosing at concentration below the therapeutic threshold. 
 
1.2.4 The importance in characterizing recurrences: relapse 
versus re-infection 
Recurrences in the absence of resistance are believed to occur via one of two ways. The 
first involves re-inoculation of the bladder with organisms derived from the 
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gastrointestinal environment (re-infection). Indeed, transfer of organisms via the fecal-
perineal-urethral route is common and supported with genetic evidence (Yamamoto et 
al., 1997). These types of infection are identified using genome sequencing, designating 
new pathogens through strain variation from previous infection episodes. When re-
infected patients are followed over a period of three months with daily urine and 
periurethral cultures, 75% of the strains causing recurrences were found to originate from 
the gut (Nickel, 2007; Chen et al., 2013). Although it can be concluded that re-
inoculation occurs in the vast majority of cases, it is also postulated that uropathogens 
can persist in dormant states within the urinary tract from previous infections, even with 
antibiotic intervention, and relapse (persistent infection) (Schilling et al., 2002). In this 
manner, organisms may be present within the urinary mucosa but not detected by 
standard culturing techniques. Evidence supporting this hypothesis is also generated 
through sequencing, which delineates genetically identical organisms from previous 
infection episodes (same-strain recurrent UTI) (Jantunen et al., 2002). In addition to 
increasing the risk of recurrence, these intracellular communities may explain other 
diseases whose aetiology remains unknown such as interstitial cystitis and overactive 
bladder. This is supported in murine studies which demonstrate animals resistant to 
antibiotic-clearance present with micro-abscesses in their urothelial tissue (Hannan et al., 
2010), albeit these findings do not disprove re-inoculation of the same organism from the 
gut.  
Although it might seem trivial, differentiating infection sources is critical for outlining 
the problem of recurrence, and in designing an appropriate management strategy. 
Continuous re-inoculation of pathogens from the gastrointestinal tract could theoretically 
be curtailed through alterations in hygienic practices, but studies have shown that 
cleanliness of the genitalia alone is not to blame for females suffering from repeated UTI. 
On the other hand, sexual activity is influential by depositing urethral and vaginal 
organisms into the bladder (Stauffer et al., 2004). In general, application of prophylactic 
antibiotics in this patient cohort is unwarranted, and may actually make conditions worse 
through the selection of resistant organisms (Kodner et al., 2010). However, physicians 
still prescribe long-term extended use prophylactic therapy for such cases (Enzler et al., 
2011). Alternatively, and especially in situations where sexual activity is believed to be a 
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major driving factor for recurrence, post-coital or patient directed therapies have been 
met with success (Kodner et al., 2010; Nickel, 2005). In this manner, the antibiotic is 
only supplied when it is perceived to be required, but depending on the frequency of 
sexual encounters, this could accumulate to be a lot of antibiotic use over time, all with 
consequences for the organisms and patient. In the case of persistent UTI, recurrences are 
thought to be driven by deficient host immune status or enhanced pathogen virulence, and 
long-term, prophylactic therapy is relied upon to decrease pathogen burden while 
ameliorating symptoms. However, whilst the desirable outcome of decreased symptoms 
and ameliorating infection can be achieved, breakthrough infections still occur and the 
treatment may be forcing bacteria to become more recalcitrant within the bladder, as will 
be discussed later. 
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1.3 PATHOGENIC MECHANISMS OF COMMON 
UROPATHOGENS 
 
1.3.1 Pathogenesis of Gram-negative UTI 
Although host factors certainly contribute to infection risk and severity, it is generally the 
virulence traits of pathogen which dictates disease progression. Enteric bacteria are the 
leading cause of UTI, the foremost of which is uropathogenic Escherichia coli (UPEC) 
which represents the cause of 75-90% of uncomplicated infections (Laupland et al., 
2007). E. coli is a Gram-negative, facultatively anaerobic, non-sporulating, rod shaped 
organism which is also a normal constituent of the gut microbiota. These traits, in 
addition to its resourcefulness in utilizing a diverse array of carbon sources, rapid 
replication rate and ability to survive in a wide variety of unfavourable environments are 
all factors that make this organism an important uropathogen. In addition to its high 
incidence, UPEC are often associated with recurrence and chronic lower tract infection 
(cystitis), necessitating application of long-term, prophylaxis management. The ability of 
UPEC to initiate such deep-rooted and stubborn infections is attributed to the wide array 
of virulence factors at its disposal (Norinder et al., 2012). While genetic studies of 
organisms isolated from human subjects have assisted in the search for critical 
uropathogenic virulence traits, murine models of disease which have been instrumental in 
elucidating the complicated interplay between host and pathogen. 
Murine models provide an ideal stage with which to study uropathogenesis. Mice are 
readily inoculated, easily monitored in time with urinalysis, and flexible with regards to 
the wide array of established genetic backgrounds which are available (Hung et al., 
2009). The biology of their urinary tracts, methods of urine voiding and host defense 
strategies are analogous to those found in humans. Prior to initiating infection, UPEC 
must ascend the urethra against urine flow in order to access the bladder. Deficiencies in 
this aspect of host defense are common in incontinent patients, and predispose to 
recurrent cystitis (Raz et al., 2000). In murine models of UTI, uropathogens are directly 
inoculated into the bladder, effectively subverting this aspect of host defense. Rapid 
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adhesion to the bladder mucosa is essential to avoid clearance during urine voiding 
(Thomas et al., 2002).  
The urinary tract is characterized by a pseudostratified epithelial layer containing the 
transitional epithelium, with the bladder covered with a single layer of unique, terminally 
differentiated superficial umbrella cells (urothelium) (Wu et al., 2009). Superficial 
umbrella cells are coated in a plaque of uroplakin which constitutes the asymmetrical unit 
membrane (AUM), and consists of four proteins, UPIa, UPIb, UPII, and UPIIIa, in 
addition to the extracellular proteoglycan mucin layer (Wu et al., 1994). Together, the 
role of the AUM is to provide structural support to superficial umbrella cells during times 
of bladder distension as well as regulating membrane permeability (Sun et al., 1996). 
These urothelial components are also thought to play an integral role in preventing 
intimate bacterial contact with the host. This is achieved through the negative charge 
imparted by the highly sulfated and carboxylated glycosaminoglycans of the AUM 
(Parsons et al., 1990). However, these defenses can be overcome by UPEC which express 
type 1 fimbriae, capable of binding mannosylated residues of the uroplakin UPIa using 
the tip adhesin FimH (Connell et al., 1996; Xie et al., 2006). Type 1 fimbriae are 
demonstrated to be critical to establishment of UTI and found in 80% of UPEC strains 
(Buchanan et al., 1985; Keith et al., 1986), and are highly upregulated in the urinary 
environment (Gunther et al., 2001). Type 1 fimbriae are phase variable, and the presence 
of both fimbriated and afimbriated organisms contributes to UTI in adherent and 
planktonic phases respectively, with both states of colonization important for 
pathogenesis (Lim et al., 1998). The production of highly mannosylated Tamm-Horsfall 
protein (THP - uromodulin) in the urine is a host defense component which capitalizes on 
the critical nature of type 1 fimbriae to UPEC infection, by binding and sequestering 
organisms from the host surface (Pak et al., 2001). On the other hand, it has been 
suggested that in some cases, THP can act as a substrate to which the UPEC adhere, 
thereby enhancing the risk of infection (Hawthorn et al., 1991) 
Once UPEC have accessed the urothelial surface, they rapidly invade superficial umbrella 
cells. This process is critical to the establishment of acute infection, and is thought to be 
mediated by the interaction of type 1 fimbriae with UPIa as it is the primary target of 
FimH. Binding then results in phosphorylation of the uroplakin receptor complex which 
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triggers invasion (Martinez et al., 2000; Zhou et al., 2001; Thumbikat et al., 2009; Wang 
et al., 2009). Internalization is mediated by the activation of Rho GTPases which triggers 
actin rearrangement and UPEC engulfment via a zippering mechanism (Martinez and 
Hultgren, 2002). Upon accessing the cytoplasmic environment, UPEC begin to 
proliferate rapidly, forming large, multicellular aggregates dubbed intracellular bacterial 
communities (IBCs) (Anderson et al., 2003). Although IBC formation has been observed 
in several species of Enterobacteriaciae, Gram-positive organisms do not appear to 
possess this pathogenic mechanism. These unique bacterial aggregates do not form in 
undifferentiated urothelial cells, making study of this process in vitro difficult. It is 
believed that the dense actin networks within undifferentiated cells (such as those found 
in immortalized lines) hinder this aspect of UPEC pathogenesis as actin destabilization 
agents induce the formation of IBC-like bodies in vitro (Mulvey et al., 2001; Berry et al., 
2009; Eto et al., 2006).  
Within this intracellular niche, UPEC are resistant to both the host immune system and 
antibiotics. This has been confirmed in vivo, as UPEC reservoirs in murine bladder 
tissues were not eradicated against a panel of 16 antibiotics representing several distinct 
drug classes (Blango and Mulvey, 2010). Generally, IBC formation begins immediately 
following invasion, and continues until 16-24 hours post infection, with the majority of 
UPEC found intracellularly at 12 hours post inoculation (Mulvey et al., 1998). During 
these later time points, UPEC undertake a filamentous morphology, fluxing away from 
the core IBC into neighbouring cells or emerging from the apical surface of dying 
urothelial cells (Justice et al., 2004). The process of umbrella cell evacuation also 
coincides with exfoliation of this urothelial layer (Mulvey et al., 1998; Justice et al., 
2006). This host immune mechanism is thought to expel adherent and IBC contained 
UPEC through urination, which is frequent during infection. As umbrella cells are lost, 
basal elements of the urothelium differentiate to fill their void. These pseudo-differentiate 
cells might hinder further rounds of UPEC invasion and IBC formation, and are thought 
to contribute to pathogen clearance in mice which spontaneously resolve infection 
(Justice et al., 2004). However, it is possible that UPEC are capable of invading distal 
layers of the urothelium through filamentation, resulting in formation of quiescent 
intracellular reservoirs (QIRs) which could feasibly contribute to future episodes of UTI 
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(Mysorekar and Hultgren, 2006). The dynamic interplay between host mucosal immunity 
and UPEC pathogenesis represents an elegant example of a co-evolutionary process. 
 
1.3.2 Pathogenesis of Gram-positive UTI 
Staphylococcus saprophyticus is the second leading cause of uncomplicated UTI and is 
implicated in approximately 10-15% of cases, affecting roughly 1 million women in the 
US alone each year (Schneider and Riley, 1996). It is a Gram-positive, coagulase 
negative uropathogen which is identified clinically on the basis of endogenous 
novobiocin resistance and lack of hemolysin activity (Raz et al., 2005; Mctaggart and 
Elliot, 1989). Compared to UPEC, the mechanisms involved in S. saprophyticus 
pathogenesis are not well understood. However, like E. coli, the major reservoir for this 
uropathogen is the gastrointestinal tract and perineal skin (Latham et al., 1983). The 
majority of infections caused by S. saprophyticus occur in young, sexually active women, 
with colonization more frequent during the summer and fall (Wallmark et al., 1978).  
A high infection frequency is likely due to the wide array of virulence factors at S. 
saprophyticus’ disposal that grant it tropism to the urogenital tract, specifically the 
kidneys (Kline et al., 2010). Reports have placed S. saprophyticus as causing ~13% of 
upper UTI, a higher incidence than that communicated for other uropathogens (Hedman 
and Ringertz, 1991). Urease is highly expressed in this organism and appears to be an 
important virulence trait, resulting in more severe infection when present (Gatermann et 
al., 1989). Some other important factors include a fimbrial surface-associated lipase 
(Ssp), lipoteichoic acid, hemagglutinin/autolysin/adhesin fibronectin binding protein, uro-
adherence factors A and B (UafA/UafB), and a surface-associated collagen-binding 
protein (SdrI) (Kline et al., 2010; Matsuoka et al., 2011; Gatermann et al., 1992; Sakinc 
et al., 2005; Sakinc et al., 2006). Of these, the uro-adherence factors appear to play the 
most critical role in pathogenesis, with adhesion greatly reduced in their absence (Kuroda 
et al., 2005). Despite their importance, the ligand for these adhesins is currently 
unknown. To complicate matters further, murine infection models for investigating 
pathogenic mechanisms of S. saprophyticus cystitis are not ideal as Uaf adhesins do not 
interact well with the murine urothelium, indicating the absence of ligand in this 
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organism (King et al., 2011). However, S. saprophyticus is still capable of colonizing the 
kidneys of mice for extended periods of time, and SdrI and Ssp are important for 
persistence in this organ (Kline et al., 2010). Although IBC formation is not observed in 
Gram-positive uropathogens, S. saprophyticus is capable of internalizing into bladder 
cells, presumably representing an important step in pathogenesis and persistence 
(Szabados et al., 2008). Unlike E. coli, the mechanisms for S. saprophyticus 
internalization are not characterized, but are thought to be distinct from those of other 
staphylococci (Szabados et al., 2008). Kidney invasion has not been investigated despite 
the importance of this organ in S. saprophyticus uropathogenesis and persistence. This 
forms a component of studies performed in this thesis. 
Whole genome analysis has revealed an abundance of open reading frames (ORFs) 
important for osmoregulation and ion transport, giving this organism the unique ability to 
persistently colonize the urinary tract despite lacking the extensive arsenal of virulence 
determinants found in S. aureus (Kuroda et al. 2005). S. saprophyticus carries a capsular 
element which appears to have been acquired through HGT due to its lower than average 
GC content. Characterization of this capsule has demonstrated an important role in 
immune evasion through resistance to complement-mediated opsonophagocytosis by 
neutrophils (Park et al., 2010). Encapsulation appears to come at a price, as its presence 
decreases the interaction of Uaf proteins with cellular targets resulting in a reduced 
adherence potential.  
Approximately 10% of S. saprophyticus UTI will result in recurrent infection following 
antimicrobial therapy (Fowler et al. 1981). Although re-infection could explain 
recurrence, intracellular organisms have been implicated in persistent colonization and 
re-emergent infections (Hunstad and Justice, 2010; Szabados et al., 2008). Furthermore, 
S. saprophyticus’ propensity to colonize medical devices resulting in recalcitrant 
infections is reminiscent of other coagulase negative staphylococci (Lang et al. 1999). 
Often, treatment of colonized devices involves removal and stringent antimicrobial 
therapy. Device replacement of chronically implanted individuals can occur quite 
frequently, greatly increasing patient morbidity and decreasing quality of life. 
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1.4 MECHANISMS OF BACTERIAL PERSISTENCE AND 
ANTIBIOTIC TOLERANCE 
In addition to achieving persistence in the urinary tract through pathogenic mechanisms, 
infecting organisms must also be able to withstand exposure to antibiotics. Bacterial 
survival following appropriate therapy is normally attributed to genetically resistant 
organisms; however, nearly all species also possess transient, phenotypic, multidrug-
tolerant (MDT) members called persister cells, named for their capacity to persist despite 
exposure to a lethal antibiotic dose. Although the evidence has been largely 
circumstantial, persisters are thought to play a role in treatment failure and in further 
pathogenesis of chronic diseases such as cystic fibrosis, recurrent UTI and tuberculosis 
(Goneau et al., 2014; Blango et al., 2010; Keren et al., 2011; Mulcahy et al., 2010). The 
role of persisters in such infections may largely be overlooked as they are not tested for 
during routine clinical microbiology diagnostic procedures. 
 
1.4.1 The nature of MDT 
Since their discovery by Joseph Bigger in 1944, persisters have remained largely 
unclassified and poorly characterized (Bigger, 1944). However, they are generally 
believed to comprise a fraction of the overall population (~0.01%), and are thought to 
have suppressed metabolic activity and replicative capacity which prevents antibiotic 
activity (Lewis, 2010). The bactericidal nature of antibiotics is thought to be mediated 
through the corruption of cellular machinery, preventing them from performing their 
normal functions required for homeostasis. Genetic resistance is achieved by preventing 
this interaction, either by altering target antibiotic binding sites, destroying or modifying 
the drug, or active removal via cellular efflux (Wright, 2005). Conversely, it is postulated 
that reduced activity would confer a protective phenotype (Lewis, 2010). Thus, 
physiological changes are thought to confer MDT in persisters. 
A consensus regarding the nature of MDT has yet to be reached, with two scientific 
camps disputing whether persisters represent truly dormant bacterial variants or simply a 
slow growing sub-population of the greater culture (Goneau et al., 2014; Balaban el al., 
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2004; Wakamoto et al., 2013; Johnson and Levin, 2013). Initial experiments involved 
sorting dormant organisms from the remaining, metabolically active population. 
Importantly, these sorting experiments successfully demonstrated that dormancy 
correlated with persistence, as dormant populations had 20-times more persisters than 
normally growing populations (Shah et al., 2006). However, the authors also conclude 
that dormancy alone is not necessary and sufficient to explain persistence. In addition, 
most persisters demonstrate levels of mRNA which can be extracted and amplified. With 
its short half-life, the presence of mRNA is indicative of active transcription, suggesting 
at least some level of physiological activity is present in persisters (Hu et al., 2000). 
Distinguishing between these two proposed models is critical in evaluating new 
therapeutic targets focused at persister eradication and the amelioration of chronic 
disease. The issue will lie in either learning how to potentiate antibiotics against already 
active persisters, or figuring out how to 'wake them up' from dormancy to enable killing 
(Allison et al., 2011
a
; Allison et al., 2011
b
). The presence of antibiotics within even 
slowly replicating persisters may potentiate hypermutator phenotypes, acquisition of 
resistance traits and establishment of breakthrough infections. Organisms in persister-
related infections such as cystic fibrosis are capable of mutagenesis and increasing their 
persister fraction >100-fold from pre-antibiotic levels (Mulcahy et al., 2010). Since 
persister traits are under antibiotic selective pressure, it is possible that organisms with 
large persister fractions may be refractory to antibiotic therapy in severe infections such 
as sepsis where rapid, successful antimicrobial intervention is critical to patient survival. 
 
1.4.2 Mechanisms and genetics of persister formation 
Although MDT is conferred through physiological changes, genetics certainly dictate the 
dynamics of persistence. Formation is believed to be driven by two processes, with Type 
I persisters classified as non-growing variants which are enriched naturally during late 
exponential and stationary phases (Luidalepp et al., 2011), and slowly-growing and 
dividing Type II persisters whose formation occurs stochastically during exponential 
phase due to random fluctuations in transcriptional and translational noise (Balaban et al., 
2004; Balaban, 2011; Kussel and Leibler, 2005). Enrichment of Type II persisters can 
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occur through various stressors such as antibiotics, resulting in fractions that can range 
from 10-100% of the overall population (Kwan et al., 2013). Such stressors generally 
result in MDT through the activation of various toxin/antitoxin (TA) systems, which are 
believed to provide a common 'emergency stop' response mechanism to halt 
environmental stress (Dörr et al., 2010; Kint et al., 2012; Moyed et al., 1983; Allison et 
al., 2011). This is an intriguing model as TA systems appear to be ubiquitous in 
prokaryotes (Grønlund and Gerdes, 1999; Schuster and Bertram, 2013). TA systems 
usually consist of a stable toxin protein, and a labile RNA or protein antitoxin which 
prevents toxicity. The toxin is involved in disruption of an essential cellular process, such 
as translation interruption via mRNA degradation or decoupling of the proton motive 
force and ATP production (Gerdes et al., 2005). Mutagenesis studies were the first to 
identify the role of TA systems in persister formation, identifying alterations in the hipBA 
locus as predisposing to persistence (Moyed et al., 1983). Characterization of the mutant 
strains, specifically the hipA7 gain of function variant, revealed that decreasing binding 
affinity of the toxin (HipA) for its cognate antitoxin (HipB) was responsible for increased 
persistence and drug tolerance (Korch and Hill, 2006). Since identification of this TA 
system's role in persistence, numerous other TA pairs have been implicated including 
YafQ/DinJ, RelE/RelB, MazF/MazE, TisB/IstR-1 and others, with overproduction of 
RelE increasing persistence as much as 10,000-fold (Keren et al., 2004). The wide array 
of TA pairs involved in persistence demonstrates the redundancy of these systems, 
suggesting no single drug will be capable of overcoming all these bacterial fail-safes. 
Additionally, different mechanisms of onset might indicate that persister cells are 
distinct, and represent a heterogeneous sub-population with unique susceptibilities to 
antibiotics (Allison et al., 2011). In this sense, MDT might not be a function of individual 
persister states, but rather the combined influence of multiple persisters with unique 
susceptibility profiles which contributes to the tolerance of the entire population. 
Activation of TA systems is intimately connected to induction of the SOS response, 
which is also a common mechanism for the establishment of genetic resistance. In fact, 
cells appear to react to stress by either: i) activating stress response elements in hopes of 
resisting it, or ii) converting part of the population to persister states through the 
activation of TA modules. Together, these represent a bet-hedging strategy which permits 
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survival of at least a fraction of the population (Dörr et al., 2010). Dynamic heterogeneity 
within individual cells determines which outcome is selected, and involves the SOS-
inducible Lon protease and subsequent degradation of antitoxin elements (Maisonneuve 
et al., 2011). Several agents appear to induce persister formation in this manner, 
including DNA gyrase, transcription, translation, ATP synthesis and transpeptidase 
inhibitors (Dörr et al., 2009; Miller et al., 2004; Kwan et al., 2013). In this way, 
antibiotics may be capable of propagating chronic and recurrent infections by 
continuously stimulating the formation of persisters.  
Persister cells are also intimately linked to high-density growth states, such as those 
found during stationary phase, increasing in frequency from ~0.01% of the population 
during early-exponential phase to over 10% at later stages of growth (Tashiro et al., 
2012). Persister cells are also enriched in biofilms, where they are thought to contribute 
to antibiotic tolerance which can be up to 1000-times higher than their planktonic 
counterparts (Roberts and Stewart, 2005; Lewis, 2001). When found in biofilms, persister 
cells are not only refractory to antibiotic therapy, but also to immune detection and 
clearance (Lewis, 2007). In many cases, biofilm infections are deep-rooted, associated 
with medical devices or other complicated patient cohorts, and are incurable. 
Surprisingly, quorum sensing does not seem to contribute to formation, as the addition of 
spent culture supernatants containing high concentrations of quorum-sensing compounds 
did not appreciably increase the number of persisters isolated for E. coli (Lewis, 2007). 
Thus, the mechanisms underlying persister formation during these growth stages remains 
a puzzle. 
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1.5 HYPOTHESIS AND OBJECTIVES 
 
It is hypothesized that low-dose antibiotic therapy will increase the risk of chronic 
and recurrent UTI through the modulation of both host and pathogen responses. 
 
As outlined above, the management of patients with recurrent UTI remains a challenge 
due to pathogen re-emergence, resistance and the risk of potentially fatal sepsis. 
Strategies typically rely on the long-term application of low-dose antibiotics as a means 
of discouraging pathogen re-propagation within the urinary tract while avoiding the 
unfavourable side-effects of prolonged exposure at higher doses. Unfortunately, this 
dosing regimen potentiates the presence of antibiotics at sub-therapeutic and sub-
inhibitory concentrations, which appear to influence microorganisms in unexpected ways, 
potentially causing unpredicted changes to virulence traits including adherence, 
invasiveness, and persistence. These changes may be reflected in the questionable 
benefits of prophylaxis which do not seem to alter long-term recurrence risk while also 
often failing to resolve established infection (Nickel, 2005; Williams and Craig, 2009). 
Bacterial changes in response to therapy may also explain cases of antibiotic failure 
despite the absence of resistant organisms (Mulcahy et al., 2010; Levin and Rozen, 
2006).  
This thesis explores these clinical observations in the context of inappropriate 
antimicrobial therapies including prophylaxis by evaluating whether they have the 
capacity to negatively influence host-pathogen interactions during UTI. Agents used 
throughout include ciprofloxacin, ampicillin, and gentamicin, for their extensive clinical 
use and distinct targeting mechanisms. Specifically, the fluoroquinolone antibiotic 
ciprofloxacin targets and corrupts DNA topoisomerases II and IV by selectively 
inhibiting ligase activity while leaving nuclease functionality unhindered (Drlica and 
Zhao, 1997). Constant nuclease activity combined in the absence of ligation introduces 
double-strand DNA breaks resulting in fragmentation. Ampicillin is a beta-lactam 
antibiotic which irreversibly binds to and inhibits the transpeptidase enzyme (Waxman 
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and Strominger, 1983). Continued autolysin activity at the cell wall results in lysis. 
Lastly, gentamicin functions by binding to and inhibiting the 30S subunit of the bacterial 
ribosome. Interruption of protein synthesis and production and intracellular accumulation 
of corrupted protein products results in cell death (Davis, 1987). All three agents share 
characteristic broad-spectrum activity and are bactericidal. 
 
Objectives: 
(1) Examine the effects of sub-inhibitory antibiotics on uropathogen virulence 
Only recently has the capacity of antibiotics to modulate aspects of bacterial virulence 
been explored, and never in the context of uropathogens. As UTI is a major reason for 
antibiotic prescription and results in complicated and debilitating disease in hundreds of 
millions of women worldwide, it is critical to understand how pathogenesis is affected 
during treatment. Thus, the ability of sub-inhibitory antibiotics, targeting distinct cellular 
processes, was assessed for virulence-modulating capacity on both the phenotypic and 
gene expression levels. 
 
(2) Demonstrate the influence of sub-inhibitory ciprofloxacin on uropathogenesis in 
a murine model of UTI 
Although transcriptomic studies are abundant, none have explored the changes in 
pathogenesis which follow sub-inhibitory treatment. Mouse models of UTI are a well 
established experimental system which permit the investigation and characterization of 
antibiotic-induced changes in vivo. Using this model, experiments were conducted to 
demonstrate that in vitro alterations in virulence factor expression are mirrored in vivo 
and influence the ability of the host to clear infection. 
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(3) Understand the ability of uropathogens to persist despite adequate antibiotic 
intervention during infection 
The role of persister cells in chronic diseases is not well documented, and the nature of 
MDT is not clearly defined. However, these unique physiological variants are thought to 
play an important role in recurrence risk following UTI antibiotic management. Thus, the 
importance of persister states in recurrent UTI were investigated using clinical isolates. In 
addition, the contribution of dormancy toward MDT in uropathogens was explored, and 
took into account the dynamics of antibiotic-dependent persister cell induction as well as 
maintenance by analyzing both Type I and Type II persister fractions. 
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MATERIALS AND METHODS 
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2 MATERIALS AND METHODS 
 
2.1 BACTERIAL STRAINS AND CULTURE CONDITIONS 
All media were acquired from BDH (Toronto, ON) or Becton and Dickinson (BD; 
Oakville, ON), with supplements from BDH or Sigma (Mississauga, ON). Bacterial 
strains were cultured from -80°C stocks and routinely grown at 37°C using media and 
conditions conducive to each strains' growth requirements. Unless stated otherwise, 
staphylococci and Escherichia were grown using lysogeny Broth (LB), supplemented 
with antibiotics when appropriate. Minimal inhibitory concentration (MIC) determination 
and antibiotic susceptibility experiments were performed at 37°C in cation-adjusted 
Mueller Hinton (MH) II medium (BDH). Human pooled urine (HPU) was also used as a 
growth substrate. Preparation involved pooling the urine from at least three volunteers, 
filter sterilization using a 250 mL Nalgene Rapid-Flow vacuum filter unit equipped with 
0.22 µm PES membrane (Thermo Scientific, Ottawa, ON), and pH adjustment to 6.5. 
Enumeration of bacterial colony-forming units (cfu) was performed using LB agar 
(Bacto-agar; BD) plates prepared as per the manufacturer's instructions and supplemented 
with antibiotics when required. All experiments made use of cultures grown in 15 mL BD 
Falcon tubes, excluding those involving murine infection models which made use of 100 
mL Erlenmeyer flasks. Cultures were grown statically unless stated otherwise. If shaking 
was implemented it was done so at 200 rpm. 
All strains are listed in Table 2.1. Both E. coli CFT073 [isolated from a woman with 
acute pyelonephritis (Kao et al., 1997)] and S. saprophyticus 15305 [UTI isolate (Shaw et 
al., 1951) - type strain] were purchased from the American Type Culture Collection 
(ATCC, Manassas, VA, USA), while the UPEC clinical isolates E. coli TOP277, 
TOP263, TOP379, TOP344, TOP345, PUTS277, PUTS278, PUTS1127, PUTS1236 and 
UTI89 (attHK022::COM-GFP; kanamycin-resistant, Kan
R
) were kindly provided by Dr. 
Scott Hultgren (Washington University School of Medicine, St Louis, MO). Briefly, each 
strain was derived from a distinct patient presenting with recurrent UTI. Patients were 
sampled over time and organisms isolated from each infection episode were sequenced  
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Table 2.1 Bacterial strains used in this study 
a
 American Type Culture Collection (ATCC) 
 
 
 
 
 
Strain (type)  Source 
S. saprophyticus strains 
   15305 
  
ATCC
a
 
   15305:C1  Toshiko laboratory 
   7108  Hultgren laboratory 
E. coli strains 
   CFT073 
  
Our laboratory 
   UTI89 attHK022::COM-GFP:Kan
R
  Hultgren laboratory 
   UTI89 pANT4::GFP  Hultgren laboratory 
   UTI89 ΔfimS (ΔfimA-fimH)  Hultgren laboratory 
   UTI89 ΔfimH  Hultgren laboratory 
   UTI89 ΔrecA  Justice laboratory 
   UTI89 lexAT355G  Justice laboratory 
   TOP277  Hultgren laboratory 
   TOP263  Hultgren laboratory 
   TOP379  Hultgren laboratory 
   TOP344  Hultgren laboratory 
   TOP345  Hultgren laboratory 
   PUTS278  Hultgren laboratory 
   PUTS1127  Hultgren laboratory 
   PUTS1236  Hultgren laboratory 
   PUTS277  Hultgren laboratory 
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(Garofalo et al., 2007). If repeat recurrences were caused by the same strain the isolate 
was assigned an SSR designation. Conversely, infections caused by a strain which varied 
from previous infections were designated as AI. SOS-deficient strains E. coli PAS0209 
(ΔrecA) and PAS0211 (lexAT355G; also referred to as lexAG85D or Ind- mutant) derived 
from the UTI89 background were provided by Dr. Sheryl Justice (The Research Institute 
at Nationwide Children's Hospital, Columbus, OH). The acapsular S. saprophyticus C1 
strain derived from the 15305 background was provided by Dr. Toshiko Ohta (Graduate 
School of Comprehensive Human Science, University of Tsukuba, Tsukuba, Japan). 
 
2.2 ANTIBIOTIC SUSCEPTIBILITY TESTING 
Susceptibility testing was performed using the Kirby-Bauer method as per standard 
Clinical and Laboratory Standards Institute (CLSI) guidelines (2007). Briefly, strains 
were grown in MH broth overnight in a shaking incubator (200 rpm) at 37
o
C. Cultures 
were diluted five-fold in phosphate buffered saline (PBS; pH 7.4) and streaked across the 
entire surface of an MH agar plate using a cotton-tipped swab. Ciprofloxacin (CIP-5 µg), 
ampicillin (AMP-10 µg), and gentamicin (GEN-10 µg) test discs (VWR, Mississauga, 
ON) were added each to one third of the plate. Zones of growth inhibition (ZOI - mm) 
around each disk were determined following overnight incubation.  The ZOI for each 
strain was compared to referenced standards to determine the clinically relevant category 
of susceptibility for each antibiotic. 
 
2.3 MINIMAL INHIBITORY CONCENTRATION 
DETERMINATION 
The MICs to ciprofloxacin, ampicillin, and gentamicin (Sigma) was determined for all 
organisms using the broth microdilution technique outlined by the CLSI (2007). Briefly, 
strains were grown in MH broth overnight in a shaking incubator (200 rpm) at 37
o
C.  
Cultures were then inoculated into MH broth containing various two-fold dilutions of 
antibiotics and grown statically for 24 hours in a 96-well plate. The MIC was regarded as 
the last well demonstrating growth based on turbidity. Experiments were carried out with 
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at least three independent replicates. MIC quality control was performed using control 
organisms recommended by the National Committee for Clinical Laboratory Standards 
with known MIC values for antibiotics used in this study. Optimal sub-inhibitory 
antibiotic dosing strategies were evaluated to determine concentrations which confer 
phenotypic effects without perturbing growth. Although a range of concentrations were 
considered, 1/4MIC levels were the maximal dose that organisms could tolerate without 
loss of fecundity. Therefore, this dose was used throughout unless stated otherwise. 
 
2.4 MICROSCOPE SLIDE ADHERENCE ASSAY 
Overnight (24 hour) cultures of S. saprophyticus 15305 grown in HPU were diluted 100-
fold into fresh HPU and incubated for three hours. Ciprofloxacin, ampicillin, gentamicin 
or vehicle were applied at 1/4MIC levels and incubated for one hour to permit 
establishment of physiological changes. Following this period, 100 µL of culture were 
transferred to the surface of uncoated glass microscope slides. Slides were covered and 
incubated for 30 minutes to permit organism adhesion. Experiments were conducted in 
duplicate. Slides were rinsed gently for 5-10 seconds with PBS to remove weakly 
adherent or unbound organisms, heat fixed, and stained for two minutes with crystal 
violet. The number of adherent S. saprophyticus 15305 was determined by enumerating 
the number of clearly defined organisms in at least five representative fields of view 
(FOVs) at a magnification of 1000x on an Axioskop microscope (Carl Zeiss, Toronto, 
ON). 
 
2.5 STENT AND CATHETER ADHERENCE ASSAY 
Overnight (24 hour) cultures of S. saprophyticus 15305 grown in LB were reconstituted 
1000-fold in fresh media. After a three hour recovery period, 1 mL of culture was 
transferred to a microfuge tube containing 1 cm segments of either Foley urethral catheter 
(BARD Medical, Covington, GA) or InLay Optima® ureteral stents (BARD Medical). 
Ciprofloxacin, ampicillin, gentamicin, or vehicle were applied at 1/4MIC levels to the 
cultures, and incubated for one hour at 37°C. At this point, 10 µL of cultures were 
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extracted from each treatment group and dilution plated to obtain total population 
numbers (each sample served as its own control). Stents and catheters were removed, 
washed twice with PBS to remove loosely attached organisms, and placed in fresh 
microfuge tubes containing 1 mL of PBS. These tubes containing the washed stents and 
catheters were transferred to a Branson 1200 ultrasonic water-bath (Emerson, Danbury, 
CT) and sonicated for 10 minutes to liberate adherent organisms. Samples were extracted 
from each tube and dilution plated to determine the number of adherent S. saprophyticus 
15305. 
 
2.6 BIOFILM FORMATION ASSAYS 
Since, ciprofloxacin, ampicillin and gentamicin are capable of inducing the SOS 
response, it is reasonable to postulate that observed antibiotic-dependent modulation of 
adherence and biofilm formation is driven through the activation of this regulon. This 
hypothesis was tested by comparing the biofilm-priming potential of antibiotics in wild-
type and SOS deficient strains of E. coli UTI89. SOS-deficient strains consisted of 
PAS0209 (ΔrecA) and PAS0211 (lexAT355G - has T-to-G change at position 355 of 
encoded by lexA; also referred to as LexAG85D or Ind mutant) derived from the UTI89 
background. Both strains were utilized in order to compare and contrast the contribution 
of severe (ΔrecA) and moderate (lexAT355G) double-strand DNA break repair and SOS 
deficiencies. 
Overnight (24 hour) cultures of S. saprophyticus 15305 or E. coli strains UTI89, 
PAS0209, and PAS0211 grown in LB were reconstituted 1000-fold in fresh media but 
not incubated further. The wells of a 96-well plate were prepared by loading with various 
sub-inhibitory concentrations of either ciprofloxacin, ampicillin, gentamicin, or vehicle in 
100 µL of LB. Organisms were added at 10 µL per well, plates were sealed, then 
incubated for either 24 or 48 hours at 37°C. If incubation periods continued for longer 
than 24 hours, wells were washed and replaced with fresh LB containing the appropriate 
concentration of antibiotic. Following these incubation periods, wells were washed with 
PBS three times to remove planktonic and weakly adherent organisms, stained with 
crystal violet for two minutes, washed again with cold dH20 and decolorized with 100 µL 
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70% ethanol. Biofilm abundance was determined by measuring the absorbance at 600 nm 
(OD600). 
 
2.7 SCANNING ELECTRON MICROSCOPY PROTOCOL 
Samples examined using scanning electron microscopy (SEM) were prepared as 
described above (stent and catheter adherence assay). Once organisms had adhered and 
stent and catheter material had been washed, samples were exposed to a pre-fixative 
solution containing 2.5% glutaraldehyde (Sigma), 50 mM L-lysine monohydrochloride 
(Sigma), and 0.75% Ruthenium Red (Sigma), in 0.2 M cacodylate buffer (pH 7.4), as 
described by Williams et al. (2010). Material segments were soaked in pre-fixative for a 
period of 20 minutes, then transferred to a fresh pre-fixative solution excluding the 50 
mM L-lysine for 24 hours, as per the protocol of Priester et al. (2007). Following pre-
fixative treatment, samples were rinsed in cacodylate buffer three times for 10 minutes, 
placed in a 2% solution of osmium tetroxide (OsO4; Sigma) in cacodylate buffer for two 
hours, then rinsed with cacodylate buffer three times for 10 minutes. Following rinsing, 
stent and catheter segments were placed in increasing concentrations of ethanol, from 
70% to 95% to 100%, three times for 20 minutes each. Samples were placed in a 
desiccator following critical point drying for at least 24 hours or until imaged.  
Imaging of samples was conducted at Surface Science Western (Western University, 
ON). Prior to imaging, stent and catheter segments were coated using platinum 
sputtering. All samples were imaged using a Hitachi S-4500 field emission SEM with 
Quartz XOne EDX system (at 10 kV. Energy dispersive X-ray (EDX) spectroscopy was 
used to determine the elemental composition of surfaces in different treatment groups. 
 
2.8 NEGATIVE STAINING AND ANALYSIS BY 
TRANSMISSION ELECTRON MICROSCOPY 
Bacteria were allowed to absorb onto Formvar® (SPI-Supplies, Toronto, ON), or carbon-
coated copper grids for one minute.  Grids were washed in dH2O and stained with 1% 
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aqueous uranyl acetate (Ted Pella Inc., Redding, CA) for one minute.  Excess liquid was 
gently wicked off and grids were allowed to air dry.  Samples were viewed on a JEOL 
1200EX transmission electron microscope (JEOL USA, Peabody, MA) equipped with an 
AMT 8 megapixel digital camera (Advanced Microscopy Techniques, Woburn, MA) at 
80 kV. 
 
2.9 IN VITRO UROTHELIUM ADHERENCE AND 
INVASION PROTOCOL 
 
2.9.1 Kidney and bladder cell maintenance 
A498 kidney cells (ATCC HTB-44) were maintained in Eagle's minimum essential 
medium (EMEM; Gibco, Burlington, ON) supplemented with 10% fetal bovine serum 
(FBS) (Gibco), 1% L-glutamine (Gibco), 1% sodium pyruvate (Gibco), and 1% non-
essential amino acids (Gibco). 5637 (ATCC HTB-9) and T24 bladder cells (ATCC HTB-
4) were maintained in RPMI-1640 medium (Gibco) supplemented with 10% FBS and 1% 
L-glutamine. All cells were maintained in T75 flasks, in a 5% CO2 tissue culture 
incubator at 37°C. Cells were routinely passed when confluency reached greater than 
90%. This was accomplished by briefly washing with warm PBS followed by 0.05% 
trypsinization (Gibco) for 6-8 minutes at 37°C and cell dislodgement via gentle tapping. 
After trypsin treatment, cells were either maintained by reconstituting five-fold in a new 
T75 flask with fresh media, or 48 hours prior to infection, 2 x 10
4
 cells were transferred 
to a 24-well plate and grown to confluency. 
 
2.9.2 In vitro tissue culture infection protocol 
Overnight (24 hour) cultures of S. saprophyticus 15305 or the acapsular C1 strain were 
grown in LB were reconstituted 100-fold in fresh supplemented EMEM for A498 kidney 
infections, or supplemented RPMI-1640 medium for 5637 and T24 bladder infections. 
Samples were grown statically for three hours at 37°C with relevant antibiotic treatments 
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at 1/4MIC or vehicle. A498, 5637, or T24 were maintained in 24-well plates and infected 
with pathogen when achieving at least 90% confluency (~1.1 x 10
5
 cells). Prior to 
infection, cells were washed at least thrice with warm PBS, with warm, fresh media 
replaced after the final wash. Infections were conducted at a multiplicity of infection 
(MOI) of 25:1 for S. saprophyticus 15305 per host cell, and carried out for four hours in a 
bacterial cell culture incubator with 5% CO2 at 37°C. 
 
2.9.3 Determining adherence frequency 
Adherence was determined by removing planktonic cells with two PBS washes. Each 
well was then replaced with fresh PBS, and cells lysed with the application of triton X-
100 (Fisher Scientific, Ottawa, ON) solution at 0.1% for 15 minutes at 37°C. Dilution 
plating of the resulting lysate permitted enumeration of the combined 'adherent' and 
'internalized' bacterial populations. As internalization occurred much less frequently than 
adhesion the relative contribution of intracellular organisms to the overall adherent 
population was negligible. Therefore, this value was taken to represent the adherent 
population. This was compared to the total population numbers to determine percent 
adherence. 
 
2.9.4 Determining internalization frequency 
Internalization frequency was determined using gentamicin protection assays. Cells were 
washed two times with PBS to remove planktonic organisms, with wells subsequently 
refilled with fresh media containing 10 µg/mL gentamicin. Samples were incubated for 
three hours in a bacterial tissue culture incubator with 5% CO2 at 37°C in order to kill 
non-internalized organisms. Cells were then washed thrice with PBS, and lysed as 
described. The percentage of intracellular organisms was determined by spread plating 
100 µL of lysate and comparing to total population numbers. 
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2.10 HEMAGGLUTINATION ASSAYS 
Type 1 fimbriae and UafA adhesins readily agglutinate guinnea pig and sheep 
erythrocytes respectively, providing a means for the rapid quantification of surface 
expression following sub-inhibitory antibiotic treatment (Salit and Gotshclich, 1977; 
Kuroda et al., 2005). This assay has the added benefit of directly measuring adhesin 
levels at the bacterial surface which is advantageous over other techniques involving 
RNA expression analysis which might not correlate with true protein expression levels. 
However, this benefit can also be influenced by false negatives when surface components 
interfere with the process of hemagglutination. This has been shown to occur when 
capsule is present (Kuroda et al., 2005; Park et al., 2010). Thus any observable changes 
in hemagglutination could presumably be due to UafA upregulation, or capsule 
downregulation. Therefore, the acapsular S. saprophyticus strain C1, derived from the 
15305 background, was also utilized in addition to the well-characterized capsule-
deficient strain 7108 (Park et al., 2010). 
 
2.10.1 Blood preparation 
Alsevers guinea pig red blood cells (RBC) (Colorado Serum Company, Denver, CO) (E. 
coli hemagglutination) or sheep RBCs (Fisher Scientific) (S. saprophyticus 
hemagglutination) were swirled to mix prior to use. An erythrocyte suspension was 
created by diluting RBCs 10-fold in chilled PBS, inverting several times to mix to avoid 
lysis. Erythrocytes were washed by repeated pelleting (spinning in a clinical centrifuge 
for ~1-2 minutes) and resuspension in chilled PBS until supernatants were clear and 
colourless (usually 1-2 washes). Once clear, supernatant was aspirated, and RBCs were 
resuspended in ~7 mL PBS until OD640 of 2.0 was achieved. RBC suspensions were 
placed on ice until needed. Absorbance was measured using a Eon microplate 
spectrophotometer (BioTek, Winooski, VT). 
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2.10.2 Bacterial  and plate preparation, and assay 
E. coli UTI89, PAS0209, or PAS0211, and S. saprophyticus 15305, or C1 were 
reconstituted 1000-fold from overnight (24 hour) cultures into fresh LB media containing 
1/4MIC of relevant antibiotics or vehicle. In addition to the wild-type strain, the 
acapsular S. saprophyticus C1 strain was used as a positive control for UafA-dependent 
hemagglutination. Organisms were grown in their respective treatment for four hours at 
37°C. Following this period, bacteria were pelleted at 6500 rpm for three minutes and 
resuspended in PBS to OD600 of 1.0. 1 mL of the resulting suspension was transferred to a 
1.5 mL microfuge tube, and centrifuged at 6500 rpm for two minutes using a Sorvall 
Legend Micro 21 centrifuge (Thermo Scientific) to pellet. Supernatants were then 
aspirated, and pellets resuspended in 100 µL of  PBS. 
V-bottom, 96-well plates were prepared by transferring 25 µL of PBS into each well. 
Additionally, % (w/v) a-methyl-D-+-mannopyranoside (Sigma) was also prepared in a 
second plate in a similar manner, and served as a negative control for type 1 fimbriae-
dependent hemagglutination. In duplicate, 25 µL of each suspension was transferred to 
the first column of the plate, and serially diluted two-fold into each subsequent well to 
create a dilution gradient of organisms. 25 µL of the prepared blood suspension was 
added per well, and mixed by gently tapping the plate. Plates were then sealed, covered, 
and placed at 4°C for 2-3 hours prior to analysis. Titers were read by determining the last 
well to display RBC agglutination. 
 
2.11 TYPE 1 FIMBRIAE PHASE VARIATION 
The expression of type 1 fimbriae fim genes is finely regulated by environmental signals 
including growth phase, nutrient abundance and culture flow (Abraham et al., 1985). 
Combined, these signals dictate the percentage of fimbriated cells in the overall 
population, a process which is phase variable and associated with the inversion of a short 
DNA fim-switch element which grants the transcriptional machinery promoter accession. 
The proportion of E. coli UTI89 type 1 fimbriae in the phase ON and OFF orientation 
was assessed using PCR. Antibiotic-dependent induction of the SOS response has been 
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linked to adhesin upregulation in S. aureus (Bisognano et al., 2000). Additionally, SOS-
deficient E. coli UTI89 strains demonstrate decreased virulence potential in a murine 
model of UTI (Justice et al., 2006). Importantly, type 1 fimbriae saturation occurs in 
static cultures, while shaking cultures are generally comprised of phase OFF variants. 
Therefore, shaking cultures were also taken advantage of to permit more sensitive 
identification of antibiotic-dependent phase switching by avoiding the saturation effects 
of static cultures. Organisms were incubated with antibiotic or vehicle for 4, 8, or 24 
hours as previously described prior to phase analysis. At these time points, 1 µL of 
culture would be extracted, and used as DNA template during PCR reactions. 
 
2.11.1 PCR mixes and protocols 
PCR recipe included 5 µL of 10x PCR buffer, 2.5 µL of 50 mM MgCl2, 1 µL of 10 mM 
dNTPs, 1 µL of 10 µM Phase Left Primer, 1 µL of 10 µM Phase Right Primer, 38 µL of 
dH2O, and 0.2 µL Taq DNA polymerase (Thermo Scientific). The master mix was 
prepared for n-reactions by multiplying each reagent by n+1 (not template) and 
transferring 25 µL of the resulting mix to PCR tubes for amplification. PCR primers A 
(5'-GAGAAGAGGTTTGATTTAACTTATTG-3') and B (5'-
AGAGCCGCTGTAGAACTGAGG-3') were used for amplification of the fim switch 
region as described by Roesch and Blomfield (1998). 
PCR amplification protocol included the following steps: i) 95°C for 5 minutes, ii) 95°C 
for 1 minute, iii) 55°C for 1 minute, iv) 72°C for 1 minute. Steps ii) through iv) were 
repeated 35 times for amplification, followed by a final 72°C elongation step for 10 
minutes. If samples were not immediately analysed, they were held at 4°C until required. 
Reactions were carried out on a MyCycler Thermal Cycler (Bio-Rad, Mississauga, ON). 
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2.11.2 Restriction digestion, gel electrophoresis, and ImageJ 
analysis to detect phase 
PCR reactions were split into another tube, so as to permit one tube for restriction digest 
and one tube as an undigested control. 1 uL of HinfI (New England Biolabs, Whitby, 
ON) was added to each tube to be cut, and incubate at 37°C for two hours. 5 uL of each 
digest and 5 uL of the original PCR reaction on was run on a 2.0% agarose gel (in TBE 
with ethidium bromide added directly to gel once sufficiently cooled). The full PCR 
product is 559 base-pairs. HinfI digestion yields 70 base-pair and 489 base-pair products 
for Phase ON, while 200 base-pair and 359 base-pair products are observed for Phase 
OFF. The intensity of the 489 and 359 base-pair products were analyzed and compared 
via densitometric analysis using ImageJ software (http://rsb.info.nih.gov/ij/). 
 
2.12 SOFT-AGAR MOTILITY ASSAY 
Flagella are the driving force behind bacterial motility, and are generally suppressed as 
organisms' transition from planktonic to adherent states (Pesavento et al., 2008). The 
activity of flagella can be measured by assessing bacterial swarming over the surface of 
soft-agar plates. Soft-agar plates (0.3% agar) were prepared by either loading with 
1/4MIC levels of antibiotic or vehicle. This concentration of agar was previously found to 
be ideal for investigating bacterial swarming motility (Croze et al., 2011). E. coli UTI89, 
PAS0209, or PAS0211 were reconstituted 1000-fold in fresh LB without antibiotic, 
incubated at 30°C with shaking (200 rpm) for four hours , and adjusted to OD600 of 1.0 
before being spot-plated onto the surface of antibiotic loaded or unloaded soft-agar 
plates. Organisms were also pre-treated with 1/4MIC levels of relevant antibiotics for 4 
hours as described previously, and spot plated onto the surface of unloaded soft-agar 
plates. These approaches permitted analysis of how antibiotics influence the expression 
and activity of flagella in planktonic phase and surface-bound E. coli. Organisms were 
incubated for 24 hours at 30°C to allow the formation of a swarming zone on the surface 
of soft-agar plates. At this time, the radius of the swarming zone (mm) was measured for 
quantification of swarming motility. 
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2.13 MURINE INFECTION PROTOCOLS 
Murine infections models (Hung et al., 2009) routinely made use of 7-9 week old female 
C3H/HeN or C57BL/6 mice. The animals were obtained from Harlan laboratories 
(Harlan Sprague Dawley® Inc.; Indianapolis, IN) at 6-7 weeks of age, and allowed a 5-7 
day rest period prior to experimentation as stress can have a significant impact on 
reproducibility. For this reason, use of mice greater than nine weeks of age was avoided. 
All animal studies were conducted in accordance to the Guide for the Care and Use of 
Laboratory Animals under the Animal Welfare Assurance number A3381-01, at the 
Washington University School of Medicine, St. Louis (St. Louis, MO). The Washington 
University School of Medicine Animal Study Committee approved all the experimental 
procedures described. Mice were housed in micro-isolator cages in a BSL2 barrier animal 
facility and fed autoclaved standard laboratory rodent diet (Purina) and autoclaved tap 
water ad libitum. 
 
2.13.1 Bacterial and syringe preparation for infection 
E. coli UTI89 and S. saprophyticus 15305 used for infections were inoculated into 10 mL 
LB directly from -80°C freezer stocks, grown statically overnight at 37°C, reconstituted 
in fresh LB media with or without ciprofloxacin and grown for another four hours at 
37°C. These cultures were then centrifuged for 10 minutes at 3000xG, resuspended in 10 
mL of PBS, and diluted to OD600 of 1.0 (~2.0 x 10
8
 cfu/mL). 50 µL of this suspension 
was used to inoculate the bladders of mice via transurethral catheterization. 
Syringes were prepared for infection by applying segments of polyethylene tubing to the 
end of a sterile 30-G hypodermic needle until fully covered. The ethylene tubing was cut 
such that one needle-length was still present after. Enough catheterized needles would be 
prepared such that one catheter was made available per experimental group. Prepared 
catheters were exposed to UV radiation for at least 30 minutes for sterilization. If not 
used immediately, sterile catheters were housed in sterile petri dishes until needed. 
 
45 
 
 
2.13.2 Murine sedation, infection, urine collection, and sacrifice 
Prior to infection, C3H/HeN mice were exposed to 4% isoflurane for induction of 
anesthesia, and subsequently 2.5%-3% isoflurane for maintenance of the anaesthetic state 
with an oxygen flow rate of 0.5 L/minute. However, C57BL/6 mice were induced using 
the above protocol, but maintained at isoflurane levels no higher than 2%. 
Anaesthetization was accomplished using a mobile respirator unit containing an E-
cylinder oxygen tank, gas regulator, and anesthetic vaporizer with reservoir and waste 
anesthetic gas scavenging containers. Five mice could be sedated at any one time using 
this set-up. Mice were constantly monitored for breathing rate to avoid death by 
asphyxiation. If breathing rate dropped to more than four seconds between breaths mice 
were removed from anesthetization. Once a breathing rate of ~1 breath per second was 
achieved, individual mice were removed from the induction chamber and placed flat on 
their back under an anesthetic nose cone to maintain sedation. Anesthetization was 
adjusted accordingly if mice showed signs of waking up (for example, rapid breathing 
and limb movement). Urine was manually expressed by gently massaging and pushing on 
the bladder. Once urine had been voided, a lubricated, catheterized inoculating syringe 
containing the bacterial inoculum was fully inserted into the urethra without resistance. 
Once the catheter was inserted, 50 µL of the bacterial inoculum (~1-2 x 10
7 
cfu) was 
delivered into the bladder at a rate of ~10 µL/second. Following inoculation mice were 
transferred back into the cage and awoken.  
Urine was collected prior to infection, in addition to during the course of infection until 
sacrifice. This was done by applying suprapubic pressure with proper hand-held restraint 
to murine bladders and collecting the urine stream in sterile, 1.5 mL eppendorf tubes. At 
least 20 µL of urine was collected from each mouse. Urine bacterial load (titer) was 
determined via serial dilution in PBS and spot plating (10 µL per drop, 50 µL total per 
plate, per sample).  
Bladders and kidneys were harvested from mice in order to permit determination of 
bacterial load in these organs. Prior to sacrifice, mice were transferred glass jars 
containing cotton balls soaked in isoflurane. Up to five mice were placed into the jar and 
maintained under anesthetic until agonal breathing was observed or breathing ceased in 
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all animals. At this time, all animals were removed from the jar, placed stomach down, 
and sacrificed via cervical dislocation. Sacrificed mice were then placed on their backs, 
and abdominal regions sprayed thoroughly with 95% ethanol to sterilize the site of 
incision. The lower abdomen was cut open using surgical scissors, and manipulated using 
sterile forceps. Bladders and kidneys were excised and placed in either 1 mL or 800 µL 
of sterile PBS respectively for future homogenization and subsequent bacterial 
enumeration. Tissues were mechanically homogenized to liberate bacteria, with 
homogenates maintained on ice until dilution plated (10 µL per drop, 50 µL total per 
plate, per sample). 
 
2.13.3 Ex vivo gentamicin protection assay 
S. saprophyticus 15305 were reconstituted 1000-fold from overnight (24 hour) cultures 
into fresh LB media containing 1/4MIC of relevant antibiotics or vehicle. Samples were 
incubated at 37°C for four hours and transurethrally infected into C3H/HeN mice as 
described. Mice were sacrifice at 3.5 hours post-inoculation (hpi), and bladders were 
excised, bisected twice, and placed in 0.5 mL of PBS. Bladder segments were washed 
three times with PBS to remove luminal S. saprophyticus 15305, then transferred to 
microfuge tubes containing 1 mL of PBS and 100 µg/mL gentamicin. Samples were 
incubated for 90 minutes at 37°C on a rocker. After gentamicin treatment, bladder 
segments were washed two times and placed in 1 mL fresh PBS and homogenized. 
Whole bladders were plated (250 µL/plate) and incubated for 48 hours at 37°C. Isolated 
colonies were confirmed as S. saprophyticus by spraying plates with a combination 
solution of isopropyl β-D-1-thiogalactopyranoside (IPTG) (Thermo Scientific) and 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) (Thermo Scientific). As S. 
saprophyticus 15305 contains endogenous β-galactosidase, conversion of colonies from 
white to blue ensured correct identification. 
 
47 
 
 
2.13.4 IBC visualization using light-microscopy 
E. coli UTI89 were reconstituted 1000-fold from overnight (24 hour) cultures into fresh 
LB media containing 1/4MIC of relevant antibiotics or vehicle. Samples were incubated 
at 37°C for 4 hours and transurethrally infected into C3H/HeN mice as described. The 
animals were sacrificed 6 hpi, and bladders were excised, bisected longitudinally, and 
placed onto a silicone bladder pinning pad. Silicone pads were prepared using silicone 
elastomer (SYLGARD 184; Dow Corning, Columbia City, IN) poured into a 6-well plate 
to about half the well height as per the manufacturer's instructions. Bladders were 
stretched, flattened and pinned in place to the silicone pad luminal side up. They were 
then fixed with 3% paraformaldehyde (Sigma), washed thrice with 2 mM MgCl2 (Sigma), 
0.01% sodium deoxycholate (Sigma), and 0.02% Nonidet P-40 (Roche, Mississauga, 
ON) in PBS. Staining was performed using 25 mg/mL X-gal (Sigma), and a solution 
containing 1 mM potassium ferrocyanide and 1 mM potassium ferricyanide (Sigma). 
After an incubation period of 16 hours at 30°C, bladders were visualized under an 
Olympus SZX12 dissecting microscope (Olympus America, Center Valley, PA), and 
appear as punctate blue stains. 
 
2.13.5 IBC visualization and volumetric analysis using confocal 
microscopy 
IBCs were also visualized using confocal microscopy to permit a more accurate 
determination of size and morphology. Infections and bladder fixation were conducted as 
described, with the exception that E. coli UTI89 carrying the green fluorescent protein 
(GFP)-expressing plasmid pANT4 was utilized. pANT4 is stably harbored during acute 
infection stages (Justice et al., 2004). Fixed bladders were washed and counterstained for 
20 minutes with nuclear ToPro3 (Molecular Probes) stain, and recombinant wheat germ 
agglutinin (r-WGA) to outline superficial umbrella cells (1:700 dilution for each). 
Bladders were imaged using a Zeiss LSM 510 Meta Laser Scanning inverted confocal 
microscope (Thornwood, NY). IBCs were rendered in three-dimensions (3D) via 
reconstructive Z-stacking of images using Volocity 4 image analysis software 
(PerkinElmer, Waltham, MA). Volumetric analysis was also conducted using Volocity 
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software, which calculates GFP volume by counting the number of green pixels within a 
given area of the region defined as an IBC (Anderson et al., 2010). 
 
2.13.6 Empiric ciprofloxacin therapeutic dose determination for 
murine UTI 
Human dosing parameters were used to determine the empiric ciprofloxacin daily dose in 
mice (Iravani et al., 1999). Recommended dosing for humans is set at ~10 mg/kg 
(drug/weight), taken bi-daily for typical therapeutic ciprofloxacin treatment of 
uncomplicated UTI. The average weight of a C3H/HeN mouse is ~20 g. Therefore, these 
mice required a total daily dose of ~400 µg ciprofloxacin for UTI treatment. The average 
water intake for a 20 g mouse was empirically determined to be ~10 mL/day. Thus, the 
drinking water of mice was supplemented with 40 µg/mL of ciprofloxacin to achieve a 
daily therapeutic dose over the course of 24 hours. 
 
2.13.7 Sub-therapeutic ciprofloxacin and UPEC urine titer 
The effect of sub-therapeutic ciprofloxacin dosing on murine response to UTI was 
investigated in both previously inoculated, but resolved mice in addition to chronically 
infected mice. The animals were prepared by inoculating with a dose of 10
8
 cfu of E. coli 
UTI89 as described previously, and were left for at least 30 days to either spontaneously 
resolve infection, or develop chronic cystitis, defined as urine titers of >10
4
 cfu/mL for ≥ 
14 dpi (Hannan et al., 2010). The mice that resolved (<10
4
 cfu/mL ≥ 14 dpi) were 
separated from those that developed chronic infection into cages containing up to five 
mice from the same group.  
The urine titers of mice were monitored for three days prior to initiation of sub-
therapeutic ciprofloxacin supplementation as previously described. This was done to 
ensure that infections had stabilised in each mouse. Ciprofloxacin was supplemented into 
the drinking water for ad libitum consumption. Water intake was monitored and did not 
differ between antibiotic-supplemented and control groups indicating ciprofloxacin did 
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not alter palatability (data not shown). Dosing ranges of <1/25 the empirical therapeutic 
dose were found to not significantly decrease bacterial urine titer over a three day period 
(data not shown). Following optimization of dosing parameters, such that UPEC were not 
negatively influenced by the level of ciprofloxacin present, 1/50th the empirical 
ciprofloxacin therapeutic dose was supplemented into the drinking water and replaced 
each day for 3-6 days. The urine titer of each mouse was monitored daily for changes as 
described. At either three or six days, the dose was further increased to 1/25th the 
empirical therapeutic dose for another 3-6 day period with urine titers again determined 
daily. Lastly, the dose was increased further to 1/10th the empirical therapeutic dose for 
three days to clear infection and ensure spontaneous development of ciprofloxacin 
resistant mutants did not occur. 
 
2.13.8 Human and murine tissue cytokine quantification 
The influence of sub-therapeutic ciprofloxacin dosing on immune activation was assessed 
during the early stages of infection. Prior to infection, mice were supplemented with 
1/50th the empirical ciprofloxacin therapeutic dose for three days. Infections, as 
described previously, were established by inoculation of 10
7
 non-treated E. coli UTI89 or 
control PBS (mock) into mice receiving sub-therapeutic ciprofloxacin or no antibiotic. 
Infections were allowed to develop for 3.5 hours to permit activation of early immune 
response elements. At this time, urines were extracted for later analysis, mice sacrificed, 
and bladders and kidneys excised and snap frozen in liquid nitrogen for future analysis. 
The cytokine expression profiles for murine bladders was conducted using a Luminex® 
bead-based assay. Cytokines were liberated from tissues using homogenization, as 
previously described, in extraction buffer containing 20 mM Tris-HCl (Sigma; pH 7.5), 
150 mM NaCl (Sigma), 1 mM phenylmethylsulfonyl fluoride (PMSF; Sigma), 0.05% 
Tween-20 (Sigma), and a protease inhibitor cocktail (100-fold dilution; Roche). 
Conversely, supernatants from in vitro human T24 tissue cell line experiments were also 
extracted and analysed. Extracts were maintained on ice, centrifuged at 14,000 rpm for 
three minutes, and supernatants removed and stored at -80°C until use. Total protein 
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levels were assess using a bicinchoninic acid (BCA) kit (Thermo Scientific) as per the 
manufacturer's instructions and diluted when required. 
Levels of cytokines IL-1β, IL-6, keratinocyte chemoattractant (KC - also referred to as 
IL-8), granulocyte colony-stimulating growth factor (G-CSF), IL-17, IL-10, and tumor 
necrosis factor alpha (TNFα) were measured using multiplexed immunoassay kits 
according to manufacturers’ instructions (Bio-Rad Laboratories Inc., Hercules, CA). The 
appropriate mouse or human kits were used for each sample. A Bio-Plex 200 readout 
system was used (Bio-Rad), which utilizes Luminex® xMAP fluorescent bead-based 
technology (Luminex Corporation, Austin, TX). Cytokine levels (pg/mL) were 
automatically calculated from standard curves using Bio-Plex Manager software (v. 4.1.1, 
Bio-Rad). Standard curves were generated in extraction buffer containing no protease 
inhibitors.  
Enzyme-linked immunosorbent assays (ELISA) were used to determine IL-8 expression 
levels in human 5637 bladder cells. Infections were carried out as previously described 
(In vitro tissue culture infection protocol), with the exceptions that lipopolysaccharide 
(LPS; Sigma) was added at 5 µg/mL in place of S. saprophyticus 15305 as a cell-free 
control, and ampicillin and gentamicin were also tested at 1/4MIC levels in addition to 
ciprofloxacin. At four hours after incubation of the pathogen with the 5637 cells, 
supernatants were removed, along with bacteria and cellular debris via centrifugation 
(14,000xG for three minutes), and the resulting extracts placed in the wells of a 96-well 
plate and frozen at -80°C until needed. Cytokines were quantified using the Human 
CXCL8/IL-8 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN) as per the 
manufacturer's instructions. 
 
2.13.9 Quantification of urine sediment polymorphonuclear 
leukocyte infiltration 
Urines collected at 3.5 hpi from mice receiving 1/50th the empirical ciprofloxacin 
therapeutic dose were further analysed for their immune cell content. Urine sediments 
were obtained by cytocentrifuging 80 µL of a 10-fold (PBS) diluted urine sample onto 
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poly-L-lysine-coated glass slides using a CytoPro 7620 cytocentrifuge (Wescor, Logan, 
UT). Samples were briefly heat fixed and stained with filter sterilized Protocol 3 Hema 3 
stains (Wright-Giemsa method, Fisher Scientific). Stained urine sediments were 
examined by light microscopy on an Olympus BX51 light microscope (Olympus 
America), and the average number of polymorphonuclear leukocytes (PMN) per 400x 
magnification field (high powered field) calculated from counting at least five fields. A 
semi-quantitative scoring system was used for analysis and is described in Table 2.2. 
 
2.13.10 Model of ciprofloxacin prophylaxis 
In general, the proof-of-principle antibiotic dosing strategies used throughout this work 
are not reflected in real-world therapeutic scenarios. However, low-dose, extended use 
prophylactic strategies are often implemented for the management of recurrent UTI. 
These aim to achieve sub-inhibitory levels throughout the daily dosing period. It is 
possible that these transient, low-dose periods are sufficient to enhance E. coli UTI89 
virulence. Therefore, a mock prophylaxis dosing scheme was applied to the current 
murine infection model. C3H/HeN mice were abandoned for prophylaxis experiments as 
they have a congenital anatomical defect which promotes vesicoureteral reflux and 
subsequent kidney infection (Hung et al., 2009; Hopkins et al., 1995). Instead, C57BL/6 
mice were utilized to avoid this issue. The model involved a 24 hour infection period as 
described previously, followed by a three day regimen of normal co-trimoxazole therapy 
as described by Schilling et al. (2002) (270 µg/mL replaced daily; Qualitest 
Pharmaceuticals, Huntsvill, AL). Together these periods mimic an infection event, 
symptom development, and subsequent initiation of antibiotic therapy. Following therapy 
cessation, mice were provided a seven day rest period prior to initiation of ciprofloxacin 
prophylaxis. They received either a typical prophylactic dose of ciprofloxacin (1/4th the 
empirical therapeutic dose) or vehicle (dH20) daily via oral gavage for seven days. Oral 
dosing was conducted by injecting 100 µL of 1 µg/mL ciprofloxacin directly into the 
stomachs of mice. Following prophylactic therapy, animals were sacrificed, and kidneys 
and bladders excised for bacterial titer, as described earlier. In some cases, murine 
bladders were gentamicin treated for determination of the intracellular population. Urine 
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was taken at least every two days throughout the course of the experiment to allow 
tracking of infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
 
 
 
 
 
 
 
 
Table 2.2 PMN Categorical Scoring Scheme 
Total PMNs
a
  Score 
0-4  0 
5-24  1 
25-49  2 
50-99  3 
100+  4 
 a Per 5x high-powered fields of views [hpf (40x objective)]. 
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2.14 TYPE I AND TYPE II PERSISTER CELL ASSAYS 
Type I persisters were isolated by directly applying lethal concentrations of ciprofloxacin 
(5 µg/mL), ampicillin (100 µg/mL), or gentamicin (10 µg/mL) to stationary phase (24 
hour) cultures of E. coli UTI89, PAS0209, PAS0211, CFT073 or S. saprophyticus 15305 
for three hours and enumerating the surviving fraction before and after treatment (Keren 
et al., 2004). Conversely, overnight cultures were first seeded 1000-fold into fresh LB 
and then grown for ~3 or ~7 hours (for UPEC and S. saprophyticus respectively) to 
deplete the Type I persister population for Type II persister assays (until early-
exponential phase; turbidity of 0.5-0.6 for S. saprophyticus and E. coli at 600 nm). A 
subsequent 1000-fold seed in fresh LB with 1/4MIC antibiotics lasting ~3-7 hours 
(turbidity of 0.5-0.6 at 600 nm) was performed to enrich the Type II persister fraction. 
Following this incubation period, cells were washed and percent survival was determined 
through the enumeration of viable cells prior to and following treatment with lethal 
antibiotics. Colonies were isolated by serially diluting cultures in PBS, spot-plating 10 
µL drops on LB agar, and counting the resulting colonies. In cases where viability fell 
below 1000 cfu/mL, 10 or 100 µL drops would be applied directly from cultures 
reconstituted in PBS and spread over the entire surface of an LB plate. Survival due to 
phenotypic tolerance and not spontaneous resistance was determined by sub-culturing the 
surviving fraction in fresh LB and determining the MIC. 
 
2.14.1 Persister resuscitation assays 
The kinetics of persister resuscitation were determined for both E. coli CFT073 and S. 
saprophyticus 15305 following Type II persister assays. After treating cultures with 
relevant antibiotics at lethal levels, cultures were resuspended in fresh LB, serially diluted 
into the wells of a 96-well plate containing LB, sealed and grown for 21 days at 37°C. 
Wells were marked daily as positive when turbidity was observed. 
 
55 
 
 
2.15 AUTOAGGREGATION ASSAY 
It is well established that organisms in the confinement of adherent high-density biofilms 
are much more refractory to antibiotic therapy then their planktonic counterparts. 
Importantly, this trait is not due to the inability of antibiotics to penetrate the extracellular 
matrix, as most agents readily diffuse to the cores of such films (Singh et al., 2010). 
Therefore, persister cells have been labelled as the biofilm constituents which confer 
high-grade MDT. In addition to surface-dependent biofilm formation, rapid planktonic-
phase aggregation has a positive influence on antibiotic tolerance and host immune cell 
evasion while enhancing adherence properties (Boll et al., 2013; Haaber et al., 2012; 
McNabe et al., 2011). However, it is unknown whether high-density growth is a 
contributor or side-effect of high frequency persisters within biofilms. A contributing role 
seems plausible as persisters comprise a significantly larger fraction of the overall 
population as cultures reach stationary phase. 
Autoaggregation was quantified in a number of ways. First, antibiotic effects on this 
process were considered. The protocols used have been described, and involved 
quantification via the microscope adherence assay protocol for S. saprophyticus 15305 
aggregation, and negative staining and analysis by transmission electron microscopy 
protocol for E. coli UTI89 aggregation. In both cases, aggregation was considered as the 
number of associated organisms per individual aggregate. Visualization of individual E. 
coli UTI89 in aggregates via light microscopy was not reliable, necessitating the TEM 
approach which was used instead. 
A third protocol was utilized to compare levels of stationary-phase, type 1 fimbriae-
dependent aggregation in the absence of antibiotics. This was accomplished using a 
sedimentation assay, which measures the rate of settling over time as a function of 
aggregate size. Type 1 fimbriae deficient E. coli UTI89 mutants ΔfimH (pili expressed 
without adhesin) and ΔfimS (pili not expressed - bald phenotype) were utilized. 
Organisms were grown to stationary phase as previously described. At this point, cells 
were harvested via gentle centrifugation at 4500xG for 10 minutes. Pellets were 
resuspended in PBS to an OD600 of 1.0. Cell suspensions were then vortexed for ~10 
seconds and incubated at room temperature for five hours to permit sedimentation. Every 
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hour, 0.1 mL of the upper suspension was gently removed and transferred to 0.9 mL of 
PBS and the OD600 measured. The autoaggregation determined was expressed as 1-
(At/A0)x100, where At represents the absorbance at time t = 5 hours and A0 the 
absorbance at t = 0. 
 
2.16 TRANSCRIPTOMIC ANALYSES 
 
2.16.1 Bacterial preparation, RNA extraction and enrichment 
protocols 
RNA sequencing was conducted in order to gain a better understanding of how 
transcription is modulated in response to sub-inhibitory antibiotics, and to complement 
the phenotypic changes already characterized. Both S. saprophyticus 15305 and E. coli 
UTI89 were grown in the presence or absence 1/4MIC ciprofloxacin until an OD600 of 1.0 
was achieved. An additional treatment group included the application of 1/4MIC 
ciprofloxacin at OD600 of 1.0 for 30 minutes to determine the early effects of sub-
inhibitory antibiotic on transcript expression. After these incubation periods, RNA protect 
was directly added at a ratio of 2:1 RNA protect:sample for 10 minutes. Solutions were 
centrifuged at 5,000xG for five minutes and pellets frozen at -80°C until required for 
RNA extraction. 
S. saprophyticus 15305 pellets were resuspended in 1 mL TE buffer containing 10 mM 
Tris-HCl, 1 mM EDTA, 20 mg/mL lysozyme (Sigma), and 50 U/mL lysostaphin (Sigma) 
at 37°C for 30 minutes, while E. coli UTI89 was incubated in the same buffer without 
lysostaphin for the same period. Samples were then centrifuged at 5,000xG for five 
minutes, supernatants discarded, and pellets resuspended in 1 mL TRIzol (Ambion, 
Burlington, ON) reagent by vortexing followed by a 10 minute incubation period at room 
temperature. 200 µL of chloroform was added to each sample then vortexed for 15 
seconds and incubated at room temperature for 10 minutes followed by centrifugation at 
16,000xG for 15 minutes. 500 µL of the upper aqueous phase was transferred to an 
RNase-free tube and 500 µL of 100% ethanol was added then vortexed. Samples were 
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then run through a PureLink RNA Mini Kit (Ambion) to purify the extracted RNA as per 
the manufacturer's instructions. In all instances, RNA was eluted in 30 µL volumes using 
RNase-free water. RNA quality and purity was determined at Robarts Research Institute, 
London Regional Genomics Centre using an Agilent 2100 Bioanalyzer (Agilent 
Technologies Inc., Palo Alto, CA) and the RNA 6000 Pico Kit (Caliper Life Sciences, 
Mountain View, CA). Only samples containing high-quality RNA [RNA integrity 
numbers (RINs) ≥ 9.0] were used for further analysis and sequencing. mRNA was 
enriched prior to sequencing using the MICROBExpress kit (Ambion). A single 
enrichment run was sufficient to deplete 16S and 23S ribosomal RNA from the S. 
saprophyticus 15305 samples; however, E. coli UTI89 samples required two depletions 
prior to sequencing.  The purity and quantity of the RNA was assessed prior to 
enrichment using a Qubit 2.0 Fluorometer (Life Technologies, Burlington, ON) and RNA 
BR Assay (Life Technologies). RNA was added to the MICROBExpress kit at a 
concentration of 0.6 µg/mL in 15 µL total volume and extracted in RNase-free water 
following ethanol precipitation. Effective ribosomal RNA depletion was confirmed using 
a bioanalyzer. 
 
2.16.2 RNA library preparation and sequencing 
Purified and depleted RNA was barcoded using ScriptSeq Index PCR Primers 1-19 
(Epicenter Biotechnologies, Madison, WI) and pooled into a library at Robarts Research 
Institute, London Regional Genomics Centre using the ScriptSeq v2 RNA-Seq Library 
Preparation Kit (Epicentre). Briefly, samples were fragmented, cDNA was synthesized, 
tagged, cleaned-up and subjected to PCR with barcoded reverse primers to permit 
equimolar pooling. In total, 50 ng of RNA was used for each library preparation. The 
quality and quantity of the library preparation was confirmed via bioanalyzer (Agilent 
High Sensitivity DNA chip) and qPCR Library Quant Kits (KAPA Biosystems, 
Wilmington, MA), with primers specific to end library fragments. Samples were 
clustered via cBOT (Illumina, Toronto, ON) and sequenced using the HiSeq 2000 
platform (Illumina) at The Biodiversity Research Centre, NGS Facility (University of 
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British Columbia). Samples were run on two lanes at 12 pM using 100 bp, paired-end 
reads as per Illumina specifications and protocols. 
 
2.16.3 Reference sequence library and mapping 
E. coli UTI89 [accession NC_007946.1 (Chen et al., 2006)] and S. saprophyticus 15305 
[accession NC_007350.1 (Kuroda et al., 2005)] were included for mapping. These 
datasets included the predicted coding sequences extracted from the complete genomes 
and plasmids available from the National Center for Biotechnology Information (NCBI) 
database. Reads uniquely mapped to coding sequences using BOWTIE 2.2.1 (Langmead 
and Salzberg, 2012) were included in the differential expression analysis (all other 
unmapped reads were discarded). Reads were trimmed by 20 nt from the 5' end and 40 nt 
from the 3' end, and a maximum of two mismatches were allowed. Reads with equal best 
hits were mapped at random to one of the locations. Amino acid translations of predicted 
coding sequences were compared using SEED Subsystems (Overbeek et al., 2005) and 
assigned by blastp with an e-value cutoff of 1e-3. The KEGG Automatic Annotation 
Server (KAAS) (Moriya et al., 2007) was used for annotation of enzyme functions 
(KOs). 
 
2.17 STATISTICAL ANALYSES 
Statistical analyses were conducted using GraphPad Prism version 4.00 for Windows 
(GraphPad Software, San Diego, CA). Significance was determined using one-way 
ANOVA and Dunnett's multiple comparison test or Bonferroni's multiple comparison 
test, Mann-Whitney test with Gaussian approximation, Logrank test, and two-tailed or 
unpaired t-test. Each test used for respective experiments is detailed in its figure legend. 
Statistical analyses for the differential expression of reads generated using RNA 
sequencing were conducted using the ALDEx R package version 2.0.6 (Fernandes et al., 
2013; Fernandes et al., 2014 - awaiting publication). A log2 median effect size of at least 
1.5 was required for genes to be considered differentially expressed. In addition, a less 
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than 1% overlap in the distributions between the two conditions was permitted for 
inclusion as described elsewhere (Fernandes et al., 2013; Macklaim et al., 2013). 
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3 RESULTS 
 
3.1 EXAMINING THE EFFECTS OF SUB-INHIBITORY 
ANTIBIOTICS ON UROPATHOGEN VIRULENCE 
The notion that sub-inhibitory antibiotics demonstrate signalling capacity in prokaryotes 
is of clinical concern and certainly warrants investigation. This is especially true in 
situations where antibiotics are applied at low-doses for prolonged periods of time such 
as during prophylactic management of recurrent UTI. Thus far, the majority of studies 
exploring phenomenon have utilized transcriptomics and reporter strains to illustrate 
global changes in gene expression. However, there is a severe deficit in our 
understanding of what exactly these changes accomplish on the phenotypic level, and 
how they influence virulence and pathogenesis. An aim of the present study was to 
investigate the capacity of sub-inhibitory antibiotics to influence various aspects of 
uropathogen virulence in vitro. 
 
3.1.1 Characterizing uropathogen strain sensitivity to various 
antibiotics 
Antibiotic dosing strategies were optimized against all uropathogens utilized before 
undertaking this work. Initial susceptibility screening was carried out using the Kirby-
Bauer method, which indicated that all strains demonstrated clinical susceptibility (Table 
3.1). Minimal inhibitory concentration (MIC) cut-offs were generated using the broth 
microdilution procedure as outlined by the Clinical and Laboratory Standards Institute 
(CLSI; 2007) (Table 3.1). S. saprophyticus strains were comparatively more tolerant of 
ciprofloxacin than E. coli isolates. Conversely, E. coli strains were much less sensitive to 
ampicillin and gentamicin challenge. 
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Table 3.1 Summary of strain MICs and antibiotic susceptibilities 
a 
ZOI, zone of inhibition; S, susceptible; I, intermediately susceptible; R, resistant (per 
CLSI guidelines). 
 
 
 
 
 
 
 
Strain (type) 
MIC (µg/mL)  ZOI (mm [susceptibility])
a
 
CIP AMP GEN  CIP AMP GEN 
S. saprophyticus strains 
   15305 0.25 0.125 0.0625 
 
26.5 (S) 28.25 (S) 20 (S) 
   15305:C1 0.25 0.125 0.0625  26.5 (S) 28.25 (S) 20 (S) 
   7108 0.25 0.25 0.0625  26 (S) 28 (S) 21 (S) 
E. coli strains 
   CFT073 0.0156 3 1 
 
25.5 (S) 17  (S) 17 (S) 
   TOP277 (SSR) 0.0125 6 0.75  22.75 (S) 19.75 (S) 16 (S) 
   TOP263 (SSR) 0.0166 8 0.5625  23.5 (S) 16.25 (S) 16 (S) 
   TOP379 (SSR) 0.0208 10 0.6875  23.25 (S) 14 (I) 15 (S) 
   TOP344 (SSR) 0.0229 10 0.875  21.75 (S) 14 (I) 15 (S) 
   TOP345 (SSR) 0.0146 8.5 0.875  26 (S) 19.75 (S) 16.25 (S) 
   PUTS277 (AI) 0.0208 9 0.3125  26.25 (S) 17.5 (S) 17.25 (S) 
   PUTS278 (AI) 0.0166 6 0.375  25 (S) 17.25 (S) 17.75 (S) 
   PUTS1127 (AI) 0.0166 9.5 1  28 (S) 17.75 (S) 16 (S) 
   PUTS1236 (AI) 0.0166 9 0.75  23.5 (S) 17.25 (S) 16.5 (S) 
   UTI89 0.0188 9 1.25  26.5 (S) 16.75 (S) 15.75 (S) 
   UTI89 (ΔrecA) 0.0009 8 1  43.75 (S) 25.75 (S) 25.25 (S) 
   UTI89 (lexAT355G) 0.0039 8 1.25  35.5 (S) 22.75 (S) 21 (S) 
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Optimal sub-inhibitory antibiotic dosing strategies were evaluated to determine 
concentrations which confer phenotypic effects without perturbing growth. Although a 
range of concentrations were considered, 1/4MIC levels were the maximal dose that 
organisms could tolerate without loss of fecundity (Figure 3.1). Therefore, this dose was 
used throughout unless stated otherwise. 
 
3.1.2 Evaluating the ability of sub-inhibitory antibiotics to induce 
adherence of S. saprophyticus to abiotic surfaces 
Colonization of surfaces represents one of the first critical steps in bacterial infection. 
Therefore, the influence of antibiotic stress on this process was the first trait to be 
evaluated in S. saprophyticus 15305. Initially, experiments were carried out using human 
pooled urine (HPU) as a growth medium. Surfaces which come into contact with urine 
are immediately coated with a conditioning film which is composed of various urine 
metabolites and host proteins such as immunoglobulins, Tamm-Horsfall protein, histones, 
and nuclear DNA-condensing proteins (Canales et al., 2009), and are important in 
surface-pathogen adherence potential. To achieve a basic understanding of antibiotic 
influence on adherence, trials were first carried out on glass microscope slide surfaces to 
permit rapid visualization of experimental outcomes. Early-exponential phase S. 
saprophyticus 15305 cultures were exposed to 1/4MIC antibiotics or control for one hour 
prior to incubation on slide surfaces. This time point was selected to demonstrate the 
rapid influence of antibiotics on colonization processes. Following a brief wash period to 
remove non-irreversibly attached organisms, slides were stained with crystal violet and 
imaged using a light microscope. Representative light-micrographs of all samples 
revealed the presence of adherent S. saprophyticus as punctate purple spots, with 
antibiotic-primed groups demonstrating visibly larger populations (Figure 3.2A). 
Enumeration of randomly selected fields of view (FOV) for each treatment group, and 
comparison with HPU control populations demonstrated that antibiotics are effective in 
increasing the relative adherence in primed pathogens (Figure 3.2B). Specifically, 
adherence was significantly increased with 1/4MIC ciprofloxacin and ampicillin 
treatments (37%; P < 0.05), and 1/4MIC gentamicin treatments (50%; P < 0.01). 
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Figure 3.1. Comparison of cfu/mL between subinhibitory antibiotic pre-treated and 
untreated uropathogens immediately prior to lethal antibiotic challenge. Negligible 
impact of antibiotic pre-treatment on uropathogen growth receiving either 1/4MIC 
ciprofloxacin (A), 1/4MIC ampicillin (B) or 1/4MIC gentamicin (C) for three hours is 
shown. Means are from at least three independent experiments. Significance determined 
using paired t-test for each pair-wise combination (all combinations are non-significant; 
P > 0.05). 
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Figure 3.1 
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Demonstrating that antibiotics can modulate bacterial adherence capacity to hydrophilic 
glass warranted further exploration of this phenotypic change using hydrophobic 
surfaces. Foley urethral catheters and InLay Optima® ureteral stents were selected as 
target surfaces both for their hydrophobic properties and application as medical devices 
for the management of urinary obstruction. These devices are widely used in urology, are 
readily colonized by uropathogens, and are often placed in conjunction with single-dose 
prophylactic antibiotics as per AUA best practice policies (Wolf et al., 2008). S. 
saprophyticus 15305 was incubated in either the presence or absence of 1/4MIC 
antibiotic and 1 cm sections of either stent or catheter in LB broth (HPU was 
discontinued for adherence assays due to the reproducibility issues associated with batch 
variations). Antibiotic-primed organisms demonstrated an increased capacity to adhere to 
both stent and catheter surfaces (Figure 3.3), as was found on hydrophilic glass slides. S. 
saprophyticus 15305 adhered more readily to catheters, with antibiotic-primed groups 
demonstrating significantly larger adherent populations. Adherence increased by 5.9, 6.1, 
and 6.2-fold on urethral catheters in the presence of 1/4MIC ciprofloxacin, ampicillin, 
and gentamicin respectively (P < 0.05), and by 2.6, 2.6, and 2.7-fold on ureteral stents (P 
< 0.05; P < 0.01). 
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Figure 3.2. Representative images of S. saprophyticus 15305 adhering to glass 
microscope slide surfaces in the presence or absence of 1/4MIC of various antibiotics (A) 
and relative adherence  (B). Attachment percent indicated as a function of the human 
pooled urine (HPU) control. Means from at least three independent experiments are 
shown with significance. Significance was determined using one-way ANOVA and 
Dunnett's multiple comparison test (*, P < 0.05; **, P < 0.01). 
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Figure 3.2 
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Figure 3.3. Percent adherent S. saprophyticus 15305 of the total population (adherent and 
non-adherent) to InLay Optima ureteral stent (A) or Foley urethral catheter (B) segments 
in the presence or absence of 1/4MIC of various antibiotics. Means from at least three 
independent experiments are shown with significance. Significance was determined using 
one-way ANOVA and Dunnett's multiple comparison test (*, P < 0.05; **, P < 0.01). 
 
 
 
 
 
 
 
 
 
70 
 
 
 
 
 
 
Figure 3.3 
 
 
 
 
 
71 
 
 
3.1.3 Evaluating the ability of sub-inhibitory antibiotics to 
modulate biofilm formation in S. saprophyticus and E. coli 
Adhesion of uropathogens to surfaces represents the first steps in establishing acute 
colonization during UTI. Since sub-inhibitory antibiotics were effective in increasing 
initial bacterial adherence, it was postulated that they would also be able to enhance their 
biofilm-forming capacity. This was explored by incubating S. saprophyticus 15305 in 96-
well plates for 24 and 48 hours in the presence or absence of sub-inhibitory antibiotic 
concentrations. Ciprofloxacin, ampicillin, and gentamicin increased maximal biofilm 
mass by 38.5%, 34%, and 27.8% respectively compared to untreated controls (P < 0.05; 
P < 0.01) (Figure 3.4A). Although antibiotics also were able to enhance biofilm mass 
after 48 hours, the effect was comparatively much less pronounced compared to 24 hours 
(Figure 3.4B), with, ciprofloxacin, ampicillin, and gentamicin increasing maximal 
biofilm amount by only 13.6%, 11.7%, and 12.8% respectively (P < 0.05). This plateau 
in biofilm mass is likely due to saturation effects as S. saprophyticus 15305 biofilms 
approach the maximal capacity supported within the well of the plate. 
Compared to S. saprophyticus, E. coli is more commonly associated with biofilm-related 
UTI, especially when indwelling urinary devices are present. Previous work has 
demonstrated this organism can increase biofilm mass in response to aminoglycoside 
antibiotics (Hoffman et al., 2005). The biofilm forming capacity of E. coli UTI89 was 
also determined following sub-inhibitory antibiotic exposure. The experiments were 
carried out as described for S. saprophyticus 15305, with the exception that only a 24 
hour time-point was considered. Sub-inhibitory ciprofloxacin, ampicillin, and gentamicin 
increased maximal biofilm amounts by 57.7%, 60.0%, and 57.9% respectively (P < 0.05; 
P < 0.01) (Figure 3.5). 
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Figure 3.4. S. saprophyticus 15305 biofilm formation in the presence of various 
antibiotic concentrations at 24 (A) and 48 (B) hours. Means from at least three 
independent experiments are shown with significance. Significance was determined using 
one-way ANOVA and Dunnett's multiple comparison test (*, P < 0.05; **, P < 0.01). 
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Figure 3.4 
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Figure 3.5. Biofilm formation of wild-type E. coli UTI89 after 24 hours in the presence 
of various antibiotic concentrations. Means from at least three independent experiments 
are shown with significance. Significance was determined using one-way ANOVA and 
Dunnett's multiple comparison test (*, P < 0.05; **, P < 0.01). 
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Figure 3.5 
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3.1.4 Assessing the contribution of the SOS response to 
antibiotic-dependent biofilm formation 
It is well known that the SOS response is activated following dosing with various 
antibiotics (Miller et al., 2004; Mesak et al., 2008). However, it has more recently been 
implicated in the regulation of various aspects of pathogenicity (Bisognano et al., 2000; 
Kelley et al., 2006). Here, the involvement of the SOS response to antibiotic-dependent 
biofilm formation is considered. SOS-deficient E. coli UTI89 strains PAS0209 and 
PAS0211 demonstrated a modest suppression in biofilm formation, amassing only 69.6% 
and 74.3% of the wild-type E. coli UTI89 levels respectively (P < 0.05) (Figure 3.6A). 
Next, the contribution of SOS activation during antibiotic-dependent biofilm formation 
was assessed. E. coli PAS0209 biofilm formation was not significantly influenced by 
ciprofloxacin and gentamicin antibiotics (P > 0.05) (Figure 3.6B, D). However, similar to 
wild-type E. coli UTI89, PAS0209 formed more robust biofilms following ampicillin 
treatment (Figure 3.6C), increasing mass by 40.0% compared to untreated controls (P < 
0.05). This result was also observed in E. coli PAS0211, with ampicillin treatment 
increasing biofilm mass by 36.6% (P < 0.05) (Figure 3.6F). Although no appreciable 
changes were noted following ciprofloxacin treatment, gentamicin was able to increase 
biofilm mass by 29.0% (P < 0.05) (Figure 3.6E, G). 
 
3.1.5 Antibiotics induce bacterial aggregation 
Initial light micrograph images appeared to exhibit S. saprophyticus 15305 cultures that 
would aggregate in the presence of sub-inhibitory antibiotics (Figure 3.2A). In order to 
investigate whether this process is an important contributor to therapy failure, qualitative 
aggregation in the presence or absence of sub-inhibitory ciprofloxacin was determined 
via direct visualization using scanning electron microscopy (SEM) for S. saprophyticus 
15305 (Figure 3.7A, B) and transmission electron microscopy (TEM) for E. coli UTI89 
(Figure 3.7C, D). Representative images of control (Figure 3.7A, C) and 1/4MIC 
ciprofloxacin treated (Figure 3.7B, D) organisms reveal extensive aggregation when 
ciprofloxacin is present. 
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Figure 3.6. Biofilm formation of E. coli UTI89 and SOS-deficient strains after 24 hours 
(A).  Biofilm formation of E. coli SOS-deficient strains ΔrecA (B-D) and lexAT355G (E-G) 
after 24 hours in the presence of various antibiotics at subinhibitory concentrations. 
Means from at least three independent experiments are shown with significance. 
Significance was determined using one-way ANOVA and Dunnett's multiple comparison 
test (*, P < 0.05; **, P < 0.01). 
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Figure 3.6 
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Figure 3.6 (continued) 
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Figure 3.7. Representative images showing adherence and aggregation of S. 
saprophyticus 15305 (A, B; SEM), and E. coli UTI89 (C, D; TEM), and the effect of 
1/4MIC ciprofloxacin treatment (B, D) on these processes. 
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Figure 3.7 
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S. saprophyticus 15305 aggregation was assessed using the glass microscope slide 
technique previously described. As expected from previous observations, antibiotic-
priming significantly increased planktonic aggregate size (Figure 3.8A). Ciprofloxacin, 
ampicillin and gentamicin increased aggregate size from a control median of 6 to 9, 8, 
and 8 organisms/aggregate respectively (P < 0.05; P < 0.01). Inability to distinguish 
individual E. coli UTI89 organisms from one-another necessitated the use of TEM for 
accurate aggregation quantification. Similar to S. saprophyticus 15305, E. coli UTI89 
was treated with 1/4MIC antibiotics for one hour prior to fixation and enumeration. 
Subsequent visualization demonstrated that like S. saprophyticus 15305, E. coli UTI89 
aggregates in the presence of sub-inhibitory antibiotics (Figure 3.8B). Aggregate size 
increased from a control median of 3 to 6 organisms/aggregate for ciprofloxacin, 
ampicillin and gentamicin treatment groups (P < 0.01). 
 
3.1.6 Evaluating the ability of antibiotics to induce S. 
saprophyticus urothelial cell adherence and internalization 
Having demonstrated that antibiotic-primed uropathogens more readily adhere to abiotic 
surfaces, it was postulated that the same outcome would occur if urothelial cells were 
used as the adhering substrate. Experiments were conducted to assess the ability of 
antibiotics to improve S. saprophyticus 15305 adherence to both 5637 bladder and A498 
kidney cell lines. These cell lines were selected for their similarity to normal urinary 
epithelium tissue. All antibiotics induced increased adherence to both cell lines, with 
ciprofloxacin, ampicillin and gentamicin improving adherence to 5637 bladder cells 12.8, 
7.4, and 7.0-fold (Figure 3.9A), and 10.7, 11.4, and 9.7-fold in A498 kidney cells 
respectively (P < 0.05; P < 0.01) (Figure 3.9C). Antibiotic-dependent modulation of 
adherence also resulted in a larger intracellular reservoir for both cell types. 
Ciprofloxacin, ampicillin and gentamicin increased the intracellular population in 5637 
bladder cells by 5.6, 6.6, and 8.3-fold respectively (P < 0.01) (Figure 3.9B). Similarly, 
ciprofloxacin and ampicillin both increased internalization 3.4-fold (P < 0.05), while 
gentamicin resulted in a 4.4-fold increase in A498 kidney cells (P < 0.01) (Figure 3.9D). 
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Figure 3.8. Average planktonic cluster size (bacteria/aggregate) of S. saprophyticus 
15305 (A) and E. coli UTI89 (B) following exposure to either 1/4MIC ciprofloxacin, 
ampicillin, gentamicin, or no antibiotic. Means from at least three independent 
experiments are shown with significance. Significance was determined using one-way 
ANOVA and Dunnett's multiple comparison test (*, P < 0.05; **, P < 0.01). 
 
 
 
 
 
 
 
 
 
84 
 
 
Figure 3.8 
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Figure 3.9. The effect of antibiotics on S. saprophyticus 15305 adherence (A, C) and 
internalization (B, D) to 5637 bladder (A, B) and A498 kidney cells (C, D). Means from 
at least three independent experiments are shown with significance. Significance was 
determined using one-way ANOVA and Dunnett's multiple comparison test (*, P < 0.05; 
**, P < 0.01). 
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Figure 3.9 
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3.1.7 Assessing the contribution of adhesin upregulation to 
improved adhesion and internalization in antibiotic-primed 
S. saprophyticus 
Antibiotic-dependent changes in adherence were much more substantial when biotic 
surfaces were used compared to abiotic urological device materials. This is likely not 
solely attributable to changes in the surface chemistry of S. saprophyticus 15305 exposed 
to antibiotic. Rather, the dramatic increase in relative adherence was postulated to be due 
to the improved expression of adhesins on the S. saprophyticus 15305 surface. As UafA 
is the most critical urothelial adhesion factor for this organism, its modulation was 
investigated. Hemagglutination experiments suggested that UafA is in part responsible 
for the increased adherence following ciprofloxacin therapy. The results demonstrate a 
dose-dependent effect, with 1/16MIC ciprofloxacin levels inducing a 45.0% increased 
level of hemagglutination (P < 0.05) (Figure 3.10A). The differences found between 
hemagglutination by wild-type S. saprophyticus 15305 and the acapsular C1 strain, 
demonstrate the blocking effect of the robust capsule. However, the greater 
hemagglutination following ciprofloxacin-priming in the absence of capsule, suggests 
that UafA surface expression was enhanced by antibiotics and not simply due to capsule 
downregulation. This effect was also observed in S. saprophyticus 7108, suggesting 
ciprofloxacin might have this affect across this species. 
Adherence capacity to 5637 bladder cells following ciprofloxacin treatment was also 
compared between wild-type and acapsular strains of S. saprophyticus. As predicted, 
ciprofloxacin increased adhesion in both strains. These results further demonstrated that 
increased adhesion is likely due to UafA upregulation, not capsule suppression. Total 
wild-type adherence was increased from 0.7% to 5.2% for control and ciprofloxacin 
treatment groups respectively (P < 0.05), while adherence increased from 18.4% to 
83.7% in the acapsular strain (P < 0.001) (Figure 3.10B). Internalization was also found 
to significantly increase in the absence of capsule, but in the presence of sub-inhibitory 
ciprofloxacin. Total wild-type internalization was improved from 0.057% to 0.294% for 
control and ciprofloxacin treatment groups respectively (P < 0.05), while internalization 
was increased from 0.323% to 1.188% in the acapsular strain (P < 0.001) (Figure 3.10C). 
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Figure 3.10. UafA-dependent hemagglutination of S. saprophyticus 15305, 7108, and the 
acapsular C1 strain following exposure to various concentrations of ciprofloxacin (A), 
and effect on 5637 bladder cell adherence (B) and internalization (C).  Means from at 
least three independent experiments are shown with significance. Significance was 
determined using one-way ANOVA and Bonferroni's multiple comparison test (*, P < 
0.05; **, P < 0.01; ***, P < 0.001). 
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Figure 3.10 
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3.1.8 Evaluating the capacity of sub-inhibitory antibiotics to 
induce adhesin expression in E. coli 
The results obtained for S. saprophyticus entertained the idea that E. coli might also 
increase biofilm forming capacity following antibiotic-priming by upregulating critical 
surface adhesins. As type 1 fimbriae have been demonstrated to be critical in urothelial 
colonization, invasion, and UTI pathogenesis, antibiotic-dependent modulation of this 
adhesin was postulated to contribute to biofilm formation. Type 1 fimbriae-dependent 
hemagglutination was assessed over 24 hours and the results showed that expression 
increased over time and in response to 1/4MIC and 1/16MIC ciprofloxacin (P < 0.05; P < 
0.01; P < 0.001) (Figure 3.11A). 
Previous results suggest that the SOS response might partially contribute to E. coli UTI89 
biofilm formation when antibiotics are applied. Thus, it was reasonable to postulate an 
SOS-dependent role in type 1 fimbriae regulation in E. coli UTI89. This was explored 
using SOS-deficient E. coli UTI89 strains PAS0209 and PAS0211. Baseline type 1 
fimbriae expression levels were not significantly changed in the SOS-deficient strains 
(Figure 3.11B). Only wild-type E. coli UTI89 significantly increased hemagglutination 
following exposure to 1/4MIC ciprofloxacin, ampicillin, and gentamicin (P < 0.05), 
leaving SOS-deficient strains unaffected by antibiotic treatment. 
 
3.1.9 Assessing the influence of sub-inhibitory antibiotics on E. 
coli phase variation as a mechanism of type 1 fimbriae 
expression 
The mechanisms by which antibiotics improve adhesin expression in E. coli and S. 
saprophyticus are unclear. However regulation of type 1 fimbriae is phase variable, and 
the proportion of E. coli in phase ON or OFF orientation can be measured using PCR of 
the fim-switch, with restriction digestion of amplicons yielding 489 and 359 base-pair 
products for phase ON and OFF respectively (Figure 3.12A). Combined with 
densitometric analysis, these bands can accurately elucidate the relative gene expression 
of type 1 fimbriae in different conditions. 
91 
 
 
 
 
 
 
 
 
 
Figure 3.11. Type I fimbriae-dependent hemagglutination of E. coli UTI89 exposed to 
various subinhibitory concentrations of ciprofloxacin over time (A). Effect of 1/4MIC of 
various antibiotics on hemagglutination of wild-type and SOS-deficient E. coli strains 
(B). Means from at least three independent experiments are shown with significance. 
Significance was determined using one-way ANOVA and Bonferroni's multiple 
comparison test (ns = not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001). 
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Figure 3.11 
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Figure 3.12. Time-course indicating Type I fimbriae gene ON/OFF phase changes in 
shaking or static cultures of E. coli UTI89 following exposure to various subinhibitory 
concentrations of ciprofloxacin (A). Densitometric gel analysis indicates the percentage 
of E. coli UTI89 with Type I fimbriae in the phase ON orientation during shaking (B) and 
static (C) growth. Means from at least four independent experiments are shown with 
significance. Significance was determined using one-way ANOVA and Bonferroni's 
multiple comparison test (ns = not significant). 
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Figure 3.12 
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Surprisingly, no significant changes were observed in OFF-ON phase variation in either 
shaking (Figure 3.12B) or static (Figure 3.12C) cultures at any time point with any sub-
inhibitory ciprofloxacin treatment. At this time it is unclear how antibiotics regulate the 
expression of type 1 fimbriae in E. coli UTI89. 
 
3.1.10 Evaluating the effect of sub-inhibitory antibiotics on 
flagellar activity in E. coli 
Sub-inhibitory antibiotics appear to signal uropathogens to upregulate factors important 
to adherence and subsequently biofilm formation. Importantly, confounding factors 
which promote motility would ideally be suppressed in order to achieve a fully sedentary, 
adherent state. Thus, it is reasonable to postulate that flagellar activity would be 
suppressed following the application of sub-inhibitory antibiotics. E. coli UTI89 and 
SOS-deficient variants PAS0209 and PAS0211 were spot plated on soft-agar plates in the 
presence or absence of sub-inhibitory antibiotics (Figure 3.13A). These strains were also 
pre-treated with sub-inhibitory antibiotics prior to loading on untreated soft-agar plates to 
assess antibiotic changes to flagella regulation during planktonic phase growth (Figure 
3.13B). Interestingly, SOS-deficient strains demonstrated less motility compared to wild-
type E. coli UTI89 in both conditions. In general, sub-inhibitory antibiotics suppressed 
motility in all strains tested, with the exception of ciprofloxacin which significantly 
upregulated swarming in the lexAT355G E. coli PAS0211 strain (Figure 3.13A). This 
finding was recapitulated in antibiotic-primed organisms, with wild-type E. coli UTI89 
demonstrating a greater swarming deficiency following ciprofloxacin treatment than its 
SOS-deficient counterparts (Figure 3.13B). 
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Figure 3.13. Swarming motility of wild-type and SOS-deficient strains of E. coli UTI89 
in the presence of sub-inhibitory antibiotics. Strains were either plated directly onto soft-
agar containing antibiotic (A), or pre-treated with antibiotics for 4 hours prior to plating 
on unloaded soft-agar (B). Means from at least three independent experiments are shown 
with significance. Significance was determined using one-way ANOVA and Bonferroni's 
multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). 
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Figure 3.13 
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3.1.11 Assessing sub-inhibitory antibiotic-depended changes in 
gene expression in both E. coli UTI89 and S. 
saprophyticus 15305 
RNA sequencing was performed in order to better understand the pathways involved in 
antibiotic tolerance and signalling, and to corroborate data generated using phenotypic 
assays. Reads mapped to genomic coding regions were grouped by their annotated 
function in order to evaluate the differences between control (no antibiotic), and short (30 
minute) or long (4-6 hour) 1/4MIC antibiotic treatment groups for both E. coli UTI89 and 
S. saprophyticus 15305. SEED Subsystem annotations were used to estimate expression 
differences for subsystem 4 functions using ALDEx and expressed in the form of strip 
plots where subsys4 functions were plotted by absolute fold-change between conditions. 
Analysis of differential expression of E. coli UTI89 genes (Figure 3.14A, B) at the 
broadest functional level (SEED subsystem 1) revealed high variation in responses 
between 30 minutes (Figure 3.14A) and 4 hours (Figure 3.14B) of sub-inhibitory 
ciprofloxacin exposure. Early responses in E. coli UTI89 are dominated by increased 
relative abundance of transcripts related to DNA metabolism. Long-term exposure 
revealed similar changes in DNA metabolism-related genes, in addition to increases in 
the relative abundance of transcripts related to virulence and phage-components. 
Transcripts related to stress, respiration, carbohydrate and amino acid metabolism were 
generally found at a lower relative abundance following long-term ciprofloxacin 
exposure.  
The responses of S. saprophyticus 15305 to sub-inhibitory ciprofloxacin were markedly 
different compared to those of E. coli UTI89 (Figure 3.14C, D). Early (30 minutes) 
responses were dominated by increases in the relative abundance of transcripts related to 
protein, DNA, and carbohydrate metabolism (Figure 3.14C). After prolonged 
ciprofloxacin exposure (6 hours), stress response transcripts are abundant, in addition to 
those related to respiration, and protein and carbohydrate metabolism (Figure 3.14D). 
Despite ciprofloxacin's ability to induce DNA-related stress, there were few changes in 
elements related to DNA maintenance in S. saprophyticus 15305 compared to E. coli 
UTI89. In addition, overall changes in transcripts related to cellular activity (respiration  
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Figure 3.14. Subsystem 1 categories indicating enriched subsystem 4 functions for E. 
coli UTI89 (A, B) and S. saprophyticus 15305 (C, D) exposed to sub-inhibitory 
ciprofloxacin for either 30 minutes (A, C), 4 hours (B), or 6 hours (D). Each point 
represents a specific subsystem 4 function, and the magnitude in change is plotted on the 
x-axis relative to ciprofloxacin treatment conditions. Points are coloured cyan (relative 
transcript abundance decreased following treatment) or red (relative transcript abundance 
increased following treatment) if significantly different between conditions, while grey 
points are non-significant changes. A log2 median effect size of at least 1.5 was required 
for genes to be considered differentially expressed. In addition, a less than 1% overlap in 
the distributions between the two conditions was permitted for inclusion. 
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Figure 3.14 
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Figure 3.14 (continued) 
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and metabolism) were increased in S. saprophyticus 15305 following ciprofloxacin 
treatment while they were decreased in E. coli UTI89. 
Assessing the changes in relative abundance of specific transcripts indicated several 
genes that might contribute to adherence, invasion, and biofilm formation in both 
uropathogens. The majority of early E. coli UTI89 responses were dominated by stress-
inducible elements including damage-inducible (din) genes (dinG, dinF, dinP, dinD), 
nucleotide excision repair (NER) factors (uvrB, uvrD), and SOS regulon-associated 
components sulA, lexA, and recN (Table 3.2). Late responses in this uropathogen were 
comparatively more diverse, and included increased relative abundance in the 
aforementioned transcripts, in addition to several phage components (kil2, erf, ninE2, 
ninB2, ninB1, ral, cro, etc) (Table 3.3). Conversely, transcripts related to cell division 
(minE, minD, minC), and metabolism regulatory elements (yjdE, lacY, nuoM, sdhA, 
nuoF, nuoJ) were relatively decreased. Transcripts of the fimbrial repressor element focX, 
and the luxR homolog sdiA were significantly decreased 1.48 and 4.37-fold following 4 
hours of sub-inhibitory ciprofloxacin treatment. Conversely, putative fimbrial FimH 
(fmlD) and hek [also known as heat resistant agglutinin-1 (Hra1)] adhesin transcripts 
were significantly more abundant 4.84 and 2.47-fold in the ciprofloxacin treatment group 
compared to control.  
Early responses of S. saprophyticus 15305 to sub-inhibitory ciprofloxacin are 
characterized by decreased relative abundance of transcripts related to cell wall 
remodelling (SSP0843, SSP0988, SSP1294), and increases in transcripts related to 
protein stabilization and folding (groEL, SSP0296), cell division inhibition (SSP1593), 
metabolism (SSP0750, SSP2178, SSP1416, SSP0333, SSP1618, etc), exopolysaccharide 
synthesis (capH, capL), and general stress responses (SSP1024) (Table 3.4). In addition, 
an increased relative abundance of recA transcripts is indicative of DNA damage; 
however, late responses demonstrate that S. saprophyticus 15305 does not commit to a 
full-fledged SOS response during sub-inhibitory ciprofloxacin treatment as SOS regulon 
transcripts (lexA, NER components, error-prone polymerases, etc) are absent (Table 3.5). 
Rather, elements related to energy production and utilization (SSP1520, SSP1819, 
SSP2178, SSP1814, SSP1358, SSP0776, SSP1068, etc), protein stabilization (SSP0296, 
SSP1800, SSP1178, SSP1176, dnaK), and exopolysaccharide synthesis (SSP0769, capH) 
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are present at greater relative abundance. In addition to exopolysaccharide, increased 
presence of other virulence-related transcripts of unknown function included putative 
virulence factor B and hemolysin III homolog. Together, the divergent responses detailed 
by these transcriptomic data indicate that E. coli UTI89 and S. saprophyticus 15305 
utilize distinct mechanisms to tolerant sub-inhibitory ciprofloxacin-dependent stress.  
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Table 3.2 Significant changes in differentially expressed transcripts - E. coli UTI89 
control versus 1/4MIC ciprofloxacin (short-term exposure) 
Gene  Fold Change (log2)  Median Effect Size  Functional Annotation 
UTI89_C1489  -0.724  -2.506  putative phage protein 
cspE  -0.692  -2.523  cold shock protein 
tqsA  -0.657  -2.375  pheromone autoinducer 2 transporter 
UTI89_C4928  -0.593  -1.923  unknown 
UTI89_C5141  -0.473  -1.83  unknown 
ydfZ  -0.395  -1.765  putative selenium-binding protein 
lysU  0.183  2.229  lysyl-tRNA synthetase 
ydeN  0.2  2.107  sulfatase 
selD  0.23  1.858  selenophosphate synthetase 
ftsK  0.272  1.626  DNA translocase FtsK 
manX  0.273  1.539  PTS system mannose-specific transporter 
UTI89_C0964  0.286  1.873  putative phage regulator Cox 
UTI89_C2924  0.287  1.555  unknown 
pgk  0.318  1.741  phosphoglycerate kinase 
selA  0.319  2.761  selenocysteine synthase 
tatB  0.349  2.477  sec-independent translocase 
int  0.421  2.904  integrase 
uvrB  0.45  1.719  excinuclease ABC subunit B 
uvrD  0.629  2.117  DNA-dependent helicase II 
ruvB  0.645  2.529  Holliday junction DNA helicase 
dinG  0.72  3.94  ATP-dependent DNA helicase 
polB  0.724  5.097  DNA polymerase II 
umuC  0.763  3.12  DNA polymerase V subunit 
UTI89_C5142  0.764  4.032  unknown 
ydjQ  0.783  2.352  nucleotide excision repair endonuclease 
ruvA  0.791  3.18  Holliday junction DNA helicase 
dinP  0.892  4.023  DNA polymerase IV 
sulA  0.998  2.459  SOS cell division inhibitor 
yebG  1.156  2.754  DNA damage-inducible protein 
dinD  1.159  2.447  DNA-damage-inducible protein 
recA  1.184  2.78  DNA repair, SOS induction 
UTI89_C4473  1.221  3.011  putative lipase 
dinF  1.3  7.118  DNA-damage-inducible SOS response protein 
lexA  1.334  2.877  repressor of LexA 
UTI89_C1922  1.371  2.442  contains a metal-dependent hydrolase 
umuD  1.58  3.75  DNA polymerase V subunit 
UTI89_C5143  2.021  5.049  putative DinI 
recN  2.255  7.558  recombination and repair protein 
Genes indicated in bold are putative SOS regulon-associated elements. 
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Table 3.3 Significant changes in differentially expressed transcripts - E. coli UTI89 
control versus 1/4MIC ciprofloxacin (long-term exposure) 
Gene  Fold Change (log2)  Median Effect Size  Functional Annotation 
adiA  -1.442  -1.986  biodegradative arginine decarboxylase 
UTI89_C1489  -1.363  -3.627  putative phage protein 
UTI89_C5141  -0.966  -3.129  unknown 
UTI89_C0936  -0.953  -2.399  small terminase subunit of phage 
UTI89_C0914  -0.88  -2.183  phage tail sheath protein 
UTI89_C0938  -0.852  -3.202  phage capsid scaffolding protein 
yjdE  -0.816  -1.872  arginine:agmatin antiporter 
UTI89_C0915  -0.69  -2.872  phage tube protein FII 
lacY  -0.683  -2.556  lactose permease 
UTI89_C1011  -0.675  -2.931  putative iron-sulfur protein, 2Fe-2S clusters 
UTI89_C5140  -0.675  -2.452  unknown 
nuoM  -0.674  -1.896  NADH dehydrogenase subunit M 
ycdB  -0.657  -2.834  unknown 
sdhA  -0.652  -1.764  succinate dehydrogenase flavoprotein subunit 
ycgE  -0.635  -2.305  HTH-transcriptional repressor 
UTI89_C3113  -0.625  -2.276  putative lipoprotein NlpD 
UTI89_C2270  -0.598  -2.1  putative phospholipase 
UTI89_C1363  -0.595  -2.616  putative prophage protein 
focX  -0.562  -2.156  repressor of S fimbrial adhesin 
minE  -0.556  -3.683  cell division topological specificity factor 
nuoF  -0.551  -1.595  NADH dehydrogenase I subunit F 
nuoJ  -0.538  -2.15  NADH dehydrogenase subunit J 
minD  -0.517  -2.349  cell division inhibitor 
UTI89_C2959  -0.507  -3.758  putative prophage protein 
minC  -0.499  -2.276  septum formation inhibitor 
nuoN  -0.49  -6.227  NADH dehydrogenase subunit N 
UTI89_C2766  -0.49  -1.517  putative acetyltransferase 
msrB  -0.486  -2.088  methionine sulfoxide reductase B 
dadA  -0.485  -2.048  D-amino acid dehydrogenase small subunit 
ldcA  -0.484  -2.924  L,D-carboxypeptidase A 
sdhB  -0.478  -1.822  succinate dehydrogenase iron-sulfur subunit 
UTI89_C0728  -0.476  -1.858  putative cytochrome d ubiquinol oxidase 
UTI89_C0965  -0.453  -2.388  bacteriophage WPhi phage protein C 
sdiA  -0.45  -2.255  putative quorum sensing homolog of LuxR 
cyoB  -0.45  -1.926  cytochrome o ubiquinol oxidase subunit I 
cydB  -0.446  -1.943  cytochrome d terminal oxidase polypeptide 
ynjC  -0.442  -2.437  ABC transporter solute-binding protein 
pntA  -0.43  -1.864  NAD(P) transhydrogenase subunit alpha 
ycdW  -0.422  -2.437  glyoxylate/hydroxypyruvate reductase A 
ompA  -0.395  -2.505  outer membrane protein A 
UTI89_C1090  -0.389  -3.108  unknown 
UTI89_C1960  -0.386  -2.637  putative NAD(P)H nitroreductase 
UTI89_P009  -0.378  -3.015  ubiquinone 
znuA  -0.375  -2.107  high-affinity periplasmic zinc transporter 
UTI89_C0750  -0.374  -2.939  homeobox protein 
UTI89_C1017  -0.374  -1.866  unknown 
accB  -0.373  -3.511  acetyl-CoA carboxylase biotin carboxyl carrier 
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Table 3.3 (continued) 
Gene  Fold Change (log2)  Median Effect Size  Functional Annotation 
ybbM  -0.372  -1.949  metal resistance protein 
gdhA  -0.369  -1.895  glutamate dehydrogenase 
dhaK  -0.363  -2.752  dihydroxyacetone kinase subunit 
ydiA  -0.361  -1.797  unknown 
fumA  -0.359  -2.513  class I fumarase 
cspD  -0.333  -1.691  stationary phase/starvation regulator 
uspC  -0.329  -2.774  universal stress protein 
cstA  -0.326  -2.034  carbon starvation protein A 
mukE  -0.323  -1.946  condensin subunit E 
narX  -0.301  -2.111  nitrate/nitrite sensor protein 
yecA  -0.3  -1.9  unknown 
gltP  -0.29  -2.84  glutamate/aspartate:proton symporter 
UTI89_C0891  -0.288  -2.945  CRISPR helicase Cas3/CRISPR protein Cas1 
metH  -0.286  -1.919  B12-dependent methionine synthase 
UTI89_C0833  -0.28  -2.111  hemin-binding lipoprotein 
folX  -0.276  -2.138  pterin biosynthesis 
ybbL  -0.272  -1.997  ABC transporter ATP-binding protein 
yjeQ  -0.272  -1.994  ribosome-associated GTPase 
mfd  -0.268  -1.821  transcription-repair coupling factor 
artP  -0.268  -1.656  arginine transporter ATP-binding subunit 
ompC  -0.256  -1.746  porin 
UTI89_C1133  -0.251  -3.115  putative HcpC beta-lactamase precursor 
hlpA  -0.247  -1.799  periplasmic chaperone 
pflB  -0.244  -1.563  putative formate acetyltransferase 1 
UTI89_C2496  -0.242  -1.872  putative outer membrane protein 
ydhO  -0.234  -1.742  putative lipoprotein 
asnC  -0.234  -1.707  asparaginyl-tRNA synthetase 
UTI89_C1472  -0.226  -1.859  unknown 
cld  -0.224  -1.839  length regulator of LPS O-antigen chains 
yfhM  -0.202  -1.85  putative lipoprotein 
UTI89_C3005  -0.189  -2.077  unknown 
sfcA  -0.158  -2.021  malate dehydrogenase 
ftsK  0.304  1.962  DNA translocase FtsK 
selA  0.306  2.218  selenocysteine synthase 
osmB  0.383  2.223  lipoprotein 
UTI89_C1937  0.395  1.826  unknown 
spy  0.432  1.99  spheroplast protein Y 
uvrB  0.483  3.317  excinuclease ABC subunit B 
int  0.518  2.698  integrase 
ibpA  0.534  1.501  heat shock protein 
endA  0.553  1.934  endonuclease I 
yebF  0.623  1.933  unknown 
UTI89_C2389  0.624  1.999  putative molybdate metabolism regulator 
yfdQ2  0.703  1.94  unknown 
ydeP  0.772  2.381  oxidoreductase 
uvrD  0.812  2.591  DNA-dependent helicase II 
UTI89_C2643  0.814  2.455  gene 16-like, phage DNA transfer protein 
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Table 3.3 (continued) 
Gene  Fold Change (log2)  Median Effect Size  Functional Annotation 
uvrA  0.919  1.976  excinuclease ABC subunit A 
ruvB  0.949  4.379  Holliday junction DNA helicase 
UTI89_C4650  0.964  1.74  putative SoxR 
ruvA  0.985  7.498  Holliday junction DNA helicase 
polB  1.149  4.389  DNA polymerase II 
rmuC  1.151  1.688  DNA recombination protein 
UTI89_C1713  1.151  3.164  HTH/AraC transcriptional regulator 
UTI89_C1753  1.158  2.055  maltoporin-like protein 
ibpB  1.171  2.118  heat shock chaperone 
yfdQ1  1.177  2.653  unknown 
dinG  1.221  6.389  ATP-dependent DNA helicase 
UTI89_C1023  1.229  2.915  unknown 
UTI89_C5093  1.256  2.315  unknown 
ydjQ  1.257  2.289  nucleotide excision repair endonuclease 
UTI89_C0582  1.276  1.653  unknown 
UTI89_C2644  1.302  3.853  gene 20-like, phage DNA transfer protein 
hek  1.304  3.475  Hek adhesin/virulence factor 
asnA  1.306  2.394  asparagine synthetase AsnA 
umuC  1.318  6.519  DNA polymerase V subunit 
UTI89_P101  1.335  5.005  unknown 
dinD  1.365  4.762  DNA-damage-inducible protein 
UTI89_C2690  1.369  1.966  putative phage protein 
dinP  1.407  3.789  DNA polymerase IV 
UTI89_C2653  1.447  2.66  gene 1-like, phage portal protein 
UTI89_P099  1.468  2.501  unknown 
sulA  1.499  4.158  SOS cell division inhibitor 
UTI89_C5142  1.585  6.784  unknown 
UTI89_C2647  1.593  2.296  gene 26-like, phage head assembly protein 
hkaH  1.598  1.913  unknown 
UTI89_C4473  1.611  3.933  putative lipase 
UTI89_P091  1.64  2.56  unknown 
UTI89_C2675  1.653  1.992  CII, involved in the initiation of lysogeny 
UTI89_C2648  1.681  3.111  gene 10-like bacteriophage DNA stabilizer 
UTI89_C5096  1.735  2.274  regulatory phage protein 
UTI89_C2649  1.744  2.331  putative P22 tail-4 accessory factor 
recA  1.751  3.75  DNA repair, SOS induction 
UTI89_C2646  1.787  2.712  gene 14-like, putative phage protein 
UTI89_C5091  1.792  1.892  putative phage protein 
UTI89_C0801  1.808  2.066  unknown 
UTI89_C2654  1.865  2.878  gene 2-like, putative phage terminase 
UTI89_C2657  1.871  2.54  putative phage regulatory protein Rha 
cro  1.93  2.69  phage Cro protein 
UTI89_C2651  1.932  2.896  putative phage capsid/coat protein 
UTI89_C2660  1.95  3.036  gene R-like, bacteriophage lysozyme 
UTI89_C2672  1.97  2.46  bacteriophage Nil2 gene P DnaB analogue 
dinF  1.988  5.541  DNA-damage-inducible SOS response protein 
yahM  1.996  2.198  unknown 
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Table 3.3 (continued) 
Gene  Fold Change (log2)  Median Effect Size  Functional Annotation 
UTI89_C1922  2  6.13  contains a metal-dependent hydrolase 
lexA  2.03  5.635  repressor of LexA 
yebG  2.081  5.7  DNA damage-inducible protein 
UTI89_C2655  2.091  2.899  putative phage terminase 
hkbD  2.094  2.575  unknown 
UTI89_C2678  2.121  2.269  regulatory phage protein 
ral  2.145  2.189  bacteriophage lambda restriction inhibitor 
UTI89_C2692  2.147  1.688  putative prophage protein 
UTI89_C2691  2.151  1.632  putative phage protein 
UTI89_C2656  2.157  1.743  putative phage protein 
yfdr1  2.191  2.945  unknown 
UTI89_C2674  2.191  3.653  unknown 
roi  2.2  2.988  DNA-binding protein 
UTI89_C2681  2.236  2.501  unknown 
UTI89_C4883  2.239  4.363  unknown 
UTI89_C2663  2.246  1.846  bacteriophage ST64T anti-terminator gp23 
UTI89_C2652  2.263  1.947  gene 8-like phage scaffold protein 
fmlD  2.275  1.891  fimbrial fimH mannose-binding 
ninB1  2.279  2.981  NinB protein encoded within prophage 
UTI89_C2673  2.301  2.895  bacteriophage replication protein O 
umuD  2.307  5.395  DNA polymerase V subunit 
UTI89_C2679  2.309  2.898  phage regulatory protein N 
UTI89_C2645  2.322  2.858  gene 7-like, putative phage protein 
UTI89_C2650  2.342  3.263  unknown 
UTI89_C1186  2.347  4.136  DinI 
UTI89_C1282  2.366  2.066  lambda ant-restriction protein 
UTI89_C2661  2.397  2.792  gene S-like, putative phage holin 
kil2  2.403  2.021  kil protein of bacteriophage HK97 
UTI89_C2685  2.456  1.98  putative phage protein 
UTI89_C2693  2.474  2.163  unknown 
ninB2  2.491  2.862  putative phage NinB protein 
rus  2.53  2.868  Holliday-junction resolvase 
hkaJ  2.546  2.29  anti-RecBCD 2, putative phage protein 
UTI89_C2682  2.546  2.385  putative lambda CIII 
ninH  2.563  2.663  putative phage NinH protein 
ninE2  2.575  2.36  bacteriophage lambda nin 60-like protein 
UTI89_C2687  2.579  2.085  bacteriophage HK97 gp40 
UTI89_C2668,   2.594  3.964  unknown 
erf  2.631  2.258  bacteriophage HK97 gp40 
UTI89_C5143  2.786  7.032  putative DinI 
UTI89_C2684  2.888  2.267  bacteriophage kil protein 
recN  2.949  15.096  recombination and repair protein 
Genes indicated in bold are putative SOS regulon-associated elements. 
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Table 3.4 Significant changes in differentially expressed transcripts - S. 
saprophyticus 15305 control versus 1/4MIC ciprofloxacin (short-term exposure) 
Gene  Fold Change (log2)  Median Effect Size  Functional Annotation 
SSP0843  -0.47  -1.969  amidohydrolase 
SSP1254  -0.431  -2.204  Fur-family transcriptional regulator 
SSP2255  -0.369  -3.692  50S ribosomal protein L25 Ctc 
SSP0308  -0.349  -1.977  unknown 
SSP0988  -0.309  -2.205  mannosyl-protein endo-beta-N-acetylglucosamidase 
SSP0831  -0.29  -1.76  putative mutS DNA mismatch repair protein 
SSP2065  -0.231  -1.626  lipase 
SSP1669  -0.222  -1.684  unknown 
SSP2275  -0.205  -3.166  Orn Lys Arg decarboxylase 
rho  -0.171  -1.582  transcription termination factor Rho 
trmD  -0.167  -2.157  tRNA (guanine-N(1)-)-methyltransferase 
SSP1294  -0.161  -3.773  penicillin-binding protein 2 
SSP1850  -0.134  -2.178  lipoyl synthase 
SSP1520  0.141  1.59  succinyl-CoA synthetase subunit alpha 
groEL  0.192  1.795  chaperonin 
SSP2237  0.192  1.873  pyridoxal biosynthesis lyase PdxS 
SSP1797  0.21  2.094  3-oxoacyl-[acyl-carrier-protein] synthase II 
SSP1024  0.215  1.861  putative general stress protein 
SSP0325  0.225  2.619  acetyl-CoA acetyltransferase 
SSP1233  0.229  1.692  geranylgeranyl pyrophosphate synthase 
gmk  0.235  2.473  guanylate kinase 
SSP1618  0.252  2.29  6-phospho-3-hexuloisomerase domain, PHI 
SSP1782  0.266  2.265  hemoglobin-like protein 
SSP2198  0.271  2.2  3-hydroxybutyrate dehydrogenase 
SSP1593  0.278  4.602  cell division inhibitor protein MraZ 
SSP0336  0.28  2.475  glucose-specific PTS transporter IIABC 
SSP0333  0.282  1.929  pyruvate oxidase 
aspS  0.286  2.449  aspartyl-tRNA synthetase 
SSP0052  0.293  5.154  restriction endonuclease S subunit 
SSP0499  0.297  2.823  formate nitrite family transporter 
SSP1470  0.31  3.996  unknown 
SSPP216  0.31  2.033  putative cadmium resistance transporter 
capH  0.311  4.685  glycosyl transferase 
rplW  0.316  2.015  50S ribosomal protein L23 
SSPP115  0.323  2.099  arsenic efflux pump protein 
rplF  0.334  1.903  50S ribosomal protein L6 
SSP1466  0.352  1.72  thiamine-precursor transporter protein 
SSP0960  0.353  1.835  putative gas vesicle protein 
SSP1059  0.362  1.586  Xaa-Pro dipeptidase 
SSP2075  0.363  1.663  nucleoside transporter 
rplE  0.375  1.787  50S ribosomal protein L5 
SSP1180  0.377  3.269  16S ribosomal RNA methyltransferase RsmE 
SSP0717  0.399  1.812  putative hemolysin III homolog 
rpmD  0.404  7.223  50S ribosomal protein L30 
SSP2208  0.427  1.508  elongation factor G 
SSP1416  0.445  1.516  transketolase 
valS  0.461  1.702  valyl-tRNA synthetase 
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Table 3.4 (continued) 
Gene  Fold Change (log2)  Median Effect Size  Functional Annotation 
capL  0.467  1.874  capsular polysaccharide synthesis protein 
SSP1124  0.488  2.209  adenine phosphoribosyltransferase 
SSP0532  0.503  1.554  major facilitator superfamily permease 
SSP0508  0.506  1.844  proton sodium-glutamate symport protein 
SSP1005  0.513  2.051  major facilitator superfamily permease 
SSP2277  0.527  2.023  unknown 
SSP2178  0.535  2.218  ribulokinase 
SSP2259  0.543  2.785  translation initiation inhibitor 
SSP2346  0.609  3.203  unknown 
SSP0197  0.689  4.328  unknown 
SSP0296  0.696  2.437  copper chaperone 
SSP0750  0.753  2.207  putative phosphopentomutase 
recA  0.765  1.82  recombinase A 
SSP2138  0.92  1.997  unknown 
Genes indicated in bold are putative SOS regulon-associated elements. 
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Table 3.5 Significant changes in differentially expressed transcripts - S. 
saprophyticus 15305 control versus 1/4MIC ciprofloxacin (long-term exposure) 
Gene  Fold Change (log2)  Median Effect Size  Functional Annotation 
SSP0584  -0.501  -1.777  unknown 
SSP1390  -0.48  -1.647  methionine sulfoxide reductase regulator MsrR 
SSP0895  -0.467  -1.839  unknown 
SSP1043  -0.432  -1.935  spermidine acetyltransferase 
SSP2255  -0.349  -9.872  50S ribosomal protein L25 Ctc 
SSP0485  -0.337  -1.968  major facilitator superfamily permease 
SSPP138  -0.315  -2.058  IS431 transposase 
SSP0021  -0.277  -2.125  two component response regulator OmpR-like protein 
SSP1267  -0.22  -2.108  thioredoxin reductase 
clpX  -0.163  -2.868  ATP-dependent protease ATP-binding subunit ClpX 
SSP2206  -0.162  -2.167  peptidase 
SSP1850  -0.15  -2.705  lipoyl synthase 
SSP2074  -0.148  -2.187  unknown 
capB  -0.123  -1.645  polysaccharide synthesis length determinator 
SSP0052  0.156  2.334  restriction endonuclease S subunit 
mutL  0.165  1.641  DNA mismatch repair protein 
SSP0623  0.17  1.525  iron-siderophore ABC transporter periplasmic protein 
SSP1520  0.188  5.695  succinyl-CoA synthetase subunit alpha 
SSP1819  0.191  3.238  NADH:flavin oxidoreductase 
prfC  0.192  1.992  peptide chain release factor 3 
SSP1300  0.195  2.844  permease 
SSP1360  0.243  1.556  putative virulence factor B 
rpmD  0.246  1.901  50S ribosomal protein L30 
capH  0.248  2.519  glycosyl transferase 
SSP1618  0.271  4.58  6-phospho-3-hexuloisomerase domain, PHI 
SSP1953  0.282  1.919  thioredoxin reductase 
SSP0834  0.283  2.595  sulfur transporter 
gatB  0.293  1.579  aspartyl/glutamyl-tRNA amidotransferase subunit B 
aroB  0.3  2.241  3-dehydroquinate synthase 
SSP1593  0.301  2.943  cell division inhibitor protein MraZ 
SSP0499  0.304  2.53  formate nitrite family transporter 
SSP0336  0.308  2.463  glucose-specific PTS transporter IIABC 
SSP1064  0.308  3.309  DNA polymerase III alpha chain 
SSP0948  0.315  2  proton glutamate symporter 
dnaK  0.316  1.829  molecular chaperone heat shock protein 70 
SSP1175  0.329  3.893  heat-inducible transcriptional repressor 
SSP0025  0.33  3.233  beta-lactamase metal-dependent hydrolase 
SSP2232  0.34  2.819  ATP:guanido phosphotransferase 
SSP1068  0.348  2.358  6-phosphofructokinase 
SSP0845  0.351  3.597  unknown 
SSP1466  0.361  3.088  putative thiamine-precursor transporter protein 
SSP0762  0.368  1.506  aldehyde dehydrogenase 
SSP0269  0.375  2.264  oligopeptide-peptide ABC transporter permease 
SSP0851  0.375  2.294  acetyltransferase 
SSP2242  0.39  2.591  dihydropteroate synthase 
rpsM  0.394  3.536  30S ribosomal protein S13 
SSP0776  0.402  2.505  ATP synthase F0F1 subunit C 
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Table 3.5 (continued) 
Gene  Fold Change (log2)  Median Effect Size  Functional Annotation 
SSP1358  0.416  2.286  aldo keto reductase 
SSP1814  0.418  2.248  argininosuccinate synthase 
SSP1176  0.421  1.576  heat shock protein GrpE 
SSP0767  0.429  1.836  rRNA or tRNA methylase 
SSP1005  0.43  2.005  major facilitator superfamily permease 
SSP1729  0.457  1.58  putative bacterial Ig-like 3-domain protein 
SSP1627  0.468  1.989  short-chain alcohol dehydrogenase 
SSP0208  0.471  4.741  nitroreductase 
SSP0960  0.473  2.961  putative gas vesicle protein 
SSPP218  0.532  3.139  cadmium efflux system accessory protein 
SSP1178  0.538  2.667  chaperone protein DnaJ 
SSP0178  0.561  1.559  glycerate kinase 
SSP2233  0.593  3.447  McsA modulator of heat shock repressor CtsR 
SSP2178  0.662  3.863  ribulokinase 
SSP0197  0.676  2.829  unknown 
gidB  0.691  2.35  glucose inhibited division protein B 
SSP1800  0.77  2.841  putative ATP-depended chaperone ClpB 
SSP2138  0.795  1.633  unknown 
SSP0296  0.85  3.989  copper chaperone 
SSP0769  1.084  1.816  exopolysaccharide-associated tyrosine-phosphatase 
Genes indicated in bold are putative SOS regulon-associated elements. 
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3.2 DEMONSTRATING THE INFLUENCE OF SUB-
INHIBITORY CIPROFLOXACIN ON 
UROPATHOGENENESIS IN A MURINE MODEL OF 
UTI 
Having demonstrated antibiotic-dependent changes in vitro, the next logical step was to 
establish the potential clinical relevance and therapeutic implications in vivo. This work 
used a well defined murine model of UTI and was conducted in the laboratory of Dr. 
Scott Hultgren (Washington University School of Medicine in St Louis, MO) over four 
months, with funding by a Canadian Institutes of Health Research - Michael Smith 
Foreign Study Supplement.  
 
3.2.1 Evaluating the pathogenic potential of ciprofloxacin-
primed S. saprophyticus and E. coli during acute phase 
infection 
The outcome of UTI is generally accepted to be determined within the first 24 hours of 
inoculation, with underlying host and pathogen factors contributing to either resolution, 
or establishment of chronic infection. Generally, these trends are observed at this time as 
a bimodal distribution of bacterial load, with ~50% of C3H/HeN mice revealing signs of 
resolution, and the remainder sustaining high titers. The bacterial load after initial 
infection with untreated or ciprofloxacin-primed uropathogens was assessed to determine 
the effect of sub-inhibitory antibiotics on colonization after 24 hpi. A typical bimodal 
distribution of bacterial loads was observed at this time point, with ciprofloxacin-priming 
prior to infection resulting in higher overall bladder and kidney titers for both S. 
saprophyticus 15305 and E. coli UTI89 after 24 hours (Figure. 3.15). Almost 100% of 
murine kidneys showed no signs of infection clearance at this time point for both 
organisms primed with ciprofloxacin. 
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Figure 3.15. S. saprophyticus 15305 and E. coli UTI89 titers in C3H/HeN mouse 
bladders and kidneys following 24 hour infections. Starter cultures were reconstituted in 
fresh media supplemented with 1/4MIC ciprofloxacin for 4 hours prior to infection. 
Dotted line indicates limit of detection. Means from at least three independent 
experiments shown with significance. Significance was determined using Mann-Whitney 
test (Gaussian approximation) (*, P < 0.05). 
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Figure 3.15   
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3.2.2 Establishing the effect of ciprofloxacin priming on chronic 
UTI risk in S. saprophyticus and E. coli infected mice 
In order to determine the frequency of chronic cystitis and pyelonephritis in antibiotic-
primed versus control pathogens, infection periods were extended to 14 days post-
inoculation (dpi). C3H/HeN mice were either inoculated with untreated or ciprofloxacin-
primed S. saprophyticus 15305 and E. coli UTI89 as described. Following sacrifice, 
bladders and kidneys were plated, and uropathogens enumerated to determine bacterial 
load. In addition to increasing bacterial load 24 hpi, ciprofloxacin-priming resulted in 
significantly worse infections 14 dpi (P < 0.05) (Figure 3.16). The clinical threshold for 
assessing lifetime chronic infection risk is the presence of E. coli UTI89 loads of >10
4
 
cfu/mL at 14 dpi (such data does not exist for S. saprophyticus) (Hannan et al., 2010). 
Control animals infected with E. coli UTI89 demonstrated expected bimodal results, with 
40% of mice spontaneously resolving their infections after 14 days. Conversely, 
ciprofloxacin-priming resulted in 100% of mice developing chronic E. coli UTI89 
infections. Similarly, 50% of control mice showed signs of kidney clearance while only 
20% showed similar results for ciprofloxacin-primed groups. Although there are no 
established clinically significant S. saprophyticus 15305 infection thresholds for this 
model, it is interesting that 100% of mice resolved cystitis in the control group while 50% 
maintained bladder titers with ciprofloxacin-priming. In addition, 100% of primed S. 
saprophyticus 15305 treated mice maintained at least some infectious kidney titer, while 
only 60% exhibited the same result in control groups. 
 
3.2.3 Evaluating ciprofloxacin modulation of pathogenic 
mechanisms which contribute to chronic infection 
Changes in intracellular bladder populations during the early stages of infection were 
assessed using gentamicin-protection assays (3.5 hpi) for S. saprophyticus 15305, and 
microscopy (6 hpi) for E. coli UTI89. Analysis parameters varied as both E. coli UTI89 
and S. saprophyticus 15305 exploit distinct pathogenic mechanisms to establish chronic 
infection. E. coli IBC formation was detected by staining for lacZ expression using X-
Gal. IBCs are visible as punctate blue stains under examination using a dissecting  
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Figure 3.16. S. saprophyticus 15305 and E. coli UTI89 titers in C3H/HeN mouse 
bladders and kidneys following 14 day infections. Starter cultures were reconstituted in 
fresh media supplemented with 1/4MIC ciprofloxacin for 4 hours prior to infection. 
Dotted line indicates limit of detection. Means from at least three independent 
experiments shown with significance. Significance was determined using Mann-Whitney 
test (Gaussian approximation) (*, P <0.05). 
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Figure 3.16 
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microscope (Figure 3.17A). This technique indicated significantly more IBCs in 
ciprofloxacin-primed groups versus control (P < 0.01) (Figure 3.17B). Ex vivo 
gentamicin protection assays of murine bladders revealed a similar trend, with categorical 
increases in intracellular S. saprophyticus 15305 populations observed in ciprofloxacin-
primed organisms (P = 0.0019) (Figure 3.17C). Although total invasion events were rare 
in S. saprophyticus 15305, intracellular reservoirs were comparatively much lower in the 
untreated group, with only 30% of mice demonstrating pathogen presence compared to 
100% in treated groups. 
 
3.2.4 Investigating IBC and cellular morphology in ciprofloxacin-
primed E. coli 
In addition to being more numerous, IBCs also appeared larger under light microscopy 
following antibiotic exposure. This observation was further explored using a green 
fluorescent protein (GFP) expressing E. coli UTI89 strain and confocal microscopy. 
Murine bladders were removed and prepared as previously described, but fixed and 
stained with fluorescent wheat germ agglutinin (WGA) and SYTO9 for cell surface and 
nuclei detection respectively. Appearance of control E. coli UTI89 was unremarkable as 
IBCs demonstrated characteristic tight, globular clustering (Figure 3.18A). Examination 
of ciprofloxacin-primed E. coli UTI89 revealed larger, diffuse IBCs with atypical 
morphology (Figure 3.18B). Early filamentation was noted in several of the IBCs 
belonging to the ciprofloxacin treated E. coli UTI89 group (Figure 3.18C). Volumetric 
analysis of the IBCs confirmed that ciprofloxacin-priming significantly increased overall 
size 2.0-fold (P = 0.0007).  
The ability for ciprofloxacin to induce filamentation was investigated further as this 
process might contribute to observed early IBC evacuation. Cultures of E. coli UTI89 
were treated with sub-inhibitory ciprofloxacin and imaged using TEM. Control E. coli 
UTI89 were unremarkable, appearing ~1-2 µm in length (Figure 3.19A). Most organisms 
in the ciprofloxacin treatment group appeared similar in nature; however, ~10% of the 
overall population presented with the observed filamenting phenotype, sometimes 
increasing to >10 µm in length (Figure 3.19B). 
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Figure 3.17. E. coli UTI89 IBC detection using lacZ staining in C3H/HeN mouse 
bladders (A) and quantification (B) following 6 hour infections. Number of intracellular 
S. saprophyticus 15305 isolated from murine bladders following a gentamicin protection 
assay (C). Whole bladders were plated and S. saprophyticus colonies identified using 
lacZ staining. Means from at least two independent experiments are shown with 
significance. Significance determined using Mann-Whitney test (B) with Gaussian 
approximation (C) (**, P < 0.01; ***, P = 0.0019). 
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Figure 3.17 
 
 
 
122 
 
 
 
 
 
 
 
 
 
Figure 3.18. Representative confocal images of control (A) and antibiotic pre-treated (B) 
E. coli UTI89 IBCs in C3H/HeN mouse bladders following 6 hour infections (red = 
GFP/UTI89; blue = SYTO9/nuclei; green = WGA/cell). Early pathogen evacuation from 
an IBC via filamentation in a ciprofloxacin pre-treated sample is shown (indicated with 
arrows - C). Volumetric analysis of confocal images is depicted for both control and 
antibiotic pre-treated IBCs (D). Means from at least two independent experiments are 
shown with significance. Significance was determined using a Mann-Whitney test (***, 
P = 0.0007). 
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Figure 3.18 
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Figure 3.19. Representative TEM images of non-treated (A) and 1/4MIC ciprofloxacin 
treated (B) E. coli UTI89 filamentation. The first panel depicts individual and clustered 
rod and coccoidal E. coli while the second panel reveals filamenting and non-filamenting 
organisms.  Magnification for each micrograph is indicated. 
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Figure 3.19 
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3.2.5 Assessing the effect of sub-therapeutic ciprofloxacin on 
recurrence risk in 'resolved' mice and infection severity 
chronically infected mice 
Thus far, experimental models have only made use of ciprofloxacin-primed 
uropathogens, with mice receiving no antibiotic exposure. To overcome this, a new 
model of infection was established whereby mice were supplemented with sub-
therapeutic ciprofloxacin in their drinking water daily. Sub-therapeutic antibiotic-
dependent changes in bacterial urine titers of mice who were previously inoculated with 
E. coli UTI89 but had spontaneously resolved (<10
4
 cfu/mL bacterial urine load) their 
infection were initially considered. Urine titers were tracked for three days in the absence 
of antibiotic to determine baseline cfu/mL. Over this period no mice presented with 
clinically significant infection (>10
4
 cfu/mL) (Figure 3.20A). Antibiotics at 1/50th the 
empirical therapeutic concentration were then supplemented into the drinking water and 
changes in bacterial urine load were tracked. This dose significantly increased the 
frequency of mice with clinically significant infection from 0% to 80% occurrence (P = 
0.0131) (Figure 3.20A). The dose was further increased to 1/25th the empirical 
therapeutic dose with no changes observed in the remaining mice (Figure 3.20A). 
Increasing the dose to 1/10th the empirical therapeutic dose resulted in retraction of 
bacterial urine loads to the limit of detection, suggesting that observed antibiotic-
dependent increases were not due to the appearance of resistant mutants (data not shown). 
Although it can be concluded that ciprofloxacin initiated infection recurrence, it is 
unclear whether this was due to re-infection with a new strain or recalcitrance of the 
previously inoculated pathogen.  
The effect of inadequate dosing was also assessed in mice with chronic infection (>10
4
 
cfu/mL for ≥ 14 dpi). This experiment was undertaken to test if antibiotics would worsen 
an already established infection, such as might occur during low-dose, extended use 
prophylaxis. Chronically infected mice were supplemented with 1/50th the empirical 
therapeutic dose for three days, with urine titers measured after this period. This 
significantly increased E. coli UTI89 urine load by an order of magnitude of 1.7 (P < 
0.001) (Figure 3.20B). Again, treatment with 1/10th of the therapeutic dose was sufficient 
to decrease cfu/mL to the limit of detection indicating spontaneous resistant mutants did  
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Figure 3.20. Fraction of 'resolved' C3H/HeN mice presenting with clinically significant 
(>10
4
 cfu/mL) bacterial urine titers following sub-therapeutic ciprofloxacin dosing over 
time (N = 10 mice; A). Antibiotic dosing period is indicated in the upper x-axis as 
fractions of the therapeutic dose. Urine titers of chronically infected mice receiving either 
no antibiotic or sub-therapeutic ciprofloxacin for three days (B). Means from at least two 
independent experiments are shown with significance. Significance was determined using 
a Logrank (A; P = 0.0131) or one-way ANOVA and Bonferroni's multiple comparison 
test (B) (***, P < 0.001). 
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Figure 3.20 
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not contribute to increased titers during dosing (Figure 3.20B). The application of 
ciprofloxacin resulted in more significant infections than when organisms were primed 
prior to inoculation. This observation suggests that additional factors unrelated to the 
pathogens themselves are potentially enhancing virulence. 
 
3.2.6 Evaluating the capacity of ciprofloxacin to modulate 
urothelial immune responses 
It was postulated that the changes in infection frequency and severity observed in mice 
could in part be attributed to the immunomodulatory capacity of ciprofloxacin on the 
host. This was first tested in a controlled in vitro experiment using bladder cell lines. 
Cytokines interleukin (IL)-6 and IL-8 were analyzed for their role in recruiting 
neutrophils to urothelial infection sites using a Luminex® bead-based assay. Baseline 
expression was compared to infection groups in the absence of antibiotics and results 
showed a typical spike in cytokine secretion for both molecules (P < 0.001) (Figure 
3.21A, B). All sub-inhibitory ciprofloxacin concentrations reduced IL-6 and IL-8 
secretion to below baseline levels (P < 0.05; P < 0.01; P < 0.001). The finding that even 
low ciprofloxacin doses induced suppression of cytokine release was reflective of the 
drug's potency at physiologically relevant concentrations.  
The findings observed in the T24 bladder cell lines were recapitulated in 5637 bladder 
cells. Ampicillin and gentamicin were also tested at 1/4MIC levels to assess the 
specificity of immune suppression. S. saprophyticus 15305 infections were carried out as 
described, and supernatants were analyzed for IL-8 expression using an enzyme linked 
immunosorbent assay (ELISA). While ciprofloxacin treatment reduced IL-8 secretion to 
below baseline levels (P < 0.05) (Figure 3.21D), ampicillin and gentamicin did not 
induce this effect. An additional experimental group containing LPS was applied as a 
cell-free control to ensure S. saprophyticus 15305 was not influencing the release of 
cytokine. LPS in the absence of antibiotic caused a predicted spike in IL-8 (P < 0.001) 
(Figure 3.21C), however, ciprofloxacin depressed IL-8 secretion (P < 0.01). Although 
ampicillin did not influence IL-8 secretion, gentamicin did demonstrate slight but not 
significant immunomodulatory activity. 
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Figure 3.21. IL-6 (A) and IL-8 (B) cytokine expression profiles for T24 bladder cells 
infected with S. saprophyticus 15305 exposed to various subinhibitory levels of 
ciprofloxacin. Release of IL-8 from 5637 bladder cells following treatment with either 
LPS (C) or S. saprophyticus 15305 (D) in the presence of 1/4MIC of either ciprofloxacin 
(C), ampicillin (A), or gentamicin (G) as indicated. Significance was determined using 
one-way ANOVA and Dunnett's (A,B) or Bonferroni's (C,D) multiple comparison tests 
(*, P < 0.05; **, P < 0.01; ***, P < 0.001; ns = not significant). 
 
 
 
 
 
 
 
 
 
131 
 
 
 
 
Figure 3.21 
 
 
 
132 
 
 
3.2.7 Evaluating the immunomodulatory effects of sub-
therapeutic ciprofloxacin during early stages of UTI in vivo 
It was hypothesized that the immunomodulatory effects of ciprofloxacin in vitro would 
suppress the secretion of pro-inflammatory mediators and decrease immune cell infiltrate 
in vivo. Both E. coli UTI89 and mock (PBS) infected mice receiving sub-therapeutic 
ciprofloxacin were found to have significantly fewer PMNs in urine sediments compared 
to controls (P < 0.05; P < 0.001) (Figure 3.22). The results for the mock infected, 
ciprofloxacin treated group were especially noteworthy, with no measurable PMN score 
being achieved. 
The cause of the reduced immune cell infiltrate in ciprofloxacin treated mice was 
postulated to be related to modulation of cytokine secretion. This was assessed using a 
Luminex® bead-based multiplex assay of bladder tissue homogenates. A total of seven 
urinary-relevant cytokines were assessed and included IL-1β, IL-6, KC (IL-8), G-CSF, 
IL-17, IL-10, and TNFα. All produced reliable profiles with the exception of TNFα (data 
not shown). Changes in IL-17 secretion were unremarkable in either control or 
ciprofloxacin treatment groups (Figure 3.23). Similarly, KC was not significantly 
impacted by ciprofloxacin, although there was a trend of reduced secretion when 
antibiotic was present (Figure 3.23). All other cytokines were significantly affected by 
the presence of ciprofloxacin. The pro-inflammatory mediators IL-1β and IL-6 were 
suppressed while secretion of the anti-inflammatory cytokine IL-10 was increased (P < 
0.05; P < 0.01; P < 0.001) (Figure 3.23). These cytokine alterations could reasonably 
account for the observed decrease in immune cell infiltrate in urine sediments. In 
contrast, the pro-inflammatory cytokine G-CSF was significantly increased in the 
presence of ciprofloxacin and E. coli UTI89 infection (P < 0.05) (Figure 3.23). Of note, 
E. coli have previously been reported to increase the expression of this cytokine. It 
remains unclear how ciprofloxacin influences this process.  
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Figure 3.22. PMN counts collected from urine sediments of either E. coli UTI89 or mock 
(PBS) infected mice treated with or without 1/50 sub-therapeutic ciprofloxacin 
supplemented drinking water (3 day exposure). Means from at least two independent 
experiments are shown with significance. Significance was determined using one-way 
ANOVA and Bonferroni's multiple comparison test (*, P < 0.05; ***, P < 0.001). 
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Figure 3.23. Murine bladder cytokine secretion following 3.5 hour E. coli UTI89 or 
mock (PBS) infection in the presence or absence of 1/50 sub-therapeutic ciprofloxacin 
supplemented drinking water (3 day exposure). Means from at least two independent 
experiments are shown with significance. Significance was determined using one-way 
ANOVA and Bonferroni's multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 
0.001). 
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3.2.8 Assessing the influence of sub-therapeutic ciprofloxacin 
on host and pathogen responses in vivo 
As ciprofloxacin modulates the immune response, it was hypothesized that mice 
receiving sub-therapeutic ciprofloxacin would develop less severe inflammation and 
decreased risk of developing chronic infection than control mice. Sub-therapeutic 
ciprofloxacin treatment did not significantly affect bacterial urine loads compared to 
untreated controls (Figure 3.24). Still, mice presented with lower infection titers at 14 dpi 
when they received ciprofloxacin supplemented drinking water (Figure 3.24D, E). Early 
kidney infection titers were slightly higher in the mice receiving antibiotic, compared to 
controls (Figure 3.24B). In addition to decreased titer, bladders from ciprofloxacin treated 
mice weighed significantly less than those from the control group, suggestive of 
decreased immune infiltration (P < 0.05) (Figure 3.24C). 
 
3.2.9 Evaluation of infection severity in a murine ciprofloxacin 
prophylaxis model of recurrent UTI 
The possibility that low-dose prophylaxis promotes virulence and enhances pathogenesis 
was investigated. Changes in bacterial urine load were assessed at least every two days to 
track the course of infection using a prophylaxis therapy model. As expected, bacterial 
urine loads decreased with the application of co-trimoxazole, with the exception of two 
mice in experiment 2 (Figure 3.25). The following 7 day rest period revealed dynamic 
changes in E. coli UTI89 urine titer, with frequent recurrences observed. In general, 
prophylactic therapy did not appear to improve the frequency of infection resolution over 
the 7 day treatment period compared to non-treated controls. Indeed, 10% of mice in the 
prophylactic group presented with clinically significant infection while 15% did so in the 
control group at the study's end (Figure 3.25). 
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Figure 3.24. Bladder and kidney titers of E. coli UTI89 inoculated mice receiving 1/50th 
sub-therapeutic ciprofloxacin supplemented drinking water or control. Mice were 
sacrificed at either 24 hpi (A, B) or 14 dpi (D, E) to determine infection severity. Bladder 
weight was also measured at 24 hpi (C). Means from at least two independent 
experiments are shown with significance. Significance was determined using Mann-
Whitney test (Gaussian approximation) (*, P <0.05). 
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Figure 3.25. Two experimental replicates follow E. coli UTI89 urine titers in C57BL/6 
mice treated prophylactically with ciprofloxacin (red) or vehicle (water - black) via daily 
gavage. Each line represents the bacterial urine load for an individual mouse. Axis labels 
indicate the start of co-trimoxazole (TMP/SMX) therapy and period of prophylaxis 
dosing. Dotted line indicates the cut off for clinically significant (>10
4
 cfu/mL) infection. 
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Figure 3.25 
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The unremarkable urine results from the prophylaxis experiments necessitated further 
investigation. Therefore, upon sacrifice both bladders and kidneys were evaluated to 
assess E. coli UTI89 colonization. Although both organs demonstrated greater bacterial 
loads in the prophylaxis group, this difference was not significant (Figure 3.26A, B).  
However, comparison of E. coli UTI89 intracellular bladder reservoirs revealed 
prophylaxis significantly increased the frequency of urothelial invasion (P < 0.05). The 
inability of prophylaxis to eradicate infection is worthy of further investigation. 
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Figure 3.26. E. coli UTI89 titers in C57BL/6 mouse bladders (A) and kidneys (B) 
following a 1 week prophylactic treatment regimen with either ciprofloxacin or vehicle 
(water). Gentamicin protection assays indicate the presence of intracellular E. coli 
reservoirs (C). Dotted line indicates limit of detection. Means from at least two 
independent experiments are shown with significance. Significance was determined using 
an unpaired, two-tailed t-test. (ns = not significant; *, P = 0.0148). 
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Figure 3.26 
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3.3 UNDERSTANDING THE ABILITY OF 
UROPATHOGENS TO PERSIST DESPITE ADEQUATE 
ANTIBIOTIC INTERVENTION DURING INFECTION 
The inability of antibiotics to eradicate bacteria during chronic diseases such as recurrent 
UTI is attributed to the presence of MDT persister cells. Yet, despite the susceptibility of 
E. coli UTI89 to ciprofloxacin, titers were unchanged by prophylaxis, and actually 
increased slightly in some cases (Figure 3.25A, B). As persister cells are known to form 
in response to environmental stress, it was hypothesized that antibiotics are capable of 
promoting onset of this MDT state. In designing studies to address this hypothesis, it was 
deemed important to characterize the nature of uropathogen persisters in order to evaluate 
novel therapeutic modalities.  
Persister cells are believed to benefit from MDT through complete, global metabolic 
dormancy. Therefore, two hypotheses were considered to evaluate the contribution of 
dormancy towards persistence: i) dormancy is necessary and sufficient to convey MDT 
such that persisters will respond to different antibiotics with the same levels of survival; 
and ii) different antibiotics will induce global dormancy such that surviving persisters 
will demonstrate tolerance to both lethal levels of the same and different agents (cross-
tolerance). This work challenges the notion that persister cells represent truly dormant 
variants of the overall population. 
 
3.3.1 Different classes of antibiotics induce persister cell 
formation in both S. saprophyticus and E. coli 
The ubiquity of antibiotic-dependent persister induction was assessed using 
ciprofloxacin, ampicillin, and gentamicin against both Gram-negative (E. coli CFT073) 
and Gram-positive (S. saprophyticus 15305) organisms. The persister traits of E. coli 
CFT073 are better characterized than those of E. coli UTI89, justifying its initial use for 
these experiments. Importantly, growth phase has a significant impact on persister levels, 
requiring growth rate characterization of all strains utilized prior to investigation. In 
general, all strains of E. coli used throughout this study demonstrated similar growth 
rates, while S. saprophyticus 15305 was comparatively distinct, warranting adjustment of 
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experimental protocols to permit accurate enumeration of the persister fraction (Figure 
3.27).  
Exposing bacteria to a lethal antibiotic dose followed by enumeration of survivors 
permits rapid characterization of the persister fraction. This approach was undertaken to 
assess the ability of antibiotics to modulate persister formation in uropathogens. Both E. 
coli CFT073 and S. saprophyticus 15305 showed significant (P < 0.05; P < 0.01 
respectively) increases in percent survival following ciprofloxacin, ampicillin, and 
gentamicin pre-treatment and challenge (Figure 3.28). Analysis of strains from these 
surviving fractions did not reveal any significant changes in MIC compared to the 
original starting culture, indicating that spontaneous resistance which developed during 
sub-inhibitory antibiotic challenge did not contribute to survival (data not shown). 
Resuscitation of persisters following therapy cessation presumably plays a critical role in 
antibiotic therapy failure. Therefore, the recalcitrance rate of persisters was evaluated in 
the presence or absence of antibiotic priming. This was accomplished by reconstituting 
presumed 'killed' cultures in fresh media and observing persister re-emergence via 
turbidity. There was a significant difference in persister resuscitation time for E. coli 
CFT073 compared to S. saprophyticus 15305, with the former emerging rapidly 
(exclusively within 24 hours) across treatment groups while the latter required ~24-72 
hours depending on the antibiotic (Figure 3.29). The antibiotic priming influenced 
resuscitation rates in S. saprophyticus 15305 but not E. coli CFT073, with ciprofloxacin 
and gentamicin pre-treatments prolonging reactivation. In some cases, persister cells 
could spontaneously emerge up to 14 days following initial challenge in S. saprophyticus 
15305 but not E. coli CFT073 cultures. 
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Figure 3.27. Comparison of  growth kinetics for all uropathogens tested. Means are from 
at least two independent experiments. Significance was determined using unpaired t-test 
(all E. coli strains are non-significant for growth variation over a 24 hour period; P > 
0.05). 
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Figure 3.27 
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Figure 3.28. Persister induction following a 1/4MIC pre-treatment with either 
ciprofloxacin, ampicillin, or gentamicin for 3 hours. Percent surviving fractions represent 
the persister sub-population following 3 hour lethal treatment with either ciprofloxacin 
(A, D), ampicillin (B, E), or gentamicin (C, F) in E. coli CFT073 (A-C) or S. 
saprophyticus 15305 (D-F). Means from at least three independent experiments shown 
with significance. Significance determined using unpaired t-test (*, P < 0.05; **, P < 
0.01; ***, P < 0.001). 
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Figure 3.28 
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Figure 3.29. Average number of days till persister resuscitation following lethal 
antibiotic challenge. Pre-treated (1/4MIC) and non-treated cultures were considered for 
both E. coli CFT073 and S. saprophyticus 15305. Means from at least four independent 
experiments shown with significance. Significance was determined using one-way 
ANOVA and Bonferroni's multiple comparison test (*, P < 0.05; ***, P < 0.001). 
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3.3.2 Evaluating antibiotic susceptibility patterns in Type I and II 
persister cells 
The efficacy of ciprofloxacin, ampicillin, and gentamicin was surveyed against stationary 
phase (predominantly Type I persister) cultures. S. saprophyticus 15305 demonstrated 
significantly greater antibiotic tolerance during stationary phase with percent survival 
increasing 443.2, 90,263.0 and 14,682.4-fold compared to exponential phase cultures for 
ciprofloxacin, ampicillin, and gentamicin respectively (P < 0.001) (Figure 3.30B). 
Similarly, E. coli CFT073 survival increased 676.2, 5,325.0, and 7,782.1-fold following 
lethal ciprofloxacin, ampicillin, and gentamicin challenge (P < 0.001) (Figure 3.30A). 
Heterogeneity in percent survival was observed across bacterial genera and antibiotic 
class. S. saprophyticus 15305 was significantly more susceptible to gentamicin (33.5% 
survival) than ciprofloxacin (80.9%) or ampicillin (80.7%) (P < 0.001). Conversely, E. 
coli CFT073 demonstrated greater survival against ampicillin (76.8% survival) and 
gentamicin (56.6%), while remaining significantly susceptible to ciprofloxacin (3.6%) (P 
< 0.001). 
 
3.3.3 Characterizing the nature of antibiotic-induced persisters 
by challenging with lethal doses of the same and different 
agents 
The large variations observed in persister fraction size between antibiotic treatment 
groups suggests heterogeneity in persister sensitivity to antibiotics. This finding 
discredits the null hypothesis that dormancy is both necessary and sufficient to convey 
MDT, such that persisters will respond to different antibiotics with the same levels of 
survival. It was therefore hypothesized that antibiotic-induced persisters would 
demonstrate similar heterogeneity, implying that dormancy is not a significant 
contributing factor of MDT.  
The nature of the antibiotic-induced persister fraction was explored by challenging with 
the same agent that induced tolerance in addition to those with different cellular targets. 
Cross-tolerance was detected for some antibiotic classes but varied with organism genus. 
Ciprofloxacin and gentamicin pre-treatments most effectively enhanced survival of  
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Figure 3.30. Fraction sizes of Type I and Type II persisters of exponential and stationary 
phase cultures. Percent survival was determined following 3 hour challenge with lethal 
ciprofloxacin, ampicillin, or gentamicin for both E. coli CFT073 (A) and S. saprophyticus 
15305 (B). Means from at least three independent experiments are shown with 
significance. Significance was determined using one-way ANOVA and Bonferroni's 
multiple comparison test (***, P < 0.001). 
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E. coli CFT073 (Figure 3.31A, C), while ampicillin pre-treatment was favourable in S. 
saprophyticus 15305 (Figure 3.31). Sub-inhibitory ciprofloxacin significantly enhanced 
survival 5.2-fold and 3.2-fold following lethal treatment with ampicillin and gentamicin 
in E. coli CFT073, while sub-inhibitory ampicillin significantly increased survival 4.1-
fold and 34.9-fold following lethal ciprofloxacin and gentamicin challenge in S. 
saprophyticus 15305 (P < 0.05; P < 0.01). The variability of surviving fraction sizes 
between sub-inhibitory antibiotic pre-treatment groups further recapitulates the 
hypothesis that dormancy does not solely account for MDT. However, the relative 
contribution of uropathogen persister cells to UTI recurrence risk, and their capacity to 
form in the presence of sub-inhibitory antibiotic doses, are not well documented and 
warrant investigation. 
 
3.3.4 Characterizing the persister fraction of E. coli strains 
isolated from same-strain recurrent and acute infections 
A direct correlation between persister fraction size and recurrence risk has never been 
explored. However, the MDT characteristics of persister cells potentiates their role in 
recurrent UTI. Although MDT is acquired through physiological changes, the persister 
fraction of an organism is genetically ordained, suggesting that these traits are subject to 
selective pressure during antibiotic therapy. This property was explored by assessing the 
persister forming capacity of E. coli strains isolated from patients suffering from either 
typical acute infection (AI) or same-strain recurrence (SSR). 
As growth phase influences the persister fraction, we first confirmed that all UPEC 
strains demonstrated similar rates of growth (Figure 3.27). Thus, any change in the 
persister fraction is due solely to variations in the organism's capacity to form persisters. 
Stationary phase cultures were considered for Type I persister frequency. Standard 
antibiotic susceptibility testing revealed all strains to be similarly susceptible to the 
antibiotics tested, with the exception of SSR organisms TOP379 and TOP344 which 
demonstrated intermediate susceptibility to ampicillin (Table 3.1). Similar to E. coli 
CFT073, all isolates within the Type I stationary fraction tolerated ampicillin and 
gentamicin while succumbing to ciprofloxacin treatment (Figure 3.32). Unexpectedly,  
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Figure 3.31. Cross-tolerance susceptibility patterns of Type II persisters induced with 
various antibiotic pre-treatments. Percent surviving fractions represent the persister sub-
population following 3 hour lethal treatment with either ciprofloxacin (A, D), ampicillin 
(B, E), or gentamicin (C, F) for both E. coli CFT073 (A-C) and S. saprophyticus 15305 
(D-F). Means from at least three independent experiments are shown with significance. 
Significance was determined using one-way ANOVA and Bonferroni's multiple 
comparison test (*, P < 0.05; **, P < 0.01). 
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some SSR organisms revealed slight growth during lethal treatment. Although antibiotics 
were already provided at therapeutic levels, we observed the same result upon 
challenging with 10x the previous lethal dose (data not shown). Viability of all AI strains 
declined as expected. When grouped, AI strains had significantly lower survival for 
ampicillin (69.15%) and gentamicin (77.93%) treatment compared to SSR organisms 
(118.0% and 151.2% respectively), which had a higher persister fraction (P < 0.01). 
Surviving organisms did not display any changes in MIC following the experiments, 
suggesting spontaneous acquisition of resistance elements did not occur (data not shown). 
Cross-tolerance assays were also conducted to determine sub-inhibitory antibiotic effects 
on Type II persister formation during exponential phase growth and to permit assessment 
of their susceptibility. Ciprofloxacin and gentamicin pre-treatments induced persister 
states at the highest frequency in SSR organisms (P < 0.05; P < 0.01; P < 0.001) (Figure 
3.33A), while most AI strains failed to respond to antibiotics (Figure 3.33B). However, 
gentamicin pre-treatment significantly (P < 0.01) increased the persister fraction in E. 
coli AI strain PUTS1236. In almost all cases, pre-treatment with ampicillin significantly 
(P < 0.05) improved the efficacy of gentamicin in both SSR and AI organisms. Some 
antibiotic/SSR-organism combinations again demonstrated slight growth in lethal 
antibiotic concentrations. This effect was amplified in strains TOP379 and TOP344 
which are intermediately susceptible to ampicillin, with growth observed following lethal 
treatment with ampicillin and gentamicin irrespective of pre-treatment compared to non-
treated controls. Taken together, these results indicate that organisms with large persister 
fractions either initiate recurrent UTI, or that persister traits are selected for during 
repeated bouts of antibiotic therapy. 
 
3.3.5 SOS-deficient E. coli persister cells are not tolerant to 
ciprofloxacin 
The involvement of SOS response systems and virulence enhancement has been a 
recurring theme of this work. SOS responses have been intrinsically linked with the 
formation of persister cells following fluoroquinolone therapy, which is a potent DNA 
damaging agent and therefore stimulator of this system. These observations permit  
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Figure 3.32. Percent survival of same strain recurrent (SSR) and acute infection (AI) E. 
coli isolates challenged with lethal ciprofloxacin (A), ampicillin (B), or gentamicin (C) 
during stationary phase growth. Dashed lines indicate average SSR or AI grouped 
survival to the respective antibiotics. Means from at least four independent experiments 
are shown with significance. Significance between SSR and AI groups was determined 
by comparing average survival using an unpaired t-test (ns = not significant; **, P < 
0.01). 
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Figure 3.33. Cross-tolerance susceptibility patterns of SSR (A) and AI (B) E. coli 
persisters induced with various antibiotic pre-treatments. Percent survival was determined 
after challenge with a lethal dose of either ciprofloxacin, ampicillin, or gentamicin. 
Means from at least four independent experiments are shown with significance. 
Significance was determined using one-way ANOVA and Bonferroni's multiple 
comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). 
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Figure 3.33 (continued) 
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further evaluation of the role dormancy plays in MDT. It was hypothesized that if 
complete metabolic dormancy is both necessary and sufficient for MDT then established 
persisters should be refractory to antibiotics regardless of the functionality of their SOS 
system. Investigation of the SOS system's contribution to persister onset with other 
antibiotics was also warranted. 
E. coli UTI89 strains deficient in RecA production (ΔrecA - PAS0209) and LexA 
autoproteolysis (lexAT355G - PAS0211) were considered in order to compare the effects of 
insufficient double-strand break repair and SOS-induction on persister cell maintenance 
and onset. E. coli UTI89 strains PAS0209 and PAS0211 were significantly (P < 0.001) 
sensitized to ciprofloxacin challenge, thus 1/4MIC pre-treatment values were adjusted 
accordingly (Table 3.1). Ciprofloxacin and gentamicin priming significantly induced 
persister cell production in wild-type E. coli UTI89 as anticipated (P < 0.01; P < 0.001) 
(Figure 3.34A-C). This effect was completely abrogated in both SOS-deficient strains 
regardless of pre-treatment and subsequent lethal dose applied (Figure 3.34A-C). 
Although less proficient in antibiotic-dependent persister induction, SOS-deficient E. coli 
strains PAS0209 and PAS0211 did produce Type II persister levels that were comparable 
to those of wild-type E. coli UTI89.  
The contribution of active double-strand break repair and SOS response to antibiotic 
tolerance was investigated using the Type I, stationary phase persister fraction. The 
surviving fractions of the SOS-deficient E. coli UTI89 strain PAS0211 was significantly 
reduced 29.7-fold following ciprofloxacin challenge (P < 0.001) (Figure 3.35). In 
addition, E. coli UTI89 strain PAS0209 which is devoid of RecA activity, was 
completely eradicated (to the limit of detection) following ciprofloxacin challenge (P < 
0.001). However, persister levels were unchanged following incubation with ampicillin 
and gentamicin compared to wild-type E. coli UTI89 indicating PAS0209 and PAS0211 
strains were not deficient in persister cell development. These finding suggest that 
topoisomerases II and IV are not only active within persisters, but corruptible with 
ciprofloxacin treatment. Furthermore, the observed eradication of recA knock-out strains 
indicates that active double-strand DNA break repair is required for tolerance. It is 
reasonable to conclude with this data that persister cells do not constitute completely 
metabolically inactive variants. 
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Figure 3.34. Cross-tolerance assays comparing persister induction capacity of wild-type 
or SOS-deficient E. coli UTI89 strains following subinhibitory antibiotic therapy. Percent 
survival was determined after challenge with a lethal dose of either ciprofloxacin (A), 
ampicillin (B), or gentamicin (C). Means from at least five independent experiments are 
shown with significance. Significance was determined using one-way ANOVA and 
Bonferroni's multiple comparison test (ns = not significant; *, P < 0.05; **, P < 0.01; 
***, P < 0.001). 
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Figure 3.35. Sensitivity of Type I E. coli persisters deficient in SOS to various 
antibiotics. Fraction size was determined following 3 hour challenge of stationary phase 
cultures with lethal ciprofloxacin, ampicillin, or gentamicin and enumerating the 
surviving population. Means from at least four independent experiments are shown with 
significance. Significance was determined using one-way ANOVA and Bonferroni's 
multiple comparison test (***, P < 0.001). 
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3.3.6 Assessing the contribution of high-density growth to 
persister cell onset 
As sub-inhibitory antibiotics promote aggregation (Figure 3.8) and persister formation 
(Figures 3.28, 3.31, 3.33), it was hypothesized that there may be a link between these two 
processes and MDT onset. This was tested using stationary phase cultures of E. coli 
UTI89 deficient in aggregation which is conferred through atypical type 1 fimbriae 
formation. Aggregation was assessed using a sediment assay which measures the rate of 
settling over time as a function of aggregate size. Type 1 fimbriae deficient strains ΔfimH 
(fimbriae expressed without adhesin) and ΔfimS (fimbriae not expressed - bald 
phenotype) were utilized. As expected, wild-type and hyper-fimbriated (Locked ON) E. 
coli UTI89 strains demonstrated significant aggregation while aggregation-deficient 
strains did not (P < 0.01) (Figure 3.36A). Stationary phase killing assays were then 
carried out and revealed that aggregation-deficient strains were also significantly 
deficient in persister formation, demonstrating ~10-fold fewer survivors than wild-type E. 
coli UTI89 (P < 0.01) (Figure 3.36B). Although direct cause-and-effect relationships 
cannot be confirmed from these results, the data presented throughout this work is 
compelling evidence that high-density growth may be a trigger for the induction of 
persister states. 
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Figure 3.36. Percent aggregation of stationary phase, wild-type, Locked ON, ΔfimH, and 
ΔfimS E. coli UTI89 strains (A), and the subsequent persister fractions of each strain 
following exposure to lethal ciprofloxacin for 3 hours. Means from at least three 
independent experiments are shown with significance. Significance was determined using 
one-way ANOVA and Bonferroni's multiple comparison test (**, P < 0.01; ***, P < 
0.001). 
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Figure 3.36 
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4 DISCUSSION 
 
4.1 THE IMPORTANCE OF UNDERSTANDING THE 
INFLUENCE OF ANTIBIOTICS ON THE HOST AND 
PATHOGEN 
Antibiotics have been used successfully in treating bacterial infections for over 60 years. 
In this time, humanity has seen their canonization from modest beginnings as soil-derived 
signalling agents to clinically available cures, saving countless lives. However, the 'post 
antibiotic era' is already quickly becoming a reality, in part driven by indiscriminate, 
inappropriate and promiscuous use. Well-respected researchers have drawn attention to 
some of these issues in recent years (Levy and Marshall, 2004), calling for the global 
banning of antibiotic use for animal weight-gain, over-the-counter sales in developing 
countries, and demanding stricter prescribing policies for physicians and dentists (Angulo 
et al., 2005; Kay, 2012; Ali et al., 2006). Models suggest that even a 1% reduction in the 
usefulness of existing antibiotics, driven by inappropriate use, corresponds with costs of 
$600 billion to $3 trillion in lost human health (Hollis and Ahmed, 2013). Aspects of 
human nature are probably reflected in this antibiotic story. When something is so 
effective at a particular job, in this case killing pathogenic bacteria, humans have a 
tendency to rapidly, exhaustively and broadly apply the discovery often without 
completely understanding the consequences of such promiscuous use. Thus, antibiotics 
are still administered for the common cold, despite it being caused by a virus (Pechère, 
2001); they are prescribed prophylactically for patients undergoing many surgical and 
dental procedures when risk of infection is low and antibiotic efficacy weak (Enzler et 
al., 2011); they are utilized in children repeatedly and often for long periods of time, in 
part because diagnostic tools are limited or poor, or physicians are guided by ‘instinct’ 
rather than evidence-based findings (Conway et al., 2007). 
It is now coming to light that issues associated with antibiotics extend far beyond those 
related to drug resistance. Only within the last decade have scientists began to understand 
the natural role of antibiotics in the environment (Linares et al., 2006; Romero et al., 
2011; Yim et al., 2007). Newly discovered inter-species signalling properties may 
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potentiate the augmentation of bacterial virulence when applied therapeutically. To 
complicate matters, some antibiotic classes are also known to directly influence the host, 
necessitating even further characterization to optimize treatment strategies (Dalhoff and 
Shalit, 2003; Čulić et al., 2001). These findings raise several important questions 
regarding contemporary antibiotic use in the clinic. Firstly, are antibiotics being applied 
unnecessarily to certain patient cohorts? If so, does their application negatively affect 
treatment outcome? Secondly, can the signalling properties of antibiotics on the host and 
pathogen be capitalized on to enhance therapeutic efficacy? Thirdly, do different 
antibiotic classes confer different phenotypic properties in different pathogens? The 
studies conducted here aim to answer these questions in the context of antibiotic therapy 
for the treatment of recurrent UTI. This disease milieu presents an ideal platform for the 
study of antibiotic management strategies, as there is growing debate over the necessity 
of its application and associated methodologies (Garin et al., 2006; Nickavar and 
Sotoudeh, 2011). In this thesis, the effects associated with inadequate antibiotic therapy 
are demonstrated, and reveal that multiple aspects of bacterial virulence are modulated 
affecting disease outcome. Ultimately, understanding the influence of antibiotics on the 
host, pathogen, and infection outcomes will provide physicians with new strategies for 
therapeutic optimization, and knowledge that helps them avoid the use of antibiotics 
when they are not effective or even detrimental to the patient. 
 
4.2 THE INFLUENCE OF SUB-INHIBITORY ANTIBIOTICS 
ON UROPATHOGEN VIRULENCE 
Studies characterizing the wider effects of sub-inhibitory antibiotics on soil organisms 
and human pathogens are still in their infancy. Thus far, techniques have focused 
primarily on the use of transcriptomic approaches, both for their high-throughput 
potential and ready application to a wide variety of organisms (Linares et al., 2006; 
Fajardo and Martínez, 2008). Although these studies have provided the first links 
between off-target antibiotics effects on bacteria and their potential contribution to 
disease, they are not ideal for the study of pathogenesis as changes in gene transcription 
do not often reflect changes in translation, protein folding or extracellular localization 
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(Straub, 2011). Therefore, one of the aims of this thesis was to characterize changes in 
virulence expression of uropathogens at the phenotypic level. 
 
4.2.1 Effect of sub-inhibitory antibiotics on uropathogen adhesin 
expression and adherence to surfaces 
The capacity for antibiotics to affect bacterial adherence to abiotic and biotic surfaces 
were characterized. This was initially done by assessing the ability of S. saprophyticus 
15305 to adhere to the surface of glass microscope slides in the presence and absence of 
antibiotics. Human pooled urine (HPU) was used as a growth substrate over routine 
culture media for its capacity to form conditioning films on contact with foreign surfaces 
(Santin et al., 1999; Canales et al., 2009). Although more relevant to the urinary tract, the 
use of HPU posed several problems, the foremost of which was poor inter-experimental 
reproducibility due to batch variation. This was despite steps being taken to avoid such 
issues, which included strict collection schedules and extraction from the same donors. 
However, the metabolic and protein profiles of urine are known to change over the course 
of a day, month, and year (Connor et al., 2004). In addition, diet, medication, and 
hormone levels heavily influence urinary composition and could not be controlled in this 
study. For these reasons, the use of this medium was thereafter discontinued. 
Experiments investigating the adherence of S. saprophyticus 15305 to glass microscope 
slides demonstrated that sub-inhibitory antibiotic exposure influenced this process. 
Ciprofloxacin, ampicillin, and gentamicin were all capable of increasing bacterial 
adherence to similar degrees despite targeting different cellular machinery. Although not 
conclusive, this finding suggests that observed induction of adherence is mediated 
through general stress response systems. Activation of the Sigma B transcription factor 
by fluoroquinolones has been demonstrated to increase adhesion in quinolone-resistant 
strains of S. aureus, but other antibiotics and response systems have not been explored in 
non-resistant strains (Li et al., 2005
a
). 
As glass exhibits hydrophilic surface chemistry not reflective of materials or tissues 
routinely found in the urinary tract, hydrophobic medical devices utilized in this 
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environment were subsequently investigated. This is an important consideration, as 
hydrophilic surfaces are poorly colonized by most bacteria due to the repulsive 
interaction of negatively charged elements (Boks et al., 2008). In addition to their 
experimentally desirable surface properties, stents and catheters are also widely used in 
urological applications and are usually readily colonized (Habash and Reid, 1999; Siddiq 
and Darouiche, 2012). Together these materials represent the greatest cause for 
nosocomial infection, and are associated with increased morbidity, hospital cost, and 
length of stay, further warranting their use in this model (Saint, 2000; Platt et al., 1982; 
Givens and Wenzel, 1980; Tambyah et al., 2002). Antibiotic priming of S. saprophyticus 
15305 resulted in greater adherence to both stent and catheter material. The change in 
adherence was more substantial than found with glass microscope slides, supporting the 
adhesion promoting properties of these devices. The hydrophobic surface chemistry of 
urological devices is often masked using hydrophilic, hydro-gel coatings for this reason 
(Beiko et al., 2004). Catheter colonization was higher than stent colonization, likely due 
to the different polymers used between these materials. The proprietary polymer utilized 
in the InLay stent prohibits inquiries into its anti-infective properties. However, the latex 
polymer surfaces used in Foley catheters are more irregular, and readily colonized 
compared to silicone material which support the findings presented (Nickel and 
Costerton, 1992; Stickler et al., 2003).  
The capacity for different antibiotic classes to promote urological device colonization is 
concerning. Single dose antibiotics are usually applied prophylactically during device 
placement as per American Urological Association guidelines, a practice which may not 
be warranted (2008), and might actually promote adhesion. In addition, the modification 
of urological materials through coating, matrix loading, and immersion in antimicrobial 
agents has become a widespread practice (Siddiq and Darouiche, 2012). Many coatings 
have become available, and incorporate bactericidal silver ions and nanoparticles, 
enzyme inhibitors, antibiotics and sometimes even bacteriophages (Saint et al., 1998; 
Furno et al., 2004; Morris and Stickler, 1998; Burton et al., 2006; Carson et al., 2010; 
Mendez-Probst et al., 2012). The aim of these enhancements are to discourage pathogen 
growth once they have been driven into the urinary environment during device 
placement. However, the efficacy of modified devices has shown no benefit over 
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untreated instruments, questioning the merit of their application (Srinivasan et al., 2006; 
Cadieux et al., 2009). This is especially true considering the capacity of antibiotics to 
improve bacterial device colonization, a process which could occur during long-term 
device placement once bio-active agents have been leached to sub-inhibitory levels. 
Antibiotic-induced changes in S. saprophyticus 15305 adherence frequency to abiotic 
surfaces warranted further investigation into downstream processes such as modulation of 
biofilm formation. Biofilm-associated organisms are common during UTI, and play an 
important role in the contribution to recurrences, especially when urinary devices are 
present (Choong and Whitfield, 2000; Hatt and Rather, 2008; Reid et al., 1992). 
Organisms growing in the sessile environment of the biofilm matrix contribute to the 
aetiology, pathogenesis and continued persistence of bacteria in the urinary tract through 
antibiotic tolerance mechanisms and subversion of host defences including shear stress 
mediated detachment during voiding and anti-phagocytic properties (Nickel et al., 1994; 
Donlan, 2002). In addition, biofilms continuously seed planktonic organisms into the 
urinary lumen contributing to disease propagation and spread to new environments 
(Costerton et al., 1999).  
The capacity for aminoglycosides to promote biofilm formation has been described, and 
is dependent on the Arr signalling pathway found in some Enterobacteriaciae (Hoffman 
et al., 2005). Similar processes were explored in S. saprophyticus 15305 and E. coli 
UTI89 uropathogens in this thesis. All antibiotics tested induced biofilm formation for 
both uropathogens. E. coli UTI89 demonstrated greater biofilm accumulation compared 
to S. saprophyticus 15305, which may have been accounted for in part by aminoglycoside 
induction of the Arr signalling pathway. However, a search for this or other homologous 
genes in either organism using the Basic Local Alignment Search Tool (BLAST; 
http://blast.ncbi.nlm.nih.gov/Blast.cgi) did not yield any results. The absence of this 
signalling system in E. coli UTI89 might be due to it being a human pathogen, and loss of 
this environmental response element through genome reduction via negative selection. 
Such processes have been demonstrated to increase fitness in site-specific, steady-state 
niches such as the human host, over those that are dynamically changing such as the soil 
environment (Koskiniemi et al., 2012). Moreover, Arr was characterized in the soil 
bacterium and opportunistic pathogen P. aeruginosa PA01, supporting this system's 
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importance in environmental but not host niches (Hoffman et al., 2005; Stover et al., 
2000). Antibiotic-dependent biofilm formation in these uropathogens could reasonably be 
driven through an alternative pathway, potentially governed by the activity of general 
stress response elements. Indeed, non-targeted stressors including nutrient deprivation, 
ethanol, and extremes in pH and salinity have all been implicated in driving biofilm 
formation (Fux et al., 2005, Gotoh et al., 2010; Davey and O'toole, 2000; Knobloch et 
al., 2002; Lapaglia and Hartzell, 1997). An organism's commitment to sessile growth 
states in response to stress makes sense in the light of the reduced metabolic requirements 
and added matrix-associated protection imparted by biofilms (Kim et al., 2009). 
However, the activity of specific antibiotic signalling systems cannot be ruled out at this 
time, especially from environmentally derived ampicillin and gentamicin. Although 
fluoroquinolones are fully synthetic compounds, they demonstrate quorum-sensing-like 
properties, which may influence biofilm development (Diggle et al., 2003; Heeb et al., 
2010). 
The contribution of a general stress response system in antibiotic-dependent biofilm 
formation was tested using SOS-deficient strains derived from E. coli UTI89. Although 
there are several stress response systems in E. coli, SOS was considered because of its 
activation when exposed to several types of antibiotics (Miller et al., 2004; Mesak et al., 
2008). In addition, SOS has been implicated previously in the modulation of other 
virulence determinants (Kelley, 2006; Bisognano et al., 2000). Even without the 
application of antibiotics, both the ΔrecA and lexAT355G strains tested had reduced biofilm 
forming capacity compared to wild-type E. coli UTI89, suggesting a role for SOS in 
normal biofilm formation, confirming previous studies (Gotoh et al., 2010). These results 
were recapitulated with antibiotic treatment, whereby antibiotic-dependent biofilm 
formation was severely depressed or non-existent in both SOS-deficient strains. 
Gentamicin was capable of inducing biofilm formation in the lexAT355G but not ΔrecA 
strain, suggesting downstream signalling via activated RecA, or its interaction with other 
cellular components might be involved. In addition, all strains were influenced by 
ampicillin regardless of the activity of their SOS response systems. These observations 
recapitulate findings which demonstrated low-dose β-lactam antibiotics enhance eDNA 
release in methicillin resistant and sensitive strains of S. aureus, resulting in the 
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production of more robust biofilms (Kaplan et al., 2012). It was thought that autolysin 
activity was important in this process; however, such observations are absent in E. coli so 
their contribution to biofilm formation in this organism is speculative. Alternatively, 
ampicillin's activity at the cell surface might activate the Cpx two-component signal 
transduction pathway, which responds to disturbances in the cell envelope, in turn 
activating regulation of adhesion genes (Otto et al., 2002). 
In addition to enhancing biofilm formation, antibiotics were able to induce rapid 
planktonic aggregation of both E. coli UTI89 and S. saprophyticus 15305. As with 
adherent biofilms, all antibiotic classes demonstrated similar capacity to induce 
aggregation. This phenotype may represent an alternative to biofilm formation when 
surfaces are not readily available. In this manner, uropathogen aggregates can benefit 
from the immuno-protective and antibiotic tolerance effects of sessile growth without 
committing to host cell adherence (Haaber et al., 2012; Rakita et al., 1999). The 
mechanism of aggregation is likely conveyed through upregulation of polysaccharide 
intercellular adhesin (PIA) in S. saprophyticus 15305, which has been suggested through 
the use of a congo red agar plate assay (data not shown), and is an important mediator of 
biofilm formation in this species (Mack et al., 1994). Expression of this adhesin has been 
shown to be induced following antibiotic therapy and exposure to other stressors (Haaber 
et al., 2012; Rachid et al., 2000). Conversely, increased expression of type 1 fimbriae and 
other fimbrial-like surface components are likely constituents of aggregation in E. coli 
UTI89, and have been previously associated with adhesive, biofilm, and aggregative 
properties (Rodrigues and Elimelech, 2009; Schembri et al., 2001). A semi-quantitative 
approach using TEM for enumerating fimbrial expression on E. coli UTI89 surface was 
attempted but did not yield any meaningful findings (data not shown). 
Since uropathogen adherence to abiotic surfaces and biofilm formation were significantly 
upregulated in response to diverse classes of antibiotics, their capacity to induce adhesion 
to urothelial surfaces was also investigated. This was accomplished using the transitional 
epithelial carcinoma cell lines 5637 and A498, which were originally isolated from 
human bladders and kidneys, respectively. The use of these tissues was justified for their 
characteristics, extraction site, and previous in vitro UTI studies (Svensson et al., 2001; 
Mulvey et al, 2001). Antibiotic incubation with S. saprophyticus 15305 resulted in 
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enhanced adhesion and internalization in both bladder and kidney cell lines. The capacity 
for S. saprophyticus 15305 to invade bladder cells has been previously documented, but 
the ability of antibiotics to modulate this process has never been explored (Szabados et 
al., 2008). In addition, this work is the first to demonstrate the S. saprophyticus 15305 is 
capable of invading kidney cells and may represent an important mechanism in urothelial 
persistence. This is especially relevant in this pathogen, which is suggested to 
preferentially colonize the kidneys (Kline et al., 2010). Other groups which have assessed 
the ability of sub-inhibitory antibiotics to enhance S. aureus invasiveness found no 
significant changes (Rasigade et al., 2011). This is despite increases in fibronectin-
binding protein expression which improved adherence (Bisognano et al., 2000). The 
discrepancies between these studies may reflect differences in proposed mechanisms that 
S. saprophyticus 15305 utilizes to invade host cells (Szabados et al., 2008). In the case of 
S. aureus, they primarily rely on their regimen of fibronectin-binding proteins to trigger 
α5β1 integrin-mediated internalization of non-phagocytic cells (Agerer et al., 2005; Sinha 
et al., 1999). Although some strains of S. saprophyticus express fibronectin and collagen-
binding proteins, S. saprophyticus 15305 does not (Kuroda et al., 2005). However, 
staphylococcal autolysins have been implicated as invasins (Hirschhausen et al., 2010), 
and thus may account for urothelial invasion in S. saprophyticus 15305. 
Antibiotic treatments had the greatest effect on S. saprophyticus 15305 adhesion when 
urothelial cell surfaces were compared to abiotic surfaces. This led to the speculation that 
specific adhesin-urothelial interactions were involved and were likely driven by 
antibiotic-induced expression of adhesion factors. Hemagglutination assays were utilized 
to determine changes in the relative surface presence of UafA, and suggested 
ciprofloxacin induced their expression. Bacterial capsules block the interaction of UafA 
with adhesins (Kuroda et al., 2005), but enhanced hemagglutination in the acapsular S. 
saprophyticus C1 strain recapitulated the previous findings. However, differential 
regulation of capsule cannot be ruled out as antibiotic-dependent modulation in capsular 
expression has been demonstrated previously in E. coli (Lu et al., 2008; Fowler et al., 
2009). The influence of ciprofloxacin-induced UafA expression on adherence was 
confirmed in 5637 bladder cells. Again, ciprofloxacin resulted in enhanced adhesion in 
the absence of capsule suggesting UafA significantly contributes to this process. In 
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addition, increased internalization in the acapsular strain treated with ciprofloxacin 
suggests UafA plays a potential role in S. saprophyticus 15305 urothelial invasion. 
However, this is conjecture and requires further analysis with UafA knock-out strains for 
confirmation. 
Antibiotics were found to also increase the expression of type 1 fimbriae in E. coli UTI89 
using hemagglutination assays. This adhesin contributes to aggregation and biofilm 
formation in this organism (Rodrigues and Elimelech, 2009; Schembri et al., 2001). It is 
interesting that antibiotics from diverse classes should have such a profound impact on 
adhesin expression, biofilm formation, and aggregation in unrelated Gram-negative and 
positive uropathogens. As the SOS response has been implicated previously in antibiotic-
dependent E. coli UTI89 biofilm formation, it was reasonable to postulate a similar role 
in type 1 fimbrial expression. These experiments revealed that antibiotics were incapable 
of increasing hemagglutination in the SOS-deficient E. coli UTI89 strains, suggesting an 
important role of this response in type 1 fimbriae regulation during stress. This is 
supported by previous studies, which have demonstrated involvement of the SOS 
response in adhesin regulation in S. aureus, but not for E. coli (Bisognano et al., 2000).  
As the SOS regulon controls the expression of dozens of genes in almost all bacteria, it 
was thought that antibiotic-dependent changes in type 1 fimbriae occurred at the 
transcriptional level. Type 1 fimbriae regulation is phase variable, and regulated by the 
fim switch element within its operon (Gally et al., 1996). However, the analysis of 
ciprofloxacin exposure on changes in this regulatory element was not revealing. This is 
not to say that transcriptional modulation does not play a role in antibiotic-dependent 
type 1 fimbriae expression, but that involvement of the fim switch is unlikely. This is 
especially perplexing considering that mannose-resistant (type 1 fimbriae-independent) 
hemagglutination was not observed (data not shown), indicating that other fimbrial 
adhesins, such as P fimbriae, were not expressed following antibiotic treatment (van den 
Bosch et al., 1980; Hull et al., 1981). 
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4.2.2 Antibiotics concomitantly downregulate motility and 
upregulate factors critical for adherence 
Both S. saprophyticus 15305 and E. coli UTI89 appear to respond to antibiotic therapy by 
increasing adhesin expression, adhering to surfaces, and adopting a sessile lifestyle. 
Reduced metabolic activity imparted by this strategy would certainly benefit both 
uropathogens to endure times of stress. Adoption of an adherent, inactive lifestyle would 
require the transition from motile, planktonic states. Demonstrating the suppression of 
flagellar-mediated motility in E. coli UTI89 in response to antibiotics supported this 
hypothesis. Furthermore, flagella regulation was also assessed in SOS-deficient strains, 
revealing that activation of this system has a negative influence on motility. This finding 
agrees with a recent observation of P. aeruginosa motility, suggesting SOS is involved in 
adhesion and biofilm formation in several organisms (Chellappa et al., 2013). 
Ciprofloxacin, a DNA targeting drug and potent SOS activator, was particularly 
efficacious in inhibiting wild-type E. coli UTI89 swarming, a phenotype which was 
depressed in the SOS-deficient strains. These findings support the hypothesis that 
ciprofloxacin concomitantly upregulates adhesin expression and downregulates motility 
to promote surface adherence. Unexpectedly, bacterial swarming motility in the presence 
of ciprofloxacin was increased in the E. coli UTI89 lexAT355G strain but suppressed in the 
ΔrecA. This suggests RecA positively regulates flagellar activity, a finding that has been 
observed in other strains of E. coli (Gómez-Gómez et al., 2007). Although not fully 
characterized, the mechanism appears to depend on RecA interacting with CheW, a 
component which governs mechanical control of the chemotaxis system during swarming 
motility. This finding is further supported, as ciprofloxacin pre-treatment of cells prior to 
swarming had no effect on flagellar activity. 
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4.2.3 Transcriptomic analysis provides insight into virulence 
modulation and antibiotic tolerance mechanisms utilized 
by Gram-negative and positive uropathogens 
The similar phenotypic responses of S. saprophyticus 15305 and E. coli UTI89 to sub-
inhibitory ciprofloxacin was suggestive of a common underlying mechanism explaining 
changes in virulence trait expression. RNA-sequencing provided a useful high-throughput 
tool to characterize the global responses during treatment conditions for these 
uropathogens. Although changes in virulence gene expression were observed for both 
organisms, the regulatory networks affected by sub-inhibitory ciprofloxacin stress appear 
to be divergent, despite similar doses relative to the MIC being provided. Specifically, E. 
coli UTI89 committed to the activation of a full-fledged SOS response while S. 
saprophyticus 15305 appeared to rely upon general stress response elements. The nature 
of cell surface components, including peptidoglycan matrix thickness, membrane 
abundance/composition and the availability of porins, influences ciprofloxacin 
penetration and intracellular availability, and might explain different tolerance 
mechanisms. It is generally accepted that ciprofloxacin is better able to access the 
intracellular compartment of Gram-negative organisms compared to Gram-positives, 
enhancing its efficacy in these pathogens (Drlica and Zhao, 1997). Here, E. coli UTI89 
effectively blocked this route of access by decreasing the availability of various porin 
transcripts. Interestingly, Berlanga et al. (2004) suggested that Gram-positive tolerance to 
ciprofloxacin may be instead related to the interaction of the drug with its target enzymes 
rather than diminished permeability. In addition, the decreased replication and 
transcription rates of S. saprophyticus 15305 compared to E. coli UTI89 may be 
conducive to its survival against DNA gyrase and topoisomerase-acting antibiotics while 
negating SOS activation. 
The activation of RecA is associated with phage commitment to the lytic cycle, and 
evacuation of host cells (Wagner and Waldor, 2002). Both E. coli UTI89 and S. 
saprophyticus 15305 initially responded to ciprofloxacin challenge by increasing the 
abundance of this important DNA repair transcript, but only E. coli UTI89 went on to 
express a number of phage-related SOS response elements. Importantly, the E. coli 
UTI89 genome contains a much larger proportion of phage-coding regions compared to 
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S. saprophyticus 15305 (as inferred from SEED strip-plots; Figure 3.15). It is possible 
that activation of RecA in E. coli UTI89 triggered the activation of a phage lysis cascade, 
which in turn contributed to further SOS response commitment in a self-propagating 
feed-back loop. The Kil-family of proteins translated from phage transcripts observed 
during ciprofloxacin treatment have been shown to induce the SOS response in S. 
enterica the past (Campoy et al., 2006), supporting this novel hypothesis. Counter-
intuitively, the phage transition into lytic cycles may enhance the virulence of E. coli by 
permitting the expression of phage-encoded virulence traits during ciprofloxacin therapy. 
This process has been demonstrated before in Enterococcus faecalis and is evolutionarily 
mutually beneficial to both the host cell and infecting phage (Matos et al., 2013). Further 
analysis using strains cured of their phages may provide insight into the cause-and-effect 
relationship between onset of the phage lytic cycle and SOS induction.  
Sub-inhibitory ciprofloxacin resulted in global suppression of transcripts related to 
metabolism including amino acid, cofactor, iron, fatty acid, cell division, and 
carbohydrates in E. coli UTI89 after four hours of exposure. This response seems 
beneficial, as limiting cellular activity decreases the need for transcription and 
replication, in turn limiting the effect that ciprofloxacin can have on these processes. 
Remarkably, transcripts related to metabolism and nutrient uptake were found at a higher 
abundance in S. saprophyticus 15305. Specifically, transcripts of enzymes important to 
glycolysis and the TCA cycle were present at increased quantities following 6 hours of 
ciprofloxacin exposure. Although the purpose of this change is unknown, TCA induction 
has been shown to be associated with virulence, survival, and persistence of 
staphylococci and other pathogens (Begun et al., 2005; Sadykov et al., 2010). These 
findings corroborate another transcriptomic-based study which characterized S. aureus 
expression changes in response to  inhibitory-doses of ciprofloxacin (Cirz et al., 2007). 
Although a full S. aureus SOS response was activated in the study, the authors' results 
reflect those of this thesis, concluding that an active SOS response is more critical in 
ameliorating damage caused by DNA-active antibiotics in Gram-negative organisms. 
Interestingly, these authors did not observe changes in the recruitment of transcripts 
related to general stress responses. This might suggest that these systems only contribute 
to the tolerance of DNA stress at levels which are insufficient to induce SOS.  
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A number of transcripts related to virulence were found to be significantly upregulated in 
both uropathogens following sub-inhibitory ciprofloxacin exposure. In E. coli UTI89, 
hemagglutination assays suggested that FimH-surface expression might be enhanced by 
sub-inhibitory antibiotics. The results of the RNA-sequencing analysis confirmed that a 
putative fimH-like element was differentially expressed following ciprofloxacin 
treatment, indicating antibiotic-dependent hemagglutination is regulated at the 
transcriptional level. As FimH is critical in the adherence and invasion strategies of 
UPEC, this finding might indicate a mechanism by which sub-inhibitory antibiotics 
enhance pathogenesis during UTI. The fimbrial repressor focX was also downregulated in 
response to ciprofloxacin, further highlighting this agent's capacity to mediate fimbrial 
adhesion. Importantly, expression and cross-talk of the putative focX-regulated fimbrial-
operon may preclude the transcription of other fimbriae (including type 1), as UPEC 
generally only express one type at any given time (Simms and Mobley, 2008). This might 
account for ciprofloxacin's inability to induce type 1 phase switching. Characterization of 
the ORFs governed by the focX regulatory element would provide insight into the 
mechanisms with which ciprofloxacin induces hemagglutination and biofilm formation in 
UPEC.  
In addition to changes in fimbrial transcripts, the autoaggregative adhesin and invasin hek 
was found to be expressed in the presence of sub-inhibitory ciprofloxacin. This virulence 
factor has been associated with severe infections including neonatal meningitis and sepsis 
(Fagan and Smith, 2007; Fagan et al., 2008). The hek gene is also present in 55% of 
UPEC isolates (Srinivasan et al., 2003), and binds to cells with greater affinity under 
shear stress suggesting a potential role in urothelial adherence (Fagan and Smith, 2007). 
Therefore, in addition to FimH, increased expression of this adhesin likely accounts for 
the ciprofloxacin-dependent aggregation that was observed using TEM. Similarly, the 
expression of sulA during ciprofloxacin treatment is sufficient to account for the 
filamentation observed using TEM. Transient SulA-mediated filamentation during the 
IBC phase of pathogenesis is essential for UPEC virulence and QIR formation in murine 
models of cystitis (Justice et al., 2006). 
The genome of S. saprophyticus 15305 is much less well characterized compared to E. 
coli UTI89, introducing problems in assigning functions to genes that were differentially 
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regulated in response to sub-inhibitory ciprofloxacin. However, increased surface 
expression of UafA was posited based on phenotypic assays which revealed a 
ciprofloxacin-dependent changes in hemagglutination capacity. Unfortunately, RNA-
sequencing did not reveal significant changes in the relative abundance of this transcript, 
suggesting one of the many uncharacterized transcripts upregulated might instead 
contribute to this observation. Efforts to produce a UafA knock-out strain were not 
fruitful, but would be essential in ruling out other sheep erythrocyte ligands which could 
account for UafA-independent hemagglutination. Interestingly, one transcript upregulated 
by ciprofloxacin encoded a putative bacterial immunoglobulin-like 3-domain (BIG III) 
protein. Proteins encoding domains belonging to the immunoglobulin-like superfamily 
are often found in bacterial adhesins (Hamburger et al., 1999). However, similar 
structures also have calcium-binding potential (Raman et al., 2010). Regardless, these 
findings provide merit in further characterizing this differentially expressed element in S. 
saprophyticus 15305. 
Transcripts encoding enzymes related to exopolysaccharide production and export were 
among those most highly abundant following ciprofloxacin treatment. Generally, it is 
thought exopolysaccharide interferes with UafA ligand interactions, a hypothesis which 
is supported in this work as acapsular strains demonstrate greater adherence to urothelial 
cells. However, hemagglutination was enhanced in the acapsular strain, suggesting that 
ciprofloxacin has an effect on either the expression of an uncharacterized adhesin (for 
example, the upregulated BIG III-containing protein), or that bacterial aggregation caused 
by this antibiotic influences the appearance of hemagglutination as observed elsewhere 
(Orndorff et al., 2004). Regardless, exopolysaccharide production is important in 
resisting opsonophagocytosis (Peterson et al., 1978), mediating mucosal surface 
adherence, aggregation, and biofilm formation (Stephens et al., 1993; Sutherland, 2001, 
Li et al., 2005
b
), contributing to persistence during staphylococcal infection (O'Riordan 
and Lee, 2004), and tolerating antibiotic exposure (Fernebro et al., 2004). Therefore, the 
increased expression of this virulence factor by ciprofloxacin could certainly enhance the 
pathogenicity of this uropathogen. In addition, the availability of TCA cycle 
intermediates are critical for exopolysaccharide production, supporting a purpose for 
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increasing the activity of this metabolic hub during ciprofloxacin treatment (Sadykov et 
al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
189 
 
 
4.3 SUB-INHIBITORY CIPROFLOXACIN AFFECTS 
PATHOGENESIS IN A MURINE MODEL OF UTI 
Ciprofloxacin-dependent modulation of pathogenesis S. saprophyticus 15305 and E. coli 
UTI89 was assessed in a murine model of UTI, developed by Dr. Scott Hultgren's group 
(Hung et al., 2009). Ciprofloxacin was solely utilized in these studies for its widespread 
administration in urology to treat acute and complicated infections (Krcméry and Naber, 
1999), in addition to its capacity to modulate uropathogen virulence. The resistance 
observed in other antibiotics, such as co-trimoxazole, further warrants investigation of 
this next-line therapeutic (Eliopoulos and Huovinen, 2001; Talan et al., 2000). The 
murine studies presented within this thesis are the first to demonstrate that antibiotic-
dependent in vitro augmentation of virulence directly influences in vivo pathogenesis. 
 
4.3.1 Ciprofloxacin priming predisposes mice to chronic UTI 
Previous results demonstrated that antibiotics are capable of 'priming' organisms for 
downstream colonization, primarily through the upregulation of adhesins. This approach 
was utilized for the characterization of both E. coli UTI89 and S. saprophyticus 15305 
pathogenesis in C3H/HeN mice as it removed the parameter of antibiotic-host 
interactions. However, long-lasting epigenetic effects could also potentially influence 
downstream virulence in this model (Davidson and Surette, 2008). Type 1 fimbriae phase 
variation is one such example, but it was not altered by antibiotic therapy here. Infections 
of C3H/HeN mice with 10
7
 cfu of E. coli UTI89 resulted in a bimodal infection outcome 
at 24 hpi, with mice showing signs of either bacterial clearance or maintaining high titers 
(Hannan et al., 2010). This distribution was observed in both control and ciprofloxacin-
primed infection groups. However, ciprofloxacin treatment prior to infection shifted the 
equilibrium towards infection persistence in bladders and kidneys. This effect was most 
dramatic in the kidneys, with both uropathogens showing no signs of clearance. The 
different colonization patterns are likely attributable to differences in defence strategies, 
the foremost of which is superficial umbrella cell exfoliation, a major contributor of 
pathogen clearance in the bladder (Mulvey et al., 2000; Zasloff, 2007).  
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This finding highlights the shortcomings of this UTI model, with C3H mice 
demonstrating severe vesicoureteral reflux (VUR) and significant pathogen kidney 
deposition upon inoculation (Murawski et al., 2010; Hung et al., 2009). However, there is 
still merit in using this model for characterization of 'worst-case-scenario' patients, who 
demonstrate high grade VUR. The results demonstrate that infection severity could be 
worsened by the application of ciprofloxacin prophylactically, a practice that is widely 
conducted (Garnica et al., 2013; Garin et al., 2006; Mattoo, 2009). In addition, S. 
saprophyticus 15305 poorly colonizes the bladder tissues of mice but showed similar 
infective capacity as E. coli UTI89 in the kidneys. The absence of UafA ligand in mice 
likely accounts for this (King et al., 2011; Matsuoka et al., 2011; Kline et al., 2010). It is 
noteworthy that despite this, ciprofloxacin-priming significantly increased bladder titers, 
suggesting that other factors might contribute towards virulence. The autolysin Aas has 
been implicated in fibronectin-binding and thus could contribute to increased adhesive 
capacity (Hell et al., 1998; von Eiff et al., 2002). 
It is established that C3H/HeN mice inoculated with 10
7
 cfu of E. coli UTI89 presenting 
with >10
4
 cfu/mL at 14 days post-inoculation (dpi) are at very high risk of chronic UTI 
(Hannan et al., 2010). The increased titers observed following ciprofloxacin priming 
alluded that these organisms were better equipped to colonize the host compared to 
untreated counterparts. The host-pathogen interactions during the first 24 hours post-
inoculation (hpi) are thought to play a significant role in infection establishment or 
resolution, suggesting increased titers at this time have some predictive value in 
determining the severity of UTI (Hannan et al., 2012). The data obtained at 14 dpi with 
E. coli UTI89 validated this hypothesis, with ciprofloxacin-priming prior to inoculation 
sufficient to increase frequency of chronic cystitis to 100% compared to 60% in untreated 
groups. While no such data exists describing the infection thresholds of S. saprophyticus 
15305, it is noteworthy that 100% of mice resolved infection when inoculated with 
untreated S. saprophyticus 15305, while 50% of ciprofloxacin-primed inoculated mice 
maintained low-grade bladder colonization. Furthermore, bacterial kidney titers were 
consistently higher in both organisms when primed. The presence of pyelonephritis in the 
absence of cystitis in this model supports the hypothesis that chronic cystitis and chronic 
pyelonephritis represent mutually exclusive disease outcomes, governed by different 
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underlying host-pathogen checkpoints in each organ (Hannan et al., 2010; Hopkins et al., 
2009).  
Though upregulation of adhesins likely contribute to persistence, immune activation is 
also an important factor in uropathogenesis, with early severe inflammatory responses 
increasing risk of chronic infection during UPEC UTI (Hannan et al., 2010). 
Overstimulation and infiltration of immune response elements are thought to promote 
destruction of the protective urothelium (Ragnarstóttir et al., 2010). This might be driven 
directly by type 1 fimbriae which are known to interact with TLR4 and promote 
neutrophil infiltration (Mossman et al., 2008; Ashkar et al., 2008), but it is also possible 
that upregulation of secreted factors which disrupt the host urothelium contribute 
significantly to enhanced virulence potential. The potential for antibiotics to promote 
toxin production in S. aureus and E. coli has been demonstrated several times, and is 
associated with increased immunogenicity (Serna IV et al., 2008; Dumitrescu et al., 
2011; Otto et al., 2013). However, primed organisms are washed prior to inoculation, 
presumably removing any secreted factors from the inoculum and requiring continued 
expression in the mouse urinary tract without antibiotics. In addition, no such toxins exist 
in S. saprophyticus 15305, suggesting this mechanism does not contribute to persistence 
during bladder infection with ciprofloxacin-primed organisms (Kuroda et al., 2005). 
Rather, it is postulated that exposure of additional surface adhesins, such as UafA and 
Aas, enhance colonization and internalization efficiency resulting in persistent cystitis. 
This is supported by ex vivo gentamicin protection experiments, which demonstrated the 
increased invasive capacity of ciprofloxacin-primed S. saprophyticus 15305. 
 
4.3.2 Ciprofloxacin priming promotes rapid urothelial invasion 
and IBC formation 
The capacity for ciprofloxacin to promote E. coli UTI89 chronic infections is likely 
dependent on its ability to induce type 1 fimbriae-dependent invasion of urothelial cells. 
Type 1 fimbriae are critical in internalization and intracellular bacterial community (IBC) 
formation (Martinez et al., 2000; Hadjifrangiskou et al., 2012; Wright et al., 2007); their 
expression in response to ciprofloxacin and subsequent chronic infection development is 
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likely paramount. Increased numbers of IBCs are associated with an increased risk of 
chronic cystitis and the establishment of quiescent bladder reservoirs, which precede 
recurrent UTI (Schwartz et al., 2011). The enhanced IBC-forming capacity observed in 
ciprofloxacin-primed E. coli UTI89 indicates that establishment of an intracellular niche 
is an important step in developing chronic infection in this model. Ciprofloxacin also 
altered the morphology of IBCs, resulting in a dispersed phenotype compared to 
untreated controls. The characteristics of these IBCs are reminiscent of those observed 
during later stages of infection (Justice et al., 2004), suggesting ciprofloxacin-priming 
triggered the upregulation of type 1 fimbriae and early invasion of urothelial tissues. The 
dynamics of E. coli fimbriation are tightly regulated, and production might not otherwise 
occur immediately upon inoculation into the urinary environment (Schwan, 2011), giving 
primed organisms an advantage over those left untreated.  
Ciprofloxacin-triggered filamentation could potentially contribute to increased urothelial 
adherence, immune evasion and invasion potential (Justice et al., 2006; Justice et al., 
2008). Filamentation is an important step in E. coli flux from IBCs and transfer to 
neighbouring cells (Rosen et al., 2007). Ciprofloxacin-induced changes in E. coli UTI89 
might hasten the spread to distal tissues before exfoliation can occur, promoting the 
establishment of quiescent reservoirs in the bladder (Mysorekar and Hultgren, 2006). 
Observed filamentation at early time-points in ciprofloxacin-treated, but not control 
IBCs, supports this hypothesis. These processes might further help uropathogens subvert 
aspects of early host immunity by rapidly gaining access to the intracellular environment 
and at a higher frequency. Combined, alterations in these pathogenic mechanisms are 
likely responsible for driving the dynamics of host-pathogen equilibrium in favor of the 
pathogen and establishment of chronic infection. 
 
4.3.3 Sub-therapeutic ciprofloxacin augments infection severity 
and recurrence risk in chronically infected and resolved 
mice 
Experiments were carried out to investigate the influence of sub-therapeutic ciprofloxacin 
on infection severity and recurrence risk. Including this parameter in the experimental 
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system was critical, as antibiotics including fluoroquinolones are known to modulate 
aspects of host immunity (Dalhoff and Shalit, 2003). Although the dosing regimens 
utilized in these experiments are not necessarily reflective of real-world therapeutic 
approaches, they are useful in studying concomitant changes in both the host and 
pathogen and therefore contribute to our understanding of antibiotic influence on UPEC 
pathogenesis in vivo.  
Two experimental groups were considered to evaluate the influence of ciprofloxacin on: 
i) the worsening of prognosis in chronically infected mice; and ii) predisposing 
previously inoculated but 'resolved' mice to clinically significant recurrences. In both 
cases, sub-therapeutic ciprofloxacin was associated with increased E. coli UTI89 urine 
titers. The effect was compounded over time, suggesting that periods of sub-therapeutic 
dosing have a cumulative effect on infection severity. Retrospective studies in humans 
have revealed that repeated exposure to antibiotics are associated with recurrent C. 
difficile infection risk, and found that the response was cumulative over time as observed 
in this study (Stevens et al., 2011). C. difficile infection severity with antibiotics could be 
due to clearance of commensal organisms from the gastrointestinal tract, decreasing 
competitive inhibition in this niche (Parkes et al., 2009). Although endogenous, non-
culturable bacteria have been noted in the urinary tract of healthy females, their role in 
mucosal defence against infection is not established (Wolfe et al., 2012). In addition, 
spontaneous development of antibiotic resistance could reasonably explain increased 
urine load with antibiotics, but no changes in susceptibility were noted over the course of 
the experiment. 
The effects that underlie changes in E. coli titer with sub-therapeutic ciprofloxacin dosing 
were concluded to be driven by suppressed host immune capability. Decreased immune 
potential in mice could reasonably account for E. coli UTI89 urine loads increasing in 
chronically infected subjects. However, the ability of ciprofloxacin to trigger clinically 
significant recurrences in resolved mice was unexpected, and might occur through several 
mechanisms. Firstly, the thresholds designating clinically significant infection do not 
preclude the presence of UPEC. In fact, several mice in these treatment groups did 
present with bacteriuria, but were considered colonized rather than infected as per clinical 
standards (Hannan et al., 2010; Schwartz et al., 2011). Thus, increased titer in these mice 
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receiving sub-therapeutic ciprofloxacin could be due to a similar phenomenon as 
observed in chronically infected mice. However, some mice that experienced recurrences 
had no visible signs of bacteriuria prior to treatment. It is possible that ciprofloxacin 
triggered re-emergence of E. coli from quiescent reservoirs in these apparently sterile 
mice. The filamentation induction observed in other experiments might cause organisms 
to flux out from tissues resulting in new infection. However, cross-infection from another 
mouse within the same cage cannot be ruled out. Interestingly, there were mice that never 
experienced recurrences with ciprofloxacin therapy, indicating urinary clearance and 
providing an argument against cross-infection. Regardless, these findings are the first to 
directly associate inadequate antibiotic therapy with increased infection risk in vivo. 
 
4.3.4 Ciprofloxacin modulates aspects of host immunity and is 
protective against chronic UTI 
Ciprofloxacin was found to have an immunomodulatory effect in urothelial tissues, which 
might account for the changes in bacterial urine titers observed in mice during treatment. 
The effect was noted in both human bladder cell lines in addition to murine tissues 
extracted following infection. Low doses of ciprofloxacin were sufficient to depress the 
release of IL-6 and IL-8 in T24 bladder cells, suggesting that residual levels left over 
following therapy might predispose to infection later on. The effects were found to be 
host-cell dependent in 5637 cells, as results in a cell-free system using LPS as an 
immune-stimulant recapitulated those from the S. saprophyticus 15305 infections. 
Furthermore, the baseline release of cytokines from unstimulated cells did not change 
with ciprofloxacin addition, rather, the antibiotic appeared to function by preventing 
secretion when LPS or S. saprophyticus 15305 was present. These finding corroborate 
those of others (Dalfhoff and Shalit, 2003).  
IL-6 and IL-8 are both important pro-inflammatory mediators for host cell immunity 
during UTI. IL-6 is a pleiotropic cytokine whose function includes amplifying signals 
involved in neutrophil recruitment (Romano et al., 1997), while IL-8 is a member of the 
CXC chemokine family and potent neutrophil chemotactic molecule (Murphy, 1997). 
Suppression of either cytokine has important implications on neutrophil chemotaxis to 
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sites of infection (Hedges et al., 1994; Hang et al., 1999). This was confirmed in mice, 
which showed significantly depressed PMN infiltrate in urine sediments when treated 
with sub-therapeutic ciprofloxacin. In addition to IL-6 and IL-8 suppression in vivo, the 
release of several other cytokines during early infection were affected by this antibiotic. 
The pro-inflammatory mediator IL-1β, produced by activated macrophages, is an 
important early response element to UPEC infection and was suppressed with 
ciprofloxacin treatment. Alternatively, the anti-inflammatory cytokine IL-10 was 
upregulated with infection and ciprofloxacin presence. IL-10 is involved in 
downregulating co-stimulatory molecules on macrophages, and might be associated with 
IL-1β suppression (Mosser, 2003; de Waal Malefyt el al., 1991). Furthermore, this 
cytokine is upregulated during UTI and is associated with urothelial protection during 
acute cystitis (Duell et al., 2011). The capacity for ciprofloxacin to induce one cytokine 
and suppress another while having no effect in some is perplexing. It might depend on the 
augmentation of immune populations and their activity within the bladder during 
infection. Unfortunately, cytological profiles were not assessed, so immune population 
changes in response to ciprofloxacin are unknown.  
A surprising outcome of these studies was the finding that ciprofloxacin dramatically 
increased the expression of G-CSF. This cytokine increases neutrophil migration from the 
bone-marrow, and UPEC are known to trigger its upregulation during UTI (Ingersoll et 
al., 2008). G-CSF presence would be effective in increasing levels of circulating 
neutrophils, however, the local suppression of chemotactic cytokines in the bladder 
would diminish the effect at sites of infection. It was not possible to collect sera from 
these mice and as such ciprofloxacin augmentation of systemic responses are unknown. 
In addition, G-CSF has immunomodulatory effects on macrophages and attenuates IL-1β 
production leading to less efficient bacterial clearance which further corroborates our 
findings (Boneberg and Hartung, 2002; Kim et al., 2006).  
The immunomodulatory and urothelial-protective effects of ciprofloxacin were further 
confirmed using infection models. In this case, decreased neutrophil infiltration and 
related reduction in urothelial damage is likely, and has been demonstrated in other 
studies (Ingersoll et al., 2008). Reduction in bladder mass in antibiotic-treated mice is 
further indicative of suppressed immune cell tissue infiltration.  Although certain 
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cytokine profiles might result in increased infection risk, those associated with 
ciprofloxacin appear to favour the host. Further studies should explore how these 
treatments modulate urothelial exfoliation, as cytokines are known to be involved in this 
process (Mulvey et al., 2001; Bower et al., 2005).  
Application of sub-therapeutic ciprofloxacin prior to E. coli UTI89 inoculation was 
sufficient in abrogating the risk of chronic infection. Although no significant changes 
were observed in organ titer, ciprofloxacin treatment was associated with decreased 
UPEC abundance. The cytokine profiles generated in this work corroborate other studies 
which have demonstrated that super-induction of IL-6, IL-8, IL-1β, and G-CSF, result in 
more severe infection and risk of chronic disease (Ragnarsdóttir et al., 2010). Treatment 
with the anti-inflammatory compound dexamethasone suppresses the release of cytokines 
during early stages of UPEC infection and provided protection from chronic infection in 
a similar manner as ciprofloxacin (Sharifian et al., 2008; Hannan et al., 2010). These 
findings suggest that application of antibiotics with immune modulating activities might 
have an overall protective benefit on the host. However, care should be taken as the risk 
of developing a resistant infection is significant, and these findings require confirmation 
in larger population cohorts. Furthermore, although ciprofloxacin is protective in the 
short-term, the effect on humoral responses has not been characterized. It is possible that 
the cytokine profiles generated with antibiotics might increase recurrence risk by 
depressing future adaptive response. Overall, the cytokine profiles detailed in this study 
demonstrate the dynamic interplay between host defences, which attempt controlled 
immune recruitment, and E. coli pathogenic mechanisms, which aim to super-induce this 
response. 
 
4.3.5 Ciprofloxacin prophylaxis is not associated with improved 
outcome and increases the intracellular bladder reservoir 
in mice 
An attempt to demonstrate the effects of ciprofloxacin therapy on UPEC pathogenesis in 
a therapeutically relevant scenario was accomplished using a murine model of 
prophylaxis. This model was developed for the purposes of this thesis and had not been 
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attempted previously. Together, it consisted of an infection event, antibiotic therapy and 
rest periods, followed by prophylaxis initiation and sacrifice. As mentioned previously, 
female C57BL/6 mice replaced C3H/HeN mice, which are susceptible to pyelonephritis 
through VUR. However, the characteristic responses of these mice to UPEC infection are 
comparable (Hung et al., 2009). 
Urine titers of mice were tracked over the course of the study. Co-trimoxazole therapy 
was successful in clearing the bacteriuria in all but two mice, who went on to suffer from 
chronic infection. During the seven-day rest period, urine titers further demonstrated 
dynamic changes in bacterial load consistent with clinically significant recurrences. 
Similar observations have been made by other groups and demonstrate the inadequacy of 
short-course antibiotic therapy to clear UTI in this model (Blango and Mulvey, 2010; 
Schilling et al., 2002). Admittedly, human patients experiencing such recurrences would 
restart normal therapy until bacteria were absent from the urine prior to prophylaxis 
initiation (Dason et al., 2011; Kodner et al., 2010). However, the timelines permitted in 
with this work did not permit such measures to be taken. As such, mice began receiving 
prophylaxis despite previous recurrences, and in some cases with positive urine cultures. 
The effect on prophylaxis on bacterial urine loads was found to be negligible. This was 
even true in the mice that had not cleared their infection with co-trimoxazole. These 
results reflect human clinical findings, which inevitably question the effectiveness of this 
management approach (Garin et al., 2006; Conway et al., 2007; Enzler et al., 2011).  
Mice were sacrificed and further assessed for augmentation in bladder and kidney E. coli 
UTI89 loads. Although there were no significant changes associated with prophylaxis or 
vehicle treatment, there was trend towards higher titers when ciprofloxacin was provided. 
In some cases, these changes might have clinical significance. For example, the bladders 
from all animals receiving prophylaxis maintained some bacterial load, while those in the 
control group showed signs of resolution. Only one animal in the control group 
maintained kidney titers while six in the prophylaxis remained colonized. The most 
important finding from these studies was in revealing the propensity for prophylaxis to 
enhance UPEC tissue invasion in bladders. These results mirror clinical observations, in 
that while prophylaxis might assist in decreasing UTI symptoms, they inexorably do not 
alter the long-term risk of recurrence, and may in fact promote future episodes by 
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establishing intracellular reservoirs. The presence of intracellular UPEC has been 
associated with recurrence risk both in humans (Garofalo et al., 2007) and mice 
(Schwartz et al., 2011) in the past. Together, the data presented in this thesis provide 
compelling evidence that low-dose antibiotics are capable of enhancing virulence and 
pathogenesis during UTI. 
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4.4 PERSISTER CELLS CONTRIBUTE TO RECURRENT 
UTI BY IMPROVING SURVIVAL DURING ANTIBIOTIC 
THERAPY 
The results from the prophylaxis model demonstrate that antibiotics, even when applied 
at therapeutic levels, are incapable of sterilizing the urinary tracts of mice. These findings 
have been noted in several other studies, using a wide variety of agents and different 
pathogens (Blango and Mulvey, 2010). Although the presence of organisms in protective 
intracellular niches could account for these findings, the observation of organisms in the 
urine and lumen of mice during prophylaxis suggest other mechanisms must also 
contribute. Antibiotic tolerant persister cells were thought to play an important role in 
survival, and were characterized in this thesis in the context of recurrent UTI. 
 
4.4.1 The nature of persistence and MDT in uropathogens 
Two population-based approaches were used to characterize the persister fractions of 
representative uropathogens. The observation of variations in persister fraction sizes 
between Type I stationary and Type II exponential sub-populations indicate that global 
dormancy cannot solely account for MDT. Rather, it is proposed that persisters can be 
classified based on the metabolic activity of distinct cellular processes such as 
peptidoglycan cross-linking, transcription and translation, with each demonstrating 
various degrees of activity and influencing a persister's susceptibility to antibiotics. In 
this way, MDT is a function of whole populations, but not individual persisters, which 
are heterogeneous in regards to their antibiotic sensitivity and tolerance. Furthermore, 
antibiotic-induced tolerance is not dependent on onset of global dormancy, as cross-
tolerance results suggest that an individual persister's susceptibility to different agents is 
contingent on its mechanism of onset. These results reflect other phenotypic 
observations, such as filamentation, which occur in only a subset of the overall 
populations. An organism's commitment to certain phenotypes may be stochastic in 
nature, perhaps due to antibiotic-dependent changes to noise propagation in gene 
networks, or augmentation in organelle and molecule partitioning during cell division 
(Pedraza and Oudenaarden, 2005; Huh and Paulsson, 2011). 
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Generally, most antibiotics appear to primarily influence their cognate target, increasing 
tolerance against further challenge with the same agent rather than resulting in global 
down-regulation of overall cellular activity as hypothesized (Grønlund and Gerdes, 
1999). However, there are notable exceptions, including that ampicillin pre-treatment 
results in heightened MDT against all agents in S. saprophyticus 15305. The ability of 
this drug to halt replication in an SOS-dependent manner and induce β-lactam tolerance 
has been demonstrated in E. coli, but is perhaps more significant in Gram-positive 
bacteria (Maisonneuve et al., 2011, Miller et al., 2004). Agents affecting transcription 
and translation may impart more broad-spectrum tolerance by influencing downstream 
processes and therefore the activity of other potential drug targets in a similar manner. 
SOS-deficient UPEC strains were deficient in antibiotic-induced persister formation 
against all agents tested. Surprisingly, gentamicin induction was also affected despite its 
reported inability to induce SOS responses in E. coli (Baharoglu et al., 2013). This might 
reflect a novel SOS-dependent mechanism of persister induction. Considering the 
heterogeneity in Gram-negative and Gram-positive responses, various antibiotics may 
demonstrate different persister-inducing potentials against different organisms. If true, 
this hypothesis may have predictive clinical value in the prescribing of antibiotics, which 
effectively ameliorate disease without unnecessarily enriching persister fractions.  
The activation of SOS systems and release of Lon protease mediates antitoxin 
degradation resulting in intracellular toxin build-up from numerous TA modules and 
persister formation (Maisonneuve et al., 2011). These modules also appear to play a role 
in dormancy maintenance, with sequestration of the toxin by its constitutively expressed 
cognate antitoxin occurring to release cells from persistence (Hansen et al., 2008). As 
antibiotics can influence SOS activity, their effect on persister stability and the dynamics 
of resuscitation were investigated. Although antibiotic pre-treatments influence the 
expression of these genes and result in dormancy onset, their presence does not seem to 
alter the general kinetics of resuscitation. However, the dichotomy in resuscitation rates 
between E. coli CFT073 and S. saprophyticus 15305 further suggests that mechanisms of 
persister maintenance can vary between organisms. The potential application to chronic 
infections is unclear and requires further exploration, as characterization of these traits 
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might have the potential to enhance treatment strategies by outlining periods of 
vulnerability during infection (Gefen et al., 2008). 
Enumeration of the Type I and Type II persister fractions of UPEC isolates revealed 
heterogeneity in both sub-populations' responses to antibiotics. Ciprofloxacin 
significantly reduced survival in stationary phase cultures compared to ampicillin and 
gentamicin treatments which were largely ineffective against both SSR and AI isolates, 
as demonstrated in other strains tested. The comparatively enhanced efficacy observed 
for the DNA gyrase inhibitor ciprofloxacin suggests significant activity in persisters. This 
may indicate that transcription and replication actively occur in persisters and that they 
are sensitive to changes affecting these processes (Ramage et al., 2009). This hypothesis 
is further confirmed through the observation that SOS-deficient mutants are severely 
inhibited when challenged with ciprofloxacin, while remaining refractory to ampicillin 
and gentamicin, agents that do not directly damage DNA. In addition to revealing DNA 
gyrase activity in persisters, this result also suggests that an active SOS response is 
required to abrogate ciprofloxacin-induced DNA damage (especially with respect to 
RecA-dependent double-strand break repair), which may be critical for fluoroquinolone 
tolerance in UPEC. The concurrent inhibition of the SOS response (such as with the 
application of RecA inhibitor N
6
-(1-Napthyl)-ADP) along with the application of 
fluoroquinolone antibiotics may be an effective means to clear persister-dependent 
chronic infections (Lee et al., 2005). 
 
4.4.2 UPEC isolated from patients with same-strain recurrences 
have larger persister fractions than those pathogens 
cleared with normal therapy 
Type II persisters were induced by antibiotics at a high frequency in SSR compared to AI 
isolates, suggesting these traits may be subject to selection and enriched over the course 
of recurrent UTI and prophylaxis. Selection of genes influencing persistence has been 
previously demonstrated, where overproduction of the persister-inducing molecule indole 
corresponded with increased antibiotic levels over time and subsequent MDT (Vega et 
al., 2012). In addition, Lewis' group observed that P. aeruginosa persister fractions 
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increased over a 96 month period in an individual suffering with cystic fibrosis and 
undergoing antibiotic therapy (Mulcahy et al., 2010). These results are intriguing as 
antibiotics often increase the incidence of mutation within organisms, thereby increasing 
the frequency with which organisms gain persister traits during long-term prophylactic 
therapy (Kohanski et al., 2010). This observation may have severe clinical ramifications 
in suggesting that a patient's history of antibiotic use may increase their risk of going on 
to suffer from recurrent infections. In some cases, SSR organisms not only survived 
lethal antibiotic dosing, but actually continued replicating in the presence of the agents 
despite their susceptibility. This resistance-like phenotype has been observed previously 
in susceptible Type II persister fractions but is often unreported. Notably, Balaban's 
group (2004) demonstrated that E. coli persisters with mutations in the TA hipQ gene 
could continue limited growth when exposed to lethal ampicillin, corroborating our 
results. Other groups have noted periods of slight replication following lethal antibiotic 
dosing (Keren et al., 2011, Wiuff et al., 2005). Wiuff et al. (2005) concluded this could 
not be explained by degeneration of the antibiotic in the growth media over time alone. 
Maisonneuve et al. (2013) recently showed that slow growing variants within an 
exponentially growing E. coli population demonstrate MDT in a (p)ppGpp-dependent 
manner. Admittedly, it is possible that the observed limited replication of persisters is a 
result of the categorical susceptibility cut-offs provided by the Kirby-Bauer method of 
testing. Although strains appeared as susceptible during this routine test, they were often 
highly tolerant with low ZOIs (nearly intermediately to resistant susceptibility). This is of 
clinical concern as antibiograms may inaccurately designate intermediately susceptible 
organisms as fully susceptible. However, the observed growth of persisters in this and 
other studies is supportive that these cells maintain at least some metabolic activity. 
Further analysis and comparisons using cross-tolerance illustrated that SSR isolates have 
a greater capacity to form persisters following antibiotic pre-treatment than AI strains. 
However, ampicillin often failed to induce persistence in clinical isolates tested, with pre-
treatment resulting in greater susceptibility especially following gentamicin challenge. 
This finding supports the notion that persister cells demonstrate limited replication, as 
ampicillin was capable of corrupting the still moderately active transpeptidase enzyme. 
The resulting leakiness likely improved the uptake of gentamicin, which in turn enhanced 
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its efficacy against the still active ribosome once available intracellularly (Maisonneuve 
et al., 2011).  This is supported by Collins' group who demonstrated that increasing 
gentamicin uptake resulted in aminoglycoside sensitivity in E. coli (Allison et al., 2011). 
The observation that persister cells do not demonstrate global metabolic dormancy 
suggests that some combinatorial antibiotic therapies may be effective in treating 
persister-related chronic infections. Larger, high-throughput screens are recommended to 
validate this hypothesis.  
In summary, persisters are differentially induced at sub-inhibitory levels by ampicillin 
and gentamicin in addition to ciprofloxacin in both Gram-negative and Gram-positive 
bacteria. Type I persister fraction analysis indicates that global metabolic dormancy is not 
solely responsible for MDT. Rather, the metabolic activity of individual targets dictates 
overall bacterial responses to agents applied, with some antibiotics imparting a greater 
inhibitive effect on multiple cellular targets than others. This is supported in SOS-
deficient strains, which are unable to specifically tolerate ciprofloxacin. Persister traits 
are enriched in organisms derived from patients with a history of antibiotic therapy. As 
low-dose suppressive antibiotic therapy and antibiotic prophylaxis are commonly utilized 
regimens in clinical medicine, they may in fact be playing a role in the development of 
MDT. The findings in this thesis raise concern that the incidence of chronic and recurrent 
bacterial infections may increase with the use of antibiotics for prophylaxis, 
corroborating a recent theory that modern recurrent UTI frequency correlates with the 
widespread use of antibiotics (Nickel, 2005). A greater understanding of these unique 
bacterial physiological states will be essential to improve management of these common 
debilitating infections. Specifically, treatment should focus not on the 'waking' of 
persisters, but rather on the characterization of cellular targets that are active and thus 
susceptible to antibiotic corruption. On a broader scale, the fact that antibiotics can 
induce persister states emphasizes the need to avoid where possible, exposure to low-
dose concentrations of these agents, either as prophylactic agents or through 
environmental contamination. 
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4.5 RE-EVALUATING ANTIBIOTIC APPROACHES IN THE 
CLINICAL SETTING 
Having delineated the off-target effects of some antibiotics we can now begin to 
approach therapy with novel strategies aimed at improving patient recovery while 
reducing the risk of complication. Simply changing the manner in which antibiotics are 
delivered may be a quick and viable approach to this problem (Craig, 1998). This is no 
easy task as organism responses can be mixed, with certain factors induced and others 
suppressed depending on the agent applied and strain challenged (Davies et al., 2006). 
Combinatorial, suppressive therapies may be the best approach to ensure lethal antibiotic 
delivery is achieved at sites of infection. Indeed, some antibiotic combinations have been 
proven to synergistically inhibit the expression of toxin genes (Subrt et al., 2011) and 
prevent resistance development (Zhanel et al., 2006; Berti et al., 2012). However, 
effectiveness is questionable as organisms not cleared during initial treatment phases can 
go on to develop multidrug resistance much quicker than had the therapy been single 
regimen (Pena-Miller et al., 2013). Similarly, hospital-wide antibiotic cycling strategies 
are currently not recommended as they promote the rapid accumulation of resistance 
traits to multiple drug classes (Masterton et al., 2010). Rather, antibiotic rotation at the 
patient level (referred to as heterogeneity mixing or Periodic Antibiotic Monitoring and 
Supervision) is a more structured and specific approach to preventing resistance 
development and spread, but more validation is needed (Masterton et al., 2010).  
A simpler approach to curtail resistance may be to adjust the timing of dosing such that a 
'mutation prevention concentration' is achieved (Cantón and Morosini, 2011). This 
involves minimizing the 'mutant selection window' by ensuring sub-inhibitory levels are 
avoided throughout the course of therapy. Thus, antibiotics which are delivered to 
therapeutic sites at high concentrations and then rapidly cleared would be optimal to limit 
onset of resistance and virulence gene expression (Krasniqi et al., 2012). In some cases, 
antibiotic therapy may be avoided all together. For example, it is well known that some 
infections can self-resolve or more quickly resolve with augmentation of probiotics (Reid 
et al., 2010). One of the largest contributors to antibiotic prescriptions worldwide is 
attributed to UTI, which also represents a major reservoir for resistance (Foxman, 2010). 
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Bleidorn et al. (2010) demonstrated that ibuprofen was just as effective as the antibiotic 
ciprofloxacin in ameliorating symptoms associated with uncomplicated UTI. This finding 
suggests that some infections may be readily cleared by host immune responses, while 
physicians can assist in minimizing patient symptoms in a 'watchful-waiting' approach, 
providing antibiotics only when it is absolutely required. Some temporary medical 
devices, such as ureteral stents that leach immune-modulating components may help 
reduce symptoms and the need for additional medication (Mendez-Probst et al., 2012). 
These approaches are worthy of more rigorous pursuit, as antibiotics should be reserved 
for when they are absolutely required. The increasing frequency of non-reverting resistant 
strains which do not demonstrate any measurable fitness cost support this (Sundqvist et 
al., 2010). Once established these strains are here to stay and hamper current 
antimicrobial stewardship programs, which are designed to curtail resistance through 
negative selection after it has arisen. 
Employing novel agents which prevent the activation of general stress response elements, 
specifically those targeting the SOS system may prove efficacious in curtailing 
hypervirulence, resistance and mutator phenotypes. RecA, a protein important to 
activation of SOS, has shown to be a promising therapeutic target when suppressed with 
inhibiting agents given in conjunction with antibiotics (Lee et al., 2005; Sexton et al., 
2010; Wigle et al., 2009; Do Thi et al., 2011). An array of RecA inhibitors have already 
demonstrated effectiveness in curtailing the rate of spontaneous resistant mutants. In 
addition, these agents may also be useful in limiting the antibiotic-dependent production 
of persister cells and virulence determinants which occur in an SOS response dependent 
manner. Similarly, SOS suppression by a novel, engineered bacteriophage served as an 
adjuvant to enhance killing by quinolone antibiotics (Lu and Collins, 2009). This 
approach was effective in vivo, successfully killing resistant organisms, persister cells, 
and biofilm associated cells. Avoiding activation of stress responses altogether may be 
another appealing alternative for managing infection. Compounds like mannosides, 
pilicides and curlicides may accomplish this and function by interfering with pathogen-
host binding. Promise in preventing and treating UTI has already been demonstrated 
(Guiton et al., 2012; Cegelski et al., 2009). High-throughput screening methods to find 
other 'non-antibiotic drugs' capable of potentiating the activity of widely used antibiotics 
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have been successful to some degree (Ejim et al., 2011). The advantage of this approach 
is that co-therapies are more selective than standard therapies in preferentially targeting 
pathogenic species while limiting destruction of the host microbiota. 
Effective treatment strategies will also need to eliminate or reduce persister fractions, 
although it seems unlikely that any single antibiotic therapy could accomplish this 
(Allison et al., 2011). Thus, novel treatment strategies must be conceived to control 
chronic, persister-dependent infections. One such strategy involves activating a surface 
protease using acyldepsipeptide (ADEP4), which leads to self-digestion and death of 
pathogens when used in combination with antibiotics (Conlon et al., 2013). Another 
method used mannitol to induce activation of various metabolic pathways in E. coli and 
S. aureus persisters, potentiating the uptake of gentamicin and promoting ribosome 
corruption (Allison et al., 2011). The issue will now be to develop such products, given 
the challenges, costs and longevity of the drug development process. However, if these 
strategies can be applied clinically they will have a great impact on not only eliminating 
chronic infections, but also in decreasing the development and spread of resistance. 
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4.6 CONCLUSIONS 
Several conclusions can be drawn from the findings presented within this thesis, which 
should be considered in the wider context for their potential implications for prophylactic 
and therapeutic antibiotic use: 
1) Sub-inhibitory antibiotics from a broad range of classes are capable of modulating the 
virulence potential of various uropathogens. This finding is suggestive of the ubiquitous 
nature of the responses observed, with regard to antibiotics applied, and organisms 
challenged. Although a number of phenotypes may be induced with antibiotics, the onset 
of a sessile lifestyle due to suppressed motility and increased adhesin and 
exopolysaccharide expression is prominent.  
2) Induction of the SOS response is in part responsible for the phenotypic changes 
incurred as a result of sub-inhibitory antibiotic treatment. The changes following 
antibiotic dosing were abolished in the SOS-deficient E. coli UTI89 strains challenged. 
Although the influence of SOS was not explored in S. saprophyticus 15305, other groups 
have found this system to impart phenotypic changes in other staphylococci with 
antibiotic exposure. However, transcriptomic analysis reveals that general stress 
responses are also involved in sub-inhibitory antibiotic tolerance in this uropathogen. 
3) Sub-inhibitory antibiotic-induced changes of virulence gene expression in vitro reflect 
pathogenic changes in vivo using a murine model of UTI. Ciprofloxacin-priming was 
sufficient to promote the establishment of chronic reservoirs in the bladders and kidney 
of mice infected, in both S. saprophyticus 15305 and E. coli UTI89. These changes likely 
depended on the rapid invasion of urothelial tissues in the first 24 hours following 
inoculation, and shifts in host-pathogen checkpoint equilibrium in favour of the pathogen 
and establishment of chronic infection. 
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4) Ciprofloxacin exhibits immunomodulatory effects in both mice and human tissues, and 
is protective against the establishment of chronic UPEC infection. These changes likely 
depend on cytokine profile augmentation in urothelial tissues, which suppress neutrophil 
recruitment and inflammation at sites of infection. 
5) Ciprofloxacin prophylaxis is not recommended for recurrent infections. Mice receiving 
prophylaxis were not associated with significant changes in UPEC urine titer compared to 
those receiving vehicle. Furthermore, animals receiving prophylaxis presented with 
greater intracellular bladder reservoirs than the control group, which might predispose to 
future recurrences. 
6) The persistence of bacteria in the urinary tracts of patients suffering from recurrent 
infections is likely due to the presence of MDT persister cells. Antibiotics are capable of 
triggering this tolerant state, and might select for organisms with larger persister fractions 
during prolonged therapy. Furthermore, persister cells do not exhibit the properties 
required for complete metabolic dormancy, suggesting that anti-persister drug 
development should focus not on the 'waking' of these variants, but on potentiating the 
activity of currently available antibiotics, such as through the use of RecA inhibitors. 
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